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Abstract 
 
 
Tuberculosis (TB) is one of the most important infectious diseases worldwide; about 9 
million people developed TB in 2013. The disease is however poorly controlled for a variety 
of reasons, a major hurdle being the lack of proper diagnostic-tools available in resource poor 
countries. In this thesis, research was conducted in order to investigate the potential of novel 
biosensing platforms utilizing optical or electrical transducer systems with known/potential 
biomarkers of TB. For optical biosensors, fluorescence and lateral flow based techniques 
were employed for the detection of a specific 16 kDa cell internal antigen protein HSP from 
Mycobacterium tuberculosis. For electrical biosensors, silicon nanowire (SiNW) field effect 
transistor (FET) biosensors and cellular impedance biosensors were explored. On the SiNW 
platform real-time and label-free detection of HSP protein was tested, while on the cellular 
impedance platform real-time and label-free detection of a model analyte was done using a G 
protein-coupled receptor (GPCR). The cell-based system could be used to detect biomarkers 
induced in the human host and can be further developed to detect TB. The detection 
platforms described in this thesis can be applied broadly for the detection of other biomarkers 
as well. This thesis may therefore hopefully contribute to other future developments of 
diagnostics in general. 
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1.1 Introduction 
 
Tuberculosis (TB) is a globally prevalent disease that is caused by the gram-positive 
Mycobacterium tuberculosis (M.tb.) [1-3]. For many decades now, TB has continued to pose 
a significant threat to human health and despite the availability of broad-spectrum antibiotics, 
which are effective against the bacterium, the social and financial burden for sufferers from 
the disease continues to be huge. Especially, in developing countries, like India and sub-
Saharan Africa, it is one of the most dreadful and prevalent diseases affecting members from 
all age groups [4]. Therefore, the national and international health agencies, governments and 
policy makers have rightly diverted a very large amount of funding towards research and 
management of TB. Unfortunately, despite declining global numbers of patients, it still 
remains a major health problem to be tackled [4, 5]. 
 
Clinically, TB is typically manifested with clinical symptoms of chronic fever (mainly 
at night), cough, anorexia, general malnutrition, weakness and significant weight loss. It 
occurs due to infection and colonization of human lung tissues and respiratory tract 
epithelium with M.tb. The bacterium spreads through aerosols produced by sneezing and 
coughing of a patient. Till date, no animal vector has been identified [4,6]. There are some 
reports that suggest passage of M.tb. from pregnant mothers to the fetuses. The M.tb. 
bacterium has a cell wall comprising lipopolysaccharides (LPS) and glycoproteins [7]. It has 
been postulated that these two components of the bacterial cell wall can both act as an antigen 
and initiate inflammatory reactions. Additionally, there are other constituent proteins in the 
bacterium, like 16 kDa Heat Shock Protein (HSP), that are also claimed to be antigenic in 
nature, although much debate exists on their structures and antigenicities [8-11]. As a 
pathogenic bacterium, M.tb. initiates inflammatory conditions resulting in fever, neutrophilia 
(in peripheral blood), weight loss, anorexia and other health conditions. Hence, TB is more 
debilitating in patients with low nutritional status or immunocompromised (like AIDS 
patients) [12, 13]. The M.tb. bacterium causes granuloma formation, often with a necrotic 
core surrounded with inflammatory tissues rich in leucocytes, which causes the typical cough 
and breathlessness [14]. In advanced stages, these necrotic granuloma tissues may be 
expelled while coughing along with blood. 
 
Apart from the conventional pulmonary TB as described above, M.tb. can also cause 
TB in other parts of the body (extrapulmonary TB), like in intestines and bones. In certain 
cases, TB can spread throughout the body causing infections at multiple sites, known as 
miliary TB [15]. These conditions can be more grave and life threatening at advanced 
conditions warranting early diagnosis and chemotherapy. Unfortunately, the availability of 
diagnostics for TB is still daunted by methods that are too expensive, require logistic support 
and highly trained personnel. Additionally, once diagnosed the need for highly expensive 
antibiotics, essential in the therapy especially in cases of multidrug resistance, represents a 
huge financial burden. As a result it is a frustrating fact that in spite of billions of Euros of 
investments by different agencies, a satisfactory level of control of TB at the international 
level remains elusive [4]. 
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1.2 Multidrug Resistant TB 
 
The emergence of Multidrug resistant (MDR) TB cases which cannot be treated by 
multiple or entire groups of antibiotics have severely complicated the management scenarios. 
The antibiotic resistance is caused by mutations in the genome of the bacterium. It is known 
that usually 1 out of 106 bacteria is inherently resistant to anyone of the first line anti-TB 
drugs, like isoniazid, rifampicin, ethambutol etc. As a result cases emerge which are resistant 
to an entire regime of such antibiotics [4]. Globally in 2013, an estimated 480 000 people 
developed MDR-TB. 
 
The MDR TB sets a major challenge in the management of TB worldwide. 
Especially, in countries like India, Vietnam and African countries, MDR cases are a prevalent 
and dominant cause for mortality. To treat MDR cases, usually a regime consisting of 
multiple first line drugs is used, which however at the same time selects for even more 
complex MDR TB strains. Research is necessary to discover and develop new antibiotics, but 
the few new drugs that are under clinical trial still require more evaluation before they can be 
introduced [16-18]. 
 
1.3 Epidemiology and statistics 
 
The WHO TB Report 2012 collected reports from 204 countries and territories under 
its jurisdiction, totally representing >99% of the global TB cases [4]. The report successfully 
compiled the existing burden of the disease and the remaining challenges in TB management. 
India and China together accounts for >40% of the total TB cases in the World although the 
overall infection rate within the population is highest in African countries where sometimes 
>80% of the population is infected with M.tb. In 2011, there were 8.7 million new cases and 
about 1.4 million people have died. Furthermore, 13% of all newly reported cases were also 
immuno-compromised with HIV. As per the WHO 2012 report, resistance to more than one 
first line anti-TB drugs is reported amongst 3.7% of new cases and 20% previously treated 
cases [4]. The good news is that the goal to halt the progression and reverse the global TB 
pandemic, as described in the Millennium Development Goal (MDG) is showing good 
promise. There was a 2.2% reduction in new cases between 2010 and 2011 and relative to 
1990 there has been even been a 41% reduction in annual new cases. This has triggered hopes 
that the MDG of reducing the number of new cases by 50% by 2015 is achievable. Since the 
initiation of the Global TB program in the 1990s, an estimated 51 million people have been 
successfully treated thanks to very large funding schemes that went into the program (US$ 8 
billion projected for 2013-2015) [4]. 
 
1.4 The current TB diagnostic methods and their drawbacks 
 
The most commonly used technique for the clinical diagnosis of TB is the chest X-ray 
(CXR) [19]. Usually, with the posterior-anterior (PA) view, the chest region is imaged to 
demonstrate the pulmonary structures. Granuloma of the TB [20] is quickly recognized with 
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areas of necrosis and distribution of nodules in the lung parenchyma. The chest X-ray 
findings are further supported with clinical findings and patient histories. 
The available diagnostic test alternatives are: 
 
(1) Tuberculin skin test (TST): this TST or Mantoux test was one of the first tests to be 
used for diagnosis in TB since 1907 and has undergone several improvements [21]. 
Usually this test comprises subcutaneous injection of a protein purified derivative 
(PPD) obtained from a sub culture of M.tb. bacteria. The immunogenic response as 
the diameter of the inflammation found in skin after 48-72 h is used to diagnose 
positive cases. It requires trained healthcare personnel to perform it. Subjects with 
immuno-deficiencies generally fail to generate sufficient responses and therefore add 
to the false negative cases, and patients with Bacille Calmette-Gúerin (BCG) 
vaccination show an 8.5% incidence of false positive cases [22-24].   
 
(2) Bacterial culture from sputum samples: A bacterial culture from sputum collected in 
the morning remains popular in detection of TB. Unfortunately, the sensitivity of 
these tests for TB varies between 34-80% and requires a bacteria-concentration of at 
least 5.000-10.000 CFU/ml. The test does not differentiate TB from other 
mycobacterial infections, and it is also very time consuming, as 2-3 weeks are needed 
to obtain the outcome. Recently, detection of bacterium using fluorescent labels in 
combination from bacterial culture has been advocated and this definitely increases 
the sensitivity of the technique [25]. A downside is that the methodology requires at 
least two independent samples taken at two different days making it harder to 
implement as a point-of-care diagnostic. One of the challenges of such sputum-based 
detection of M.tb. through microscopy of the smear is the fact that M.tb. is quite hard 
to differentiate from other prevalent Mycobacterium sp., like Mycobacterium kansasii, 
Mycobacterium marinum and Mycobacterium Avium Complex (MAC) [26]. 
 
(3) Interferon gamma (IFN-γ)-based assays: In these assays, the amount of IFN-γ 
released from the human immune T-cells upon exposure to M.tb.-specific antigens, 
like ESAT-6 and CFP-10, is quantified. Usually, these kits are either ELISA 
(QuantiFERON) or enzyme linked immunospot (ELISPOT) assays (T-spot TB test) 
[27]. Unfortunately, these assays offer no better sensitivities or specificities compared 
to the TST tests and cannot differentiate between active and latent TB infections. 
These tests are also highly expensive and therefore, WHO has stopped endorsing 
these tests especially for lower and middle-income countries [28]. 
 
(4) Urine-based assays: In these assays, a simple commercially available kit detects an 
antigen, lipoararabinomannan (LAM), as part of the cell wall of M.tb. Although this 
test is cheap (~$3.5/test) and simple to perform, the accuracy is low (28.2%). This test 
also fails to differentiate between active and latent cases. Interestingly, the accuracy 
of the test increases to ~66% with if a CD4 cell count is included (<50 cells/µl) and 
has a better potential to diagnose TB cases with HIV and can be useful in African 
countries where TB is the leading cause of mortality in AIDS cases [29]. 
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(5) Nucleic acid amplification-based assays: In these types of assays, certain parts of the 
bacterial DNA are amplified, either by RT-PCR or by line probe assays before 
detection. For RT-PCR usually either of two kits is used: Amplicor M.tb. From Roche 
Diagnostics or Amplifier Mycobacterium tuberculosis Direct Test from Gen Probe 
Inc., and for line probe assays, Inno-LiPA Mycobacteria assay and GenoType 
Mycobacterium assay. The advantages of the line probe assays are that they are 
simpler to execute. They usually detect the 16S and 23S genes by amplification of the 
nucleic acid sequences on a nitrocellulose membrane. The advantage of these assays 
is that they can differentiate between M.tb. and other Mycobacterium sp. more 
precisely, and can also detect MDR M.tb. resistant against drugs like rifampicin, 
ethambutol, isoniazid and fluoroquinolones [30]. 
 
(6) Immune response-based detection assays: One of the most popular assays for 
detection of TB is latex agglutination based antibody binding assays with the M.tb. 
antibodies present in the blood of M.tb. infected persons. Due to the antigen-antibody 
reactions, there are significant aggregations of particles that can later be quantified. 
Unfortunately, this technique has a low sensitivity of only 53% with inability to 
differentiate between active, latent and carrier stages. However, the specificity 
(~98%) of the technique is acceptable [31]. 
 
(7) As a new diagnostic technique in December 2010 the WHO endorsed the use of a 
cartridge based automated diagnosis test called Xpert M.tb./RIF which detects DNA 
sequences specific for M.tb. as well as rifampicin resistance utilizing polymerase 
chain reaction by Nuclic acid amplification test (NAAT) within 100 min. It is 
estimated that by June 2012, 1.1 million units were purchased with South Africa 
leading the way in implementing it. The initial reports are quite promising. Apart 
from that, WHO targets to licence at least one vaccine for TB prevention by 2020 
[32]. 
 
1.5 Gaps between current diagnostic techniques and need 
 
At close inspection it can be concluded, that many of the current diagnostic tests in 
TB fall short of the requirements for an early diagnosis or suitability for resource poor 
countries. Most of them have inadequate sensitivity and/or specificity or do not differentiate 
between active and latent cases. The points leading to such problems with TB diagnostics are: 
(1) M.tb. is a very slow growing bacterium taking 2-3 weeks to grow, (2) Pulmonary TB 
often shows symptoms only at advanced stages making an early diagnosis difficult and (3) 
even the active cases often exhibit low bacteria content of sputum thus making it difficult to 
detect with the current diagnostic tests. There is an urgent unmet need, therefore, for 
innovative TB diagnostic platforms, which are cheap, fast, sensitive, reproducible, can 
identify and differentiate between active and latent cases, require single visits from patients, 
cause minimum discomfort, require minimum logistic support and trained personnel, assess 
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drug susceptibility, can measure non-sputum samples, are user friendly, smart, tailor-made 
and can be used in resource poor settings. 
 
1.6 Biosensors in TB detection 
 
Biosensors offer unique opportunities for the detection of TB. According to the 
International Union of Pure and Applied Chemistry (IUPAC), “biosensors are devices that 
use specific biochemical reactions mediated by isolated enzymes, immunosystems, tissues, 
organelles or whole cells to detect chemical compounds usually by optical, thermal or 
electrical signals”. In addition some would add that biosensors should also allow for real 
time, preferably reversible and label free measurements of certain analytes [33]. Such 
biosensors can be broadly classified into mass/piezoelectric, biochemical, optical and 
electrical based systems. A review on the current state-of-the-art techniques that have been 
implemented in relation to TB is given in Chapter 2 of this thesis. The main motivation 
behind using these analytical devices is the simplicity offered by real time monitoring of the 
target-analyte interaction. To enable this, a biosensor consists of a detection area where 
essentially an analyte is detected through its coupling to a biological sensing layer. The 
reaction or interaction and the physico-chemical changes resulting from the reaction or 
interaction between the analyte and the detection molecule are thereby detected by different 
transducer systems. The main advantages that biosensing method should ideally possess over 
conventional techniques are that they are fast in execution, require only small amounts of 
sample, have the flexibility to be tailor-made for a specific or a group of unique target 
molecules. It is based on these achievements, that biosensors in some areas like blood glucose 
measurements are popularly used nowadays. In an effort to also implement biosensing 
methods towards sensitive and specific detection of tuberculosis infections, this thesis focuses 
on three different biosensing principles involving optical and electrical transducer systems 
and protein and cell based functionalizations. 
 
1.6.1 Optical biosensors 
 
1.6.1.1 Nanoparticle (NP) based protein biosensors 
 
With the rapid growth of nanotechnology, carbon nanoparticles (CNPs) have 
experienced an explosive growth both in production and utility [34, 35]. Expectedly, a new 
range of applications for carbon nanomaterials has emerged in applications such as cancer 
treatment, medical imaging, disease diagnosis, gene therapy, drug delivery and many other 
areas. These CNPs could serve as replacement for existing signalling labels such as gold, 
latex, coloured silica or quantum dots in diagnostic assays. There are three naturally 
occurring allotropes of carbon i.e. graphite, diamond and amorphous carbon. Relatively 
poorly defined amorphous CNPs have been used in lateral flow immunoassays (LFIA) as 
indicators of the presence of a particular protein or nucleic acid ligand in a sample [37]. The 
sensitivity of these types of assays may in principle be improved by the use of other types of 
particles which are visible not by the absorption of light but by the emission of fluorescence. 
These amorphous CNPs are often produced from carbon soot and are an excellent tool in 
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developing simple, inexpensive but highly sensitive readout assay-based platforms in LFIA 
[37]. The amorphous CNPs are also quite stable which facilitates their uses in developing 
stable and reliable nanoprobes for such NP-based sandwich ELISA assays. Such CNPs can 
also be produced in bulk quantities, which is an added advantage. The assay result can also be 
presented with an easy readout using simple imaging software.  
 
Also quantum dot type of NPs may exhibit qualities that are suitable for diagnostic 
applications [34, 35]. Due to their extremely small size (< 20 nm), these particles are able to 
sensitively detect molecules or chemical species at the nm scale. In a recent development it 
was shown that carbon quantum dots (similar to silicon or CdSe/ZnS quantum dot) may emit 
fluorescence after being exposed to bright light [36]. These carbon quantum dots showed 
adequate quantum yield and were resistant to photo bleaching. Additionally, they provide 
sufficient scope for surface functionalization (including binding to specific antibodies) to 
enhance its capability in detecting biomolecules including proteins. 
 
1.6.1.2 Fluorescence based protein biosensors 
 
Optical detection of (changes in) fluorescence is one of the most prominent and 
mature techniques for the visualization of biomolecules or molecular events in the field of 
molecular biology. Advancements in these techniques over the past few decades have not 
only outlined the roles and locations of various biomolecules of interest but also successfully 
demonstrated extra- and intracellular relationships between those molecules. Attributes such 
as ease of use, high sensitivity, specificity, selectivity, sufficient temporal and spatial 
resolution at low costs have placed fluorescence techniques into the lime light as one of the 
most promising choices for biosensing transducers [38]. Many fluorescence-based biosensors 
have been utilizing synthetic and biological receptors such as DNA, proteins and aptamers 
[39]. The design of a fluorescence based biosensor basically involves the selection of an 
appropriate macromolecular receptor or binding molecule which has affinity and specificity 
for the target molecule in consideration, followed by the signal transduction unit required to 
sense the molecular binding event at the surface of the receptor. Usually the receptor or 
binding molecules are not fluorescent, thus they require coupling to foreign reporter moieties 
such as green fluorescent protein (GFP) [40] or synthetic fluorophores (Alexa-Fluor) [41] at 
appropriate positions on the receptor component. Upon binding to ligands, the fluorescence 
properties change due to change in the biochemical environment. Examples of such 
biosensing molecules are Molecular Beacon and Cameleon proteins. Fluorescence based 
biosensors can be very sensitive as the excitation and emission wavelengths are different.  
 
1.6.2 Electrical biosensors 
 
1.6.2.1 Silicon nanowire-based biosensors 
 
Silicon nanowire (SiNW) field effect transistor (FET)-s offer a unique diagnostic tool 
for real-time and label free detection of molecules. Due to the fact that the nanowires have a 
diameter in the range of bound charged ligand molecules, each binding molecule may directly 
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influence the electrical conductivity along these semiconductor wires. As a result much 
higher sensitivities have been reported than in regular immunoassays [42,43]. In general, 
SiNW FET-based biosensor systems where the SiNWs are placed between source and drain 
electrodes, while a gate electrode regulating the conductance and sensitivity [43]. Usually, 
they are surface functionalized with bio-receptor molecules in order to capture specific target 
molecules. Upon binding of the target molecules (analytes), the electric current changes due 
to an altered resistance induced by the field effect of the bound molecule [43]. For example, 
if the receptor molecules capture negatively charged analyte molecules, the anionic analyte 
molecules repel the anions close to the surfaces of the SiNWs and thus, decreasing the 
electric current. 
 
SiNWs of various thickness (20-60 nm) and lengths up to 100 nm have been used in 
development of such biosensors [44]. These biosensors have been used to detect different 
protein biomarkers for diseases, like prostate specific antigen (PSA) in prostate cancer, ions, 
small molecules, viruses, and cells [45]. Considering the availability of highly characterized 
antibodies [46], these SiNW-based biosensors may possibly also be used effectively in TB-
detection.  
 
1.6.2.2 Impedance based cell biosensors  
 
Sensing devices utilizing specific receptors and signalling pathways present in living 
cells are known as cell based biosensors. Cell based sensing can be achieved utilizing a wide 
variety of transducers such as electrical, optical, mechanical, thermal principles. Impedance 
spectroscopy is a well-established technique in electrochemical and (bio)chemical sensing, 
redox reactions, and in studying morphological responses of a wide range of organisms like 
bacteria, neuromuscular cells, and eukaryotic cells [47, 48]. Eukaryotic cell based biosensors 
have been used as a model system for a wide range of applications that include drug 
discovery, single cell analysis, pathogens and toxin detection, taste receptors analysis, cancer 
detection etc. by exploiting the complex, but advanced bio-recognition elements and signal 
transduction pathways present on and in eukaryotic cells [49]. Impedance responses are 
transduced by induced morphological changes in cell shape a result of the activation of 
receptors such as G protein-coupled receptors (GPCRs) [50]. GPCRs are a family of 800 
genes coding for different types of GPCRs, which may be utilized for sensing various 
analytes/targets depending on the research question [51]. These receptors include recognition 
of specific extracellular stimulants like photons, glycoproteins, cytokines, hormones, 
neurotransmitters, growth factors and odorant molecules [52]. Though there are three main 
GPCR pathways that are mediated by four (Gαs, Gαi/o, Gαq/11 and Gα12/13) subclasses of G-
proteins, the pathway that appears most relevant for impedance-based measurements is the 
Gα12/13 pathways which upon activation triggers a signal transduction pathway causing a 
change in cell shape [53]. Receptor-cell based studies may enable diagnosis of a specific host 
response to infection by TB. 
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1.7 Aims and objectives of the thesis 
 
The primary aims of the thesis are: (1) to develop, optimize and validate new 
diagnostic methods in order to detect biomarkers for TB; (2) to devise tests which exhibit 
improved sensitivities and specificities compared to the various currently available diagnostic 
tests. 
 
The secondary aims of the thesis are: (1) to successfully implement nano-
microtechnology, such as silicon nanowire sensing, in order to develop advanced biosensing 
tools for TB biomarker detection; (2) to design biosensing tools with potential as a user-
friendly point-of-care diagnostic for TB detection – especially for resource-poor areas; (3) to 
further extend and explore possibilities of integration and miniaturization of such biosensing 
platforms in order to develop devices enabling high-throughput screening (HTS) capabilities.  
 
1.8 Outline of the thesis 
 
The work presented in this thesis describes the development of a variety of different 
biosensing methods towards the goal of the detection of TB biomarkers in patients. The 
diversity of approaches described in this thesis was partly invoked by the fact that the 
platform at which we aimed originally, based solely on silicon nanowire FETs (Chapter 6), 
did not materialize until the very end of the project, due to a late supply of sufficient and/or 
functional nanowire chips. 
 
Chapter 2 gives an overview of the available biosensing techniques that are either 
already in use or under development for TB detection. This chapter also focuses on newly 
emerging biosensing approaches while comparing their advantages and disadvantages with 
conventional techniques.  
 
Chapter 3 focuses on the identification and characterization of the M.tb. 16 kDa HSP 
epitopes in relation to different VHH antibodies along with evaluating the suitable capture-
detection probe combinations for detection of tuberculosis on robust protein-based diagnostic 
platforms using these antibodies. In this chapter it was demonstrated that HSP protein from 
heat-inactivated M.tb. exists as a homodimer. 
 
In chapter 4, fluorescence based biosensing tool was employed for the detection 16 
kDa HSP which is a specific cell internal antigen protein of M.tb. In order to do so, first the 
M.tb. bacteria were concentrated on microsieves functionalized with PolyDADMAC, which 
could later be lysed using standard lysis protocols to give the cell internal lysate protein. This 
lysate protein contains the 16 kDa HSP target protein that was detected in a sandwich assay 
using microsieves functionalized with specific llama antibodies. It was also shown in this 
chapter that due to the homodimer nature of the 16 kDa HSP, it is also capable of 
agglutinating when in contact with specific antibodies coupled to a surface, beads or other 
protein capable of binding multiple antibodies. 
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Chapter 5 utilizes the knowledge and methods of chapter 3 and 4 to demonstrate how 
HSP released from concentrated M.tb. bacteria could be implied in an application involving a 
lateral flow immunoassay (LFIA) technique for the detection of TB. Characterization of 
various parameters like adequate concentration and VHH combinations for anchoring, 
capture and detection were carried out to achieve acceptable sensitivity of the LFIA test. 
 
Chapter 6 reports the development of a compact modular biosensing system and an 
application to carry out SiNW-based electro-physical detections inside a re-sealable glass 
microfluidic flow cell. It validates the set up by measuring with silicon nanowire FETs 
developed at DIMES (TU Delft) flow injected iso-ionic pH solutions, and M.tb.-specific HSP 
binding kinetics in real time on the nanowire surface. 
 
In chapter 7, the modular biosensing system of chapter 6 is used to test the efficiency 
of interdigitated microelectrodes for impedance measurements of live mammalian cells 
expressing specific GPCRs. Certain biomarkers circulating in patient’s serum are specifically 
induced by TB infections and some are targeting specific GPCRs. Highly sensitive 
measurements were achieved and approaches are outlined to convert the system into a high 
throughput assay for the detection of multiple analytes in a single run of 5 min. 
 
Finally, chapter 8 presents an overview of the main findings of this thesis along with 
pending issues that remain to be solved and aims to provide recommendations for future 
directions of research. 
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Abstract 
 
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb.), is one of the most 
prevalent and serious infectious diseases worldwide with an estimated annual global 
mortality of 1.4 million in 2010. Diagnosis of TB in the developing world is very challenging 
due to the limited suitability of currently available techniques under tropical field conditions. 
M.tb. is a slowly growing Mycobacterium that takes around six to eight weeks to be detected 
via sensitive culture methods. There is also hardly any clinical symptom at an early stage of 
infection, thereby causing a delay in diagnosis and treatment, and the complexity of the 
disease is further increased by the emergence of multiple drug resistance (MDR) strains.  
 
A lot of work has been done over the last few decades to develop effective point of 
care diagnostic techniques that are cheap, robust and can be performed at high throughput in 
rural areas. However, despite considerable technical improvements reported from the lab, 
such economical full proof diagnostic assays are still lacking on the market. The objective of 
this review is to evaluate currently available biosensing techniques that are either already in 
use or under development for detection of TB. The focus of the review is on the emerging 
field of diagnostic biosensors that combine ligand capture and detection in a one-step assay. 
A comparison will be made with conventional multistep techniques.  
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2.1 Introduction 
 
2.1.1   Background 
 
Tuberculosis (TB) is an age-old infectious disease of the human race [1, 2], which 
recently re-emerged globally as an important health-related issue, especially due to the 
emergence of multi-drug resistant (MDR) strains [3, 4]. The specific characteristics of the 
gram-positive bacteria, Mycobacterium tuberculosis (M.tb.) causing TB [5] makes it 
currently one of the most prevalent diseases [6]. TB bacteria can remain inactive or in 
dormant state for years without causing symptoms or spreading to other subjects, but as soon 
as the immune system of the host becomes weakened the bacteria become active and infect 
mainly the lungs along with other parts of body. TB cases are further aggravated by other 
illnesses that affect the immune system, such as HIV, which is very prevalent in resource 
poor countries. Unfortunately, in spite of sustained efforts at national and global levels, only 
limited success has been achieved in detection and management of TB worldwide [7, 8].  
 
The main obstacles facing successful field detection and treatment of TB are:  
 
1. The omnipresence of the pathogen and disease across different continents which 
complicates management and eradication programs [9]. Most of the reported cases 
(~98 %) are concentrated in developing countries, due to which TB is also known as a 
disease of poverty, with two-thirds of cases estimated to occur among people aged 15-
59, adults in their most productive years [6]. However, also developed Western 
countries continue to report TB cases [10].  
 
2. The high costs of the first line anti-TB drugs to treat TB (like isoniazid, rifampicin, 
pyrazinamide, ethambutol) bar their use especially when multiple first line drugs need 
to be applied to suppress resistance [11-14]. This follow-up is often lacking in several 
affected countries like India [15-17].  
 
3. Emergence of resistance in M.tb. against major first line chemotherapeutic agents has 
hindered the treatment of TB cases. 
 
4. To date, most diagnostic procedures rely largely on immuno-assays that are not 
sufficiently specific. M.tb. shares antigens to many other Mycobacterium species 
resulting in false positive cases in ~35% of patients with active TB [18-20]. Other 
techniques that have been employed like flow cytometry, radiometric detection, latex 
agglutination etc. have their own set of disadvantages which will be discussed in 
detail in the coming sections. 
 
The objective of this study is to present a succinct review of the available biosensing 
techniques that are either already in use or under development in detection of TB. The focus 
of the review will be on emerging biosensor-approaches that are compared to conventional 
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techniques. Special attention will be given to their potential for deployment under field 
conditions in resource poor countries. 
 
2.1.2 Epidemiology 
 
The WHO Global TB Control Report 2012 reported that the WHO’s Millennium 
Development Goal to halt the growth of the TB epidemic by 2015 is showing some success 
with a decrease of 2.2% observed between 2010 and 2011 for new TB cases, along with a 
41% mortality rate decreases relative to 1990. Between 1995 and 2011, 51 million people 
were successfully treated for TB, saving 20 million lives. Despite this progress, the global 
burden of TB remains enormous with 8.7 million new cases of TB were registered in 2011, 
out of which 13% patients were co-infected with HIV. The mortality in 2011 due to TB was 
1.4 million, including almost one million deaths among HIV-negative individuals and 0.4 
million among people who were HIV-positive. The distribution of TB cases also shows a 
gender-dependence with men reporting more cases compared to females in all age groups and 
from every geographical region of the world. India and China together account for 40% 
whereas the African region contributes 24% of the world’s TB cases. The statistics of the 
MDR cases in TB are alarming according to the WHO 2012 report. It reported resistance to 
more than one first line anti-TB drugs among 3.7% of new cases and 20% previously treated 
cases. In recognition of the problem, 26 nations have already listed MDR-TB as a top priority 
health programme and founded a global fund to support Directly Observed Therapy (DOT) to 
ensure the effectiveness of given medications [21-23].  
 
2.1.3   Current TB diagnostics 
 
2.1.3.1 Immunological and microbiological tests 
 
For the diagnosis of TB, five conventional tests are available:  
 
1) Smear Microscopy: microscopy based smear tests are rapid, inexpensive, simple and 
relatively easy to perform methods for the detection of acid-fast bacterium such as M.tb. 
bacterium. Conventionally the Ziehl-Neelsen staining is utilized requiring a minimum of 
1 × 104 bacterium per ml of sputum [24]. Fluorescence microscopy utilizing auramine-
rhodamine staining was found to be more sensitive though expensive, as it requires a 
fluorescence microscope [25]. The fluorescence-based method is more sensitive as slides 
can be examined at lower magnification [24]. Results from this method can be obtained 
within an hour. 
 
2) Immunological assays like Latex Agglutination, ELISA, and Mantoux tests: in these tests, 
typically the binding of antibodies in serum to M.tb. antigens is tested [26, 27]. For 
example, in latex agglutination tests, the polystyrene (latex) beads are functionalized with 
antigens extracted from a pathogenic Mycobacterium that are then reacted with serum 
samples [28]. In case of a reaction, the latex beads coagulate showing a positive test. The 
sensitivity of these tests are not high enough [29]. Hence, when the bacterial load is low, 
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these tests will fail. Also, the serum could contain antibodies (due to vaccinations like 
Bacille-Calmette–Guérin/BCG) that might interfere with the tests adding further to the 
shortfalls of these assays. 
 
3) Radiometric detection test: in this type of test, the metabolic activity of M.tb. is detected  
radiologically [30]. For example, M.tb. (and also some other mycobacteria) are known to 
produce CO2 from carbon sources like glycerol or acetate. The important selective 
criterium is that M.tb. cannot form CO2 from glucose. This helps to differentiate M.tb. 
from other Mycobacterium sp. and bacteria. Utilizing this selective property, the 
capability of M.tb. in producing 14CO2 from 14C-U-glycerol or 14C-U-acetate, but not 
from 14C-U-glucose is measured. Due to the technical complexity this technique is not 
suitable for developing countries. 
 
4) Flow cytometry test: In the last few years, use of flow cytometry has increased rapidly in  
the detection of TB cases [31-33]. This technique is based on the ability of viable M.tb. 
bacterium to absorb fluorescein diacetate (FDA) and to hydrolyse it into fluorescein, 
which upon accumulation in metabolically active bacterium could successfully be 
detected by flow cytometry. The reproducibility is high and it does not require active cell 
division of mycobacteria [34, 35]. The technique, however, needs logistic support from a 
specialized laboratory that makes it difficult to implement in developing countries [36].   
 
5) Cultivation detection tests (like MB/Bact, Bactec MGIT 960 systems): In these 
techniques, biological samples are selectively cultured on solid media to detect and 
quantify the presence of M.tb. [37-40]. Although quite accurate, this technique is time 
consuming, as it requires a growth period of 9-42 days. It also requires a laboratory back-
up which complicates applications under field conditions in developing countries [40]. 
2.1.3.2 Genotypic tests 
 
DNA-based techniques are becoming increasingly important, especially for the 
detection of resistant strains of M.tb. They need a laboratory setting, however, so that for 
field use they do not yet represent a suitable method. The most popular techniques are the 
following:  
 
1) Polymerase chain reaction (PCR)-based techniques: PCR is one of the most sensitive 
methods to detect the presence of M.tb. strains, also sequencing of PCR amplified DNA 
fragments is the most direct technique of detecting codons responsible for resistance in 
M.tb. [41-43]. PCR amplified DNA fragments are generally analysed by the following 
two methods: 
 
a) Electrophoresis: This method mainly relies on the difference in electrophoretic mobility 
of mutated DNA fragments of M.tb. especially of resistant strains. By electrophoretic 
techniques, PCR amplified DNA can be compared with the electrophoretic mobility of a 
wildtype/reference M.tb. DNA, and thus caution for any resistance [44]. A heteroduplex 
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analysis method has also been developed in recent years where strands with a single-base 
mismatch can easily be identified and separated utilizing conformation-sensitive gel 
electrophoresis from the strands containing no mismatches [45, 46].  
 
b) Hybridization-based techniques: This type of technique relies on the hybridization of 
clinical DNA with complementary DNA and the binding is then compared with the 
results of wild/reference M.tb. DNA [47, 48]. In case the complementary strand is 
sufficiently homologous, the binding of clinical DNA can be detected using ELISA 
readers. The hybridization can be done user-friendly on strips, microtiterplates as well as 
microarrays. 
 
c) Real-time PCR: with the help of fluorescently labelled DNA strands, it is possible to 
visualize the increase of the product in “real time” [49-51]. Different types of fluorescent 
labels have been applied in a diverse range of real-time PCR techniques, like TaqMan 
probes [50, 52, 53], Beacons [54, 55] and FRET probes [56, 57]. 
The main disadvantages of PCR-based tests are the relatively high costs of equipment and 
reagents. It also requires highly skilled personnel along with dedicated pre- and post- PCR 
rooms to avoid contamination. Even if it were less expensive, the technological and sample 
preparation complexities make it largely inappropriate for use in resource poor settings. 
 
2.2 Biosensors in TB detection 
 
Considering the fact that 98% of all TB cases occur in areas of developing countries 
without access to specialized laboratories, there is a strong need to develop alternative, 
simpler and lower cost techniques for TB diagnosis. Biosensors are analytical devices that 
transduce biochemical reactions/interactions of isolated enzymes, receptor proteins, 
antibodies, nucleic acids, organelles, whole cells or tissues with specific chemical compounds 
into an optical, thermal or electrical signal, which can be more easily measured and 
quantified. The main advantages of biosensors over conventional diagnostic techniques can 
be stated as follows:  
 
1. Technical advantage: In biosensors often a high level of device and capture/detection 
integration is achieved allowing single step detection. 
 
2. Ease of use: Many of the designed biosensors are tailored with user-friendly interfaces 
connecting them to advanced instrumentation.  
 
3. Quick Response: Response time is typically a few minutes for most biosensors 
enabling rapid and better control over the measurement. 
 
A general framework of different classes of biosensors that could be used for the 
detection of TB is given in Fig. 1 to guide the reader through the upcoming sections of the 
review and will be discussed in more detail within relevant sections. 
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2.2.1 Electrochemical and electrical biosensors 
 
Electrochemical and electrical biosensors are among the most popular biosensors that 
are used today in detection of not only TB but also a large number of other diseases [60-62]. 
The mechanism of detection relies on specific changes in electrical signals (conductance, 
impedance, potential, capacitance) at a surface-functionalized electrode by either chemical 
reactions or physical interactions. For example, monoclonal antibodies rose against M.tb. cell 
wall components can be immobilized onto an electrode surface exposed to a suspension of 
M.tb. and detect the interaction between the M.tb. bacteria and the antibodies by a change of 
conductance [63]. Similarly, an electrode-based DNA biosensor can also be made where 
certain probes that specifically bind to specific regions of M.tb. DNA are immobilized on the 
electrode [62]. For electrodes carbon paste, gold or zirconia (ZrO2-) coated carbon nanotubes 
have been used [60, 62, 64-66]. These sensors are sensitive, flexible and allow a high degree 
of multiplexing, but they also present some disadvantages. Firstly, a constant pH and ion 
concentration of the reaction compartment is very critical, as they directly affect the baseline 
conductance of the electrodes. Secondly, the obtained electrical signal strictly depends on 
many molecular factors, like the positive or negative net charge or neutrality of the analyte 
etc. 
 
 
Figure 1: Generic classification of biosensors tested as TB diagnostics [59, 60] 
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2.2.1.1 Electronic nose-based biosensors 
 
Electronic “nose” type biosensors are designed to recognize volatile substances 
produced by M.tb. in liquid medium (Fig. 2) [67-70]. It basically consists of three main 
building blocks i.e. (i) a volatile gas chamber that passes the volatile molecule products over 
a sensor array, (ii) a pattern of more or less specific responses by the sensor array and (iii) a 
data analysis system to interpret the output pattern of the detection system. In an 
electrochemical transducer based system metal oxide semiconductors (MOS-FETs like ZnO, 
MnO, TiO2, SnO2) or conducting polymers (like polypyrroles, polyanilines) coupled to the 
transducer are used. To obtain reliable signals, the humidity and temperature must be 
regulated well. The principle is based on the observation that M.tb. produces specific volatile 
organic compounds that are significantly different from the volatiles produced by other gram 
positive bacteria, like Mycobacterium avium, Mycobacterium scrofulaceum and 
Pseudomonas aeruginosa [67]. Electronic nose appliances have been used successfully to 
detect the presence of M.tb. [68]. 
 
 
Figure 2: An electronic nose based biosensor consisting of three main parts i.e. a sample 
delivery chamber, a detection array/pattern recognition system and a computing system for 
data analysis and result interpretation. This is fundamentally a sensor assay where a specific 
pattern is produced upon interaction with volatile/gaseous by-products from specific 
bacterial species [71] 
 
2.2.1.2. Nanowire-based biosensors 
 
Biosensors built with nano-sized transducing elements are most prominently 
represented by silicon nanowires that operate as field effect transistors (FETs). A detailed 
discussion on the design of such FET sensors falls beyond the scope of this review. However, 
most commonly, a silicon nanowire with a low p-type doping is connected with a higher 
doped source and drain region, whereas the more heavily doped silicon support wafer is 
designed to serve as a back gate via an intermediate 100 to 500 nm thick silicon oxide layer. 
The backgate voltage controls the nanowire channel resistance and in case of a positive 
voltage (e.g. +2V) a depletion layer is created in the silicon nanowire where the majority 
charge carriers (positively charged holes) are repelled, herewith creating a lower conductance 
(Fig. 3). For measurement, when a drain-source voltage is applied, a drain current (Id) is 
generated between the source and drain regions that can then be measured and plotted against 
time. Any change in the amount of a (charged) target molecule binding to the surface gets 
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reflected in a charge displacement in the wire (attraction or repellence of holes) and results in 
a variation in the Id that can be interpreted against a calibration curve. Usually, silicon 
nanowires [72, 73] or carbon nanotubes [66, 74-76] are used to obtain the properties of 
nanowires. The testing system is often made on a microchip-like set up where the nanotubes 
are fixed along with surface functionalization with antibodies or antigens depending on the 
samples to be used. For example, boron-doped silicon nanowires were used to detect different 
bacterial antigens by the change of conductance after binding [77, 78]. Similarly, carbon 
nanotubes (both single and multi-walled) have been used to detect various antigens [79] 
including M.tb. antigens or ssDNA specific for M.tb. [80]. 
 
The major advantage offered by this category of biosensors is its higher than normal 
sensitivity, because of two main factors i.e. (1) The size of the biological species/analyte to 
be detected is comparable to the size of the nanowire, hence the charge of the incoming 
species can sensitively control the conductivity of the charge carriers in the semiconductor 
material within the Debye length [82], (2) The wire represents a serial circuit where 
interaction at each receptor molecule can control the current flowing through the entire 
nanowire [83]. The chemical nature of silicon and carbon wires and tubes allow a wide scope 
of surface functionalizations, which is an advantage compared to metal electrodes. However, 
the delicate surface functionalization and nature of silicon nanowires, makes it 
technologically much more challenging to actually design and implement these types of 
sensors [84]. 
 
 
Figure 3: A silicon nanowire based biosensor: a change in conductance of an antibody-
functionalized nanowire is measured upon binding of the antigen [81] 
 
2.2.2 Optical biosensors 
 
2.2.2.1 Fibre-optic biosensors 
 
 Light propagating through an optical fibre consists of two components i.e. the light 
propagating through the core of the fibre and the exponentially decaying evanescent field 
outside the core of the fibre (Fig. 4). In case of total internal reflection (TIR), the intensity of 
the reflected light does not decay rapidly as only a very small amount of light passes through 
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the thickness of the tube and hence not able to interact with the fibre's surroundings. The 
decay of the transmitted light (evanescent wave) is exponentially related to the distance 
travelled (d) outside the core and is typically 100 to 200 nm. This rate of decay of the 
evanescent wave can be reduced by decreasing the thickness of the cladding layer (walls) of 
the tube, making the method suitable for sensing applications. In this situation, the evanescent 
wave interacts with the fibre's surrounding causing an energy flow that could activate 
fluorophores bound to the outer surface of the fibre tube. The emitted light from the 
fluorophores can then also be detected using a spectrophotometer. These sensors can be 
tailor-made to detect specific pathogens. For example, M.tb. produces niacin which after 
reaction with cyanogen bromide and aniline produces a compound of yellow colour [72]. 
Hence, a M.tb.-rich sputum sample will contain high levels of niacin which after reaction 
with cyanogen bromide and aniline will produce a colour which can be detected by fibre-
optics. Similar types of sensitive fibre-optics-based biosensors for TB detection have also 
been reported elsewhere [85-88]. Multiplexing is required to render such detection platforms 
more reliable. 
 
 
Figure 4. A fibre optics based biosensor where specific binding at the exterior of fibre optic 
waveguide via specific antibodies is measured by determining the change in the angle of 
reflection of the incident light. The system works using the principle of evanescence [89]. 
 
Another interesting class of biosensors with good potential for TB detection is the so-
called optical ring resonance (ORR) detectors. The principles of optical ring resonance are 
complex and fall beyond the scope of this review. In summary, these ORR systems are based 
on total internal reflection and constructive interference [90]. Recently, such ORR detectors 
could be designed on lab-on-a-chip platforms [91, 92] with multiple parallel channels with 
one channel coated with specific antibody (test channel) and others coated with non-specific 
antibodies (reference channel). With binding of the antigens with their specific antibodies, 
there are changes observed in total internal reflection and simultaneous interference patterns 
which are recorded by a CCD camera and compared to the data obtained from reference 
channels. Pending the availability of highly specific antibodies to M.tb. antigens, these ORR 
detectors may be of potential in early detection of TB although the surface functionalization 
has the same challenges as in case of nanowire functionalization, because the core material of 
the fibre is mostly silicon based. 
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2.2.2.2 Surface plasmon resonance (SPR)-based biosensors 
 
Surface plasmon resonance (SPR) is an optical principle frequently used in 
biosensors. Surface plasmons (evanescent waves) are produced when a polarized light is 
incident at the back of a thin film of noble metals like gold and silver. The angle of reflection 
changes depending on mass bound to the surface on the other side. The other side of these 
noble metals are therefore coated with bio-recognition elements or receptor molecules that 
interact with an analyte molecule present in a liquid sample. A light wave can excite surface 
plasmons at metal-dielectric interface only when the component of the light wave vector 
parallel to the interface matches with that of the surface plasmon. For this, the light wave 
vector needs to be enhanced so that it matches the surface plasmons, as the real part of the 
propagation constant is always larger than that provided by the light wave vector in the 
dielectric. Usually attenuated total reflection methods with a prism are employed for 
excitation of the surface plasmons. A light wave passing through an optical prism is allowed 
to fall on the metal film of about 50 nm thick at an angle of incidence that is larger than the 
critical angle for the prism-dielectric system. Now this light is totally reflected producing 
evanescent waves propagating along the metal film. A portion of the light energy is 
transferred into energy of these surface plasmons and is dissipated in the metal field resulting 
in a drop of intensity of reflected light. The coupling conditions can be fulfilled for multiple 
combinations of angle of reflection and the wavelength. Therefore, a characteristic dip 
associated with the excitation of surface plasmons can be observed both in angular and 
spectral domains. The instrumentation of SPR consists of a convergent monochromatic beam 
source directed onto the prism coupler, over which the sample containing the metal layer 
modified with receptor molecule is passed (Fig. 5). 
 
 
Figure 5. A surface plasmon resonance based biosensor. In this type of biosensor, a thin gold 
plate is functionalized with antibodies that upon binding to the antigen cause a change in the 
angle of reflection of the polarised light incident at the other side of the gold film [93] 
 
Chapter 2  
 26 
2.2.2.3 Breathalyzer biosensors 
 
Breathalyzer sensors have specifically been developed to diagnose pulmonary TB in 
patients. Typically, in these types of sensors the patients are asked to cough in a masked bag-
like structure containing a collection tube (usually 10 cm in length and 3.5 cm in width) after 
administration of a nebulized dose of saline [104,105]. The samples thus collected are 
distributed across the surface of a coated prism at the bottom of the glass tube. This prism 
surface is coated with a M.tb. specific antibody and fluorescent peptide epitopes [104]. The 
peptide analogue comprises artificially modified peptide sub-sequences of the T-cell epitope 
from M.Tb Ag85B [106]. The antibody has a higher affinity for TB bacterium compared to 
the fluorescent peptide analogues, which enables a competition assay on such platforms 
[104]. In the presence of TB bacterium, the fluorescent-coated analogues are displaced by TB 
bacterium and this biochemical process is interrogated by the diode laser of the measuring 
device. The sensitivity of the system for detection of M.Tb cells was 50-75 CFU/ml [104]. 
The biosensors are portable, rapid and sensitive encouraging their use in outdoor clinics in 
the developing World. The collection tube is cheap and easy to dispose after one use per 
patient [104].   
 
2.2.3 Mechanical Biosensors 
 
2.2.3.1 Piezoelectric quartz crystal biosensor 
 
 Piezoelectric quartz crystal biosensors are based on the Sauerbray equation (∆F= -2.3 
X 106F2∆M/A, where ∆F is change in frequency, F is resonant frequency, ∆M is change in 
deposited mass and A is area of electrode), which shows that change in frequency of the 
crystal is directly related to the change in deposited mass over the electrodes. Due to this 
unique resonant frequency property of quartz crystals, any changes in resonating mass by the 
binding of specific biomolecules or microbes and bacteria like M.tb. can be sensitively 
detected (Fig. 6) [107-109]. Piezoelectric biosensors of three types have been described: 
quartz crystal microbalance (QCM), multi-channel series piezoelectric quartz crystal sensor 
(MSPQC) and acoustic wave biosensor. 
 
2.2.3.1.1. Quartz crystal Microbalance (QCM) 
 
In QCM systems applied to TB, the crystal electrode was first coated with protein A 
followed by binding of an anti-TB-cells antibody (rabbit IgG against M.tb.) and then 
incubated with weakened TB cells. Binding of M.tb. cells on the crystal electrodes was 
monitored in real time and the frequency shift was calculated. The sensitivity using this 
system was 105 CFU/ml [110]. The main advantage of QCM lies in the fact that it is fast, 
reusable (after washing), label-free, requires minimal sample preparation and is easily 
operated. The major disadvantage lies in the fact that the density, temperature, viscosity and 
electrical conductivity of the sample may affect the results and require calibration correction 
and that it is relatively insensitive. 
 Biosensor-based detection of tuberculosis 
 
27 
 
Figure 6.  A piezoelectric quartz crystal based biosensor where the change in resonating 
frequency of a piezoelectric crystal is measured. The resonance frequency of the crystal 
shows a change after binding of antigens with specific antibodies immobilised on the crystal 
[110] 
2.2.3.1.2. Multi-channel series piezoelectric quartz crystal sensor (MSPQC) 
 
In the MSPQC system, there are eight sample detectors along with a microprocessor 
and a data output system. The system relies on detection of volatiles produced by the growth 
of M.tb. such as NH3 and CO2. These volatiles cause an impedance change when they are 
absorbed by a KOH absorbing solution, which in turn will change the oscillating frequency. 
The limit of detection with this system is 107 CFU/ml at the time of detection [111]. Apart 
from being time consuming involving a laborious M.tb. culture process (eight days in case of 
a low M.tb. burden), another major drawback of this system is the sample pre-treatment 
required to remove contamination with other bacteria. 
 
2.2.3.1.3. Acoustic wave biosensor 
 
Acoustic wave biosensors rely upon acoustic waves propagating near the surface of a 
piezoelectric crystal. The sensor electrically produces a mechanical wave that is sensitive to 
any change or binding at the piezoelectric crystal and then transduces the mechanical output 
waves back into an electrical signal, which is compared with the input electrical signal for 
changes in amplitude, phase, and frequency [112]. In one application apart from the acoustic 
signal also the conductivity change (impedance) of the medium over the crystal was 
measured. Here the conductivity change due to growth of M.tb. cells and by-product 
production was studied [113, 114]. The limit of detection with this bulk acoustic wave 
impedance biosensor was 2×103 CFU/ml. The disadvantage of the system is the time 
consuming and laborious M.tb. culture process that reduced the applicability for field uses. 
 
2.2.3.2 Magnetoelastic biosensors 
 
Magnetoelastic biosensors possess a magneto-elastic strip, often made up of 
ferromagnetic alloys comprising iron, boron, nickel and molybdenum. Capture molecules 
(like antibodies) that can bind target molecules, microbes or viruses are immobilized on the 
strip (Fig. 7) [115-117]. Exposure of the magnetoelastic strip to a varying external magnetic 
field causes the magnetoelastic strip to resonate at a specific (fundamental) frequency. The 
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fundamental resonant frequency for longitudinal vibration of a thin ribbon like strip vibrating 
in its basal plane is given by the equation 
 f =  � E
ρ(1 − σ2)2L 
 
where E denotes modulus of elasticity, σ is the Poisson's ratio, ρ is the mass density of the 
sensor material, and L is the longitudinal dimension of the sensor. The change in resonant 
frequency also depends on mass change when the initial mass, temperature and humidity are 
constant and is given by the equation. 
 
∆𝑓 =  −  𝑓2 �∆𝑚𝑀 � 
 
where f is the initial resonance frequency, M is the initial mass, ∆m is the mass change, and 
∆f is the shift in the resonant frequency of the sensor [118]. It is due to this dependence on 
mass change, that upon binding of antigens or M.tb. bacteria to the antibody, there is a shift in 
fundamental resonant frequency, which is often monitored wirelessly on a frequency counter. 
 
 
Figure 7: A magnetoelastic biosensor where the change in basal resonating frequency of a 
magnetoelastic strip as a result of binding of antigens with specific antibodies under varying 
magnetic fields is measured in order to detect analyte [119] 
 
The advantages of these types of sensors over SPR-based sensors are their ease of use 
as the sensors are (i) freely hanging inside a sample solution, (ii) do not require complicated 
integration with microfluidics pumps and (iii) do not produce a complex signal. The 
fundamental resonating frequency of the strip immersed in liquid (culture media) can also be 
altered due to the consumption of nutrients. M.tb.in the liquid media, upon proliferation 
decomposes macromolecule into by products (such as ammonia, carbon dioxide, organic 
acid) thereby causing a change in the physical properties of the culture that can then be 
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detected with the help of such biosensors. A suitable calibration curve must be made to detect 
a specific M.tb. signature [117]. The sensor resonant frequency shift upon immersion in 
liquid is given by the equation 
 
𝑓 =  −  �𝜋𝑓𝑜2𝜋𝜌𝑠𝑑 (ηρ𝑙)1 2�  
 
where f0 is the resonant frequency of the sensor in air, ρs and d are the density and thickness 
of the sensor, η and ρl are the density and viscosity of the liquid, respectively. Under liquid 
medium, the shear wave created due to the sensor vibration reduces the oscillation of the 
sensor. The detection limit of this biosensor can be as low as 104 M.tb. cells/ml [117]. 
 
2.2.4 Magnetic Biosensors 
 
2.2.4.1 Diagnostic Magnetic Resonance (DMR) 
 
         DMR system is an automated, high-throughput miniaturized lab-on-a-chip scale 
adaptation of conventional nuclear magnetic resonance (NMR). Its principle is based on 
detection of changes in the spin relaxation time of surrounding water molecules i.e. when 
antibodies coated on mono-dispersed nanoparticle binds to target (M.tb. cells) forming a 
cluster or aggregate and thus becomes more efficient in dephasing the nuclear spin of 
surrounding water molecules, thereby causing a decrease in spin-spin relaxation time. It 
consists of four miniaturized modules i.e. a microcoil array for applying the magnetic field, a 
small permanent magnet, feedback based read out electronics for temperature compensation 
and a microfluidic network for automated sample injection [120, 121]. Capture antibody 
functionalized magnetic nanoparticles are used which can specifically detect the 
mycobacterium cells. By virtue of its operating principle, highly sensitive (20 CFU/ml) 
magnetic measurements can be done on easier to handle turbid and unprocessed sputum 
samples without pre-treatment or false positives as biological samples show virtually no 
magnetic background [122, 123]. The decreased assay time, small sample volumes, 
versatility and multiplicity make it suitable for point of care diagnostics. The low cost of the 
setup and disposable chip could be an advantage for use in remote clinics and hospitals in the 
developing world. In 2013, the DMR was further miniaturized for very small volume sample 
detection (2 ml) and rapid, high throughput operations in point of care settings [124]. This 
approach has been used to analyse varied bacterial mixtures with specific probes. Another 
improvement is the amplification of 16S rRNA from total RNA extracted from whole 
bacterial cells by asymmetric RT-PCR. Single-strand DNA ampliﬁed from 16S rRNA is then 
captured by magnetic beads conjugated with capture probe. After which hybridization with 
magnetic NPs (MNPs) coated with detection probe is done to form a magnetic sandwich 
complex detectable using µNMR system. Though the magneto-genetic assay has not been 
utilized yet for tuberculosis detection, it has a strong potential to be applied for clinical and 
point of care settings [124].  
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2.2.4.2 Magnetic barcode platform 
 
            A novel platform for the detection of nucleic acids is based on a magnetic bar coding 
strategy. PCR-amplified mycobacterial genes can be sequence-specifically captured on 
microspheres, labelled by magnetic nanoprobes and detected by nuclear magnetic resonance. 
This significant improvement of µNMR in terms of size and design has resulted in glass slide 
sized magnetic barcode platform detection. The sample volume to be analysed passes through 
a microfluidics channel enclosed by an electromagnetic coil. This sensing component 
eliminates the use of permanent magnets [125]. The coil functions as a sensing element 
where a shift in relaxation time is measured using a feedback of the readout electronics [120, 
121]. The platform also integrates lab on a chip PCR for assay optimization. For TB detection 
the total RNA is extracted from the tuberculosis cells and the 16S rRNA is amplified by 
asymmetric Real Time-PCR to single-strand DNA which is then immobilised on conjugated 
beads, followed by hybridizing with magnetic nanoparticles (MNPs) and coated with a 
detection probe to form a magnetic sandwich complex. The complex thus formed is allowed 
to pass through microfluidic channels, where it is detected [125]. In an example using 92-nt 
fadE15 amplicons, they showed that magnetic bar coding assays had a strong magnetic signal 
within 1 min of labelling at 37ºC. The costs of the device can potentially be scaled down to 
<$200 in contrast with existing diagnosis instruments that cost over $10,000 [125].  
 
2.3 Challenges and outlook 
 
            TB remains one of the major unresolved global health problems, especially in the 
developing parts of the world, predominantly due to the complexity of a proper and economic 
affordable diagnosis and treatment in time along with recently arising issues like multiple 
drug resistance and other allied infections that decrease body immunity, like HIV. Current 
technologies for diagnosis are either too insensitive, too laboratory intensive or utilize 
expensive detection modules, which are all a challenge in resource poor settings. An 
overview comparing the analyzed sample and detection limits of different biosensors are 
shown in Table 1. With WHO’s aim to completely eliminate TB by 2050, development of 
techniques for early and accurate detection of tuberculosis is crucial. To build an effective 
biosensor for TB detection, criteria that need to be fulfilled are: (1) cost-effectiveness (2) 
high sensitivity (3) reliability (no false positives) (4) portability and (5) disposability. 
Unfortunately, designing a biosensor with all these advantages has not yet been completely 
successful, as each attempt has specific drawbacks. It is a challenge to satisfy all these needs 
in a single biosensing device. Nevertheless, the advances in nanosensors and other upcoming 
technologies reviewed here, suggest that biosensors to detect TB can be expected to play a 
larger role in the near future. Such platforms will also need to solve issues around sample 
collection and preparation. Currently most diagnosis techniques available utilize sputum 
samples as test sample, which due to its high viscosity and sticky nature is very difficult to 
work with. Hence other sources like blood or urine should also be considered as test samples. 
Lack of reliable and tested biomarkers in those samples is, however, an issue that needs 
attention. 
 Biosensor-based detection of tuberculosis 
 
31 
 
Table 1: Comparison of different biosensors for M.tb. detection 
# Transducer Sensing 
technique 
Sample 
analysed 
Detection 
limit 
References 
2.1 Electrochemical Electronic Nose 
Sensor 
M.tb.  produced 
volatiles 
compounds 
N.A. Pavlou et.al. 
[67] 
Nanowire/nanot
ube based 
biosensor 
M.tb specific 
ssDNA 
N.A. Das et.al. 
[80] 
2.2 Optical Fibre-optics M.tb. produced 
organic 
compounds 
N.A. Lee et.al. 
[72] 
SPR CFP 10 M.tb. 
antigen or 
Protein complex 
100 ng/ml 
 
30 ng/μl 
Hong et.al. 
[102] 
Duman et.al. 
[97] 
Breathalyzer M.tb. cells 50-75 CFU/ml McNerney 
et.al. [104] 
2.3 Mechanical QCM M.tb. cells 105cells/ml He et.al. 
[108] 
MSQC Volatiles 
produced by the 
growth of M.tb. 
such as NH3 and 
CO2 
 
107 CFU/ml 
 
Ren et.al. 
[111] 
Acoustic Wave M.tb. cells 2×103 CFU/ml He et.al. 
[114] 
Magnetoelastic M.tb. cells by-
products 
10,000 cells/ml Pang et.al. 
[117] 
2.4 Magnetic DMR M.tb. cells 20 CFU/ml Lee et.al. 
[123,126] 
Magnetic 
Barcode 
RNA from M.tb. 
cells 
100 CFU/ml Liong et.al. 
[125] 
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Abstract 
 
The 16 kDa heat shock protein (HSP) is an immuno-dominant antigen, used in 
diagnosis of infectious Mycobacterium tuberculosis (M.tb.) causing tuberculosis (TB). Its use 
in serum-based diagnostics is limited, but for the direct identification of M.tb. bacteria in 
sputum or cultures it may represent a useful tool. Recently, a broad set of twelve 16 kDa 
specific heavy chain llama antibodies (VHH) has been isolated, and their utility for diagnostic 
applications was explored. To identify the epitopes recognized by the nine (randomly 
selected from a set of twelve 16 kDa specific VHH antibodies), distinct VHH antibodies 14 
overlapping linear epitopes (each 20 amino acid long) were characterized using direct and 
sandwich ELISA techniques. Eight out of 9 VHH antibodies recognized 7 out of 14 epitopes. 
The two highest affinity binders B-F10 and A-23 were found to bind distinct epitopes. 
Sandwich ELISA and SPR experiments showed that only B-F10 was suitable as secondary 
antibody with both B-F10 and A-23 as anchoring antibodies. To explain this behaviour, the 
epitopes were matched to the putative 3D structure model. Electrospray ionization time-of-
flight mass spectrometry and size exclusion chromatography were used to determine the 
higher order conformation. A homodimer model best explained the differential 
immunological reactivity of A-23 and B-F10 against heat-treated M.tb. lysates. The 
concentrations of secreted antigens of M.tb. in sputum are too low for immunological 
detection and existing kits are only used for identifying M.tb. in cultures. Here we describe 
how specific combinations of VHH domains could be used to detect the intracellular HSP 
antigen. Linked to methods of pre-concentrating M.tb. cells prior to lysis, HSP detection may 
enable the development of protein-based diagnostics of sputum samples and earlier diagnosis 
of diseases. 
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3.1 Introduction 
 
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb.), is one of the most 
prevalent and serious infectious diseases worldwide [1]. Each year ~9.4 million new cases are 
reported with an estimated global mortality in 2010 of 1.4 million people [2]. With problems 
like multiple drug resistance (MDR), treatment of diagnosed TB cases is becoming more and 
more difficult and challenging [3]. TB cases are often intensified due to malnutrition and 
other allied infections that decrease body immunity, like HIV, especially in the developing 
parts of the world [4, 5]. Early detection of TB guarantees fast treatment and can offer much 
better prognosis. Therefore, development of techniques for early and accurate detection is 
called for [6, 7].  
 
There are many different types of diagnostic assays available for detection of 
tuberculosis. Bacterial cultures are sensitive, but too time consuming, taking 2-3 weeks for 
detection under optimal conditions [8]. Microscopic identification of acid-fast bacilli in 
sputum smears is a fast technique but less sensitive then culture techniques, laboratory 
intensive and dependent on high concentrations of bacteria [8]. Nucleic acid amplification 
methods are fast, highly specific and sensitive, but they are technically complex, expensive 
and require skilled personnel with high quality standards for accurate performance [9]. Other 
immunological methods tend to detect secreted antigen protein from M.tb. Sensitivity and 
specificity of these methods is also too low to detect the antigens in sputum. As a result they 
are mainly used on cultures that take a long time to grow, i.e. around 2-6 weeks [9-12].   
 
TB is most prevalent in poor, remote areas of the world, where reliable DNA-based 
diagnostic procedures that need costly, advanced laboratory infrastructure and personnel are 
not available. This contrasts with antibody-dependent assays that are more easily 
implemented. The development of better target antigens are, therefore, a high priority, 
especially if they are less subject to generating false positives [13, 14] from cross reactivity 
with similar antigens of non-pathogenic Mycobacterium sp.  
 
Monoclonal VHH antibodies have recently gained considerable attention due to their 
unique physico-chemical stability [15] as well as low molecular weight of ~15 kDa. 
Considering the limitations of existing diagnostics of TB, VHH antibodies can be utilized as 
tools for improvement of the existing immunological tests in detection of TB. They are 3-4 
times smaller (4 nm) in volume than conventional antibodies due to lack of light chains and 
removal of conserved domains. Furthermore, they can be produced at low cost in yeast or 
bacteria, and are easy to handle with long shelf life [16, 17]. 
 
Previously, we described the selection and preliminary characterization of a panel of 
12 VHH antibodies against M.tb. [18]. Using ELISA and SPR techniques it was demonstrated 
that these VHH antibodies were specific for TB-causing mycobacteria and exclusively 
recognized the 16 kDa heat shock protein (HSP) [18], which is known to be a major 
contributor to the pathogenicity of the M.tb. bacterium [19]. During latent phase, M.tb. 
persists inside macrophages due to the presence of the 16 kDa HSP protein, and it is also the 
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most dominant protein in the extract of M.tb. [20]. The best VHH antibody showed a high 
affinity for HSP, with a dissociation constant (Kd) of 4 × 10-10 M [18]. HSP is a cell-internal 
protein, which is peripherally associated with the membrane [21]. For diagnostics purposes, it 
can be isolated in higher concentrations than secreted proteins by pre-concentrating the 
bacteria [18]. 
 
The main objective of this study was to characterize the binding of M.tb. HSP 
epitopes, protein and lysates to different VHH antibodies and to evaluate optimal capture-
detection probe combinations. The information can be used to develop low cost, robust 
protein-based diagnostic platforms for TB based on these antibodies. 
 
3.2 Materials and methods 
 
3.2.1 HSP peptides and proteins and VHH proteins 
 
Fourteen overlapping linear peptide epitopes (20 amino acid in length and with a 10 
amino acid overlap; numbered 1-14, Fig. 1) covering the entire HSP sequence (Fig. S1) [22, 
23], each covalently linked at the C-terminal with either an amide  (-NH-R) group or biotin 
residue for direct and sandwich ELISA studies, were synthesized (Peptide 2.0 inc.). The 
synthesized peptides were purified by HPLC and their sequences were verified by mass 
spectrometry by the supplying company (Peptide 2.0 inc.). Two forms of VHH antibodies 
were used in this study, i.e. biotinylated VHH (VHH-AVI) and VHH with VSV tag (VHH-
VSV). The production and purification of these different VHH antibodies were done as 
described before [18, 24]. 
 
 
Figure 1. Summary of affinity interactions of 14 overlapping peptides derived from the HSP 
protein with 9 different anti-HSP VHH antibodies. VHH numbering is according to Trilling 
et al. 2011[18]. VHHs are indicated above the central portions of the interacting peptides 
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The four forms of HSP used in the present work were: 
1. Recombinant HSP with AVI and HIS tag (rHSP-tag), produced and purified 
recombinant from E. coli strain BL21 as described before [18]. 
 
2. Recombinant native HSP (rHSP) lysate, produced by PCR-amplifying the HSP from 
M.tb. lysate using the primer HSP16.3-PstI-F (5′-
AAAAAAACTGCAGAAAATGGCCACCACC CTTCCC-3′) and HSP16.3-NotI-
no.tag-RV(5’-TATATGCGGCCGCTTAGTTGGTGGACC GGTCTGA-3’) (PstI and 
NotI restriction sites are underlined). The digested fragment was inserted in a PstI-
NotI cut PRI expression vector. This vector is based on the earlier described PRI-VSV 
expression vector [18]. The construct was transformed into E. coli XL-1 blue for 
multiplication. The cloned HSP sequence is identical to GenBank accession number 
S79751. Isolated plasmid DNA was transformed into E. coli strain BL21-AI for 
expression. Expression was performed as described before [18] and French press lysis 
was performed in native extraction buffer (150 mM NaCl, 5mM imidazole, 20µl 
DNase, 50mM KH2PO4 at pH 8) supplemented with 1mM PMSF and 2 µg/ml 
aprotinin and 1 mg/ml lysozyme to final concentration. 
 
3. Heated recombinant native HSP (heated-rHSP) lysate, production and expression of 
heated-rHSP was as described for rHSP. The only difference between the two samples 
was that, in case of heated-rHSP the cell pellet was heated for 30 min. at 80ºC before 
French press.  
 
4. HSP from Mycobacterium tuberculosis (M.tb.-HSP) lysate, produced and lysed as 
described before including a heat treatment as in 3 [18]. 
 
3.2.2 ELISA-based epitope mapping of HSP 
 
3.2.2.1 Direct ELISA  
 
I. Linear epitopes as capture species: Flat-bottom medium binding ELISA plates 
(Greiner Bio One) were coated via physical adsorption with 100 µl of each peptide at 
a concentration of 10-4 M in phosphate buffer saline (PBS) by incubating overnight at 
4°C. Once these antigen-peptide coated wells were prepared, a standard ELISA 
method was followed as described by Trilling et al. [18] to determine the interacting 
epitopes of the 9 different VHH antibodies A-23, A-44, A-50, A-89, B-A1, B-B12, B-
D8, B-F9  and B-F10. 
 
II. VHH antibody as capture species: ELISA plate wells (GreinerBioOne) were coated 
via physical adsorption with VHH antibodies (either A-23 or B-F10) as a capture 
element by incubating 100 µl of each antibody in PBS at a concentration of 2 µg/ml 
and incubated overnight at 4°C. These antibody-coated wells were washed with PBS 
and blocked using a blocking solution of 4% non-fat powdered (w/v) milk in PBS 
(PBSM) for an h. Later a mixture of 100 µl of each biotinylated peptide in PBS at a 
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concentration of 10-4 M was added and allowed to interact for an h. After incubating 
with antigen peptides, the wells were washed again with a solution of 200 µl of 0.05% 
TWEEN-20 in PBS (PBST). The wells were then subjected to streptavidin POD 
conjugate (Sigma Aldrich, USA) for an h at a dilution of 1:4000 in PBSM. Successive 
washing steps and measurements were done as described above. This procedure was 
applied to 6 different peptides (i.e. #1, #3, #5, #6, #9 and #11), which were selected 
on the basis of their response to VHH antibodies A-23, B-F10, A-44 and A-50. 
 
3.2.2.2 Sandwich ELISA 
 
Wells of ELISA plates were coated with VHH antibody A-23-AVI as capture element 
by incubating 100 µl of antibody in PBS at a concentration of 2 µg/ml and incubated 
overnight at 4°C, followed by an h of blocking with PBSM at room temperature. Wells were 
then washed thrice with PBS solution followed by an hour of incubation with either rHSP-tag 
or M.tb.-HSP lysates, as described above. Plates were then blocked again for 1 h with PBSM 
and washed three times with PBST. Then, the wells were incubated for an h with the 
secondary sandwich VHH antibody A-23 or B-F10 with VSV tag, followed by three times 
washing with PBST and incubation for an h with the detection antibody i.e. anti-VSV-HRP 
(Sigma Aldrich, Missouri, USA) before assay with 1-StepTM Ultra TMB substrate for 
ELISA (Pierce, IL).  
 
3.2.3 Size exclusion chromatography of HSP 
 
For calibration of the column (Superdex 200 10/300 GL with length of 30 cm and 
diameter of 10 mm, GE life sciences), a mixture of known standards, i.e. Blue Dextran 2000, 
Ferritin, Catalase, Aldolase, Albumin, Ovalbumin, Chymotrypsinogen A and Ribonuclease A 
were first injected to obtain a calibration table (Supporting Information, Table S1, Fig. S2). 
Once the column was calibrated, 250 µl of each HSP sample i.e. either rHSP-tag, rHSP, 
heated-rHSP with a concentration of 750 µg/ml or M.tb.-HSP lysates with concentration 450 
µg/ml were loaded on to the column (at a flow of 0.75 ml/min, using PBS as running buffer). 
Fractions of 1 ml each were collected for further analysis. Diluted samples obtained from 
individual fractions were concentrated using the Amicon® Ultra centrifugal spin columns 
(Millipore Ireland Ltd. Ireland) with a cut off 10 kDa following the protocol supplied by the 
supplier. The concentrated fractions thus obtained were analyzed on dot blot. For dot blot, 
100 µl of concentrated fractions were blotted in a circular spot with the help of SRC 96D 
S&S Minifold 1 dot blotter (Schleicher & Schuell, Germany) on nitrocellulose membrane 
(Trans-Blot, Bio-Rad, Hercules, CA) at room temperature. The membrane was then blocked 
with PBSM to avoid unspecific binding, washed with PBS and incubated with VHH antibody 
B-F10-VSV. A blocking step followed by washing and re-incubation of the membrane with 
anti-VSV-HRP antibody. Detection was done using 3,3,5,5′-Tetramethylbenzidine (TMB) 
liquid substrate system for membranes (Sigma-Aldrich, The Netherlands), by incubating the 
membrane for 10 min in the dark with TMB and then washing the substrate off with milliQ 
water and scanning the bands using a desktop scanner (Biorad GS-710). 
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3.2.4 Electrospray ionization time-of-flight mass spectrometry 
 
Electrospray ionization time-of-flight mass spectrometry (ESI-TOF-MS) is a native 
mass spectrometry method, which is used to identify oligomerization of non-covalently 
associated protein oligomers [25, 26]. The method utilizes the soft ionization technique of 
nanoelectrospray ionization (nESI) to produce gas-phase ions, avoiding structural destruction 
of thermally labile large supramolecules, such as proteins and non-covalent protein 
complexes [27, 28]. The rHSP-tag sample was analyzed using nESI-TOF-MS to deduce the 
oligomerization after urea-based isolation. A small fraction of 20 µl of the sample was also 
retained for samples qualitative analysis on denaturing PAGE gel. The sample was first 
buffer-exchanged from PBS pH 7.4 to 150 mM ammonium acetate pH 9.0 using 5 kDa 
molecular weight cut off filter (Vivaspin 500, Sartorius Stedim Biotech GmbH, Goettingen, 
Germany). The protein was sprayed at a concentration of 20 μM on an ESI-TOF mass 
spectrometer (LCT, Waters, Manchester, UK) using gold-coated borosilicate capillaries made 
in-house (using a Sutter P-97 puller [Sutter Instruments Co., Novato, CA] and an Edwards 
Scancoat Six sputter-coater [Edwards Laboratories, Milpitas, CA]). Source backing pressure 
was increased to 6 mbar. Capillary voltage and cone voltage were set to 1300 and 200 V 
respectively. Mass calibration was performed using 25 mg/mL Cesium iodide. Data were 
analyzed using MassLynx V4.1 for experimental mass determination.  
 
3.2.5 Epitope mapping using surface plasmon resonance 
 
Surface plasmon resonance (SPR)-based sandwich experiments were performed using 
streptavidin-coated chips (GE Healthcare) in a Biacore 3000 system at 25°C, using HBS-EP 
buffer (pH 7.4, consisting of 10 mM 4-(2-hydroxyethyl) piperazine-1-ethane sulfonic acid, 
150 mM sodium chloride, 3mM ethylenediaminetetra acetic acid, 0.005% v/v surfactant 
polysorbate 20) as running buffer at a constant flow of 10 µl/min. The experimental setup 
was same as described before by Trilling et al. [18]. The chips had four independent channels 
out of which the first channel served as reference surface containing of VHH-M200 [18] that 
does not bind to the HSP (negative control), whereas the second and third channels contained 
VHH antibodies A-23 and B-F10, respectively. The fourth channel however was left 
untreated as a blank control. A total immobilization of 3000 ± 100 RU was achieved with 
every antibody individually, used for anchoring purposes. Once the anchoring VHH 
antibodies were captured, all four channels were connected and subjected collectively to 50µl 
of HSP at a concentration of 4 µg/ml. Binding yield of 2500RU in channel 2 and 3. The chip 
was then subjected to 40 µl of secondary/sandwiching antibody VHH A-23 and the binding 
signals were recorded in terms on RU. The surface was regenerated using 10 μl of 10 mM 
hydrogen chloride solution (HCl). The process was then repeated by injecting HSP, followed 
by secondary/sandwiching VHH antibody B-F10. To verify the reproducibility, the whole 
experiment was repeated thrice. 
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3.3 Results  
 
3.3.1 ELISA- and SPR-based epitope mapping of HSP  
 
To study the region of the HSP protein responsible for interacting with VHH 
antibodies ELISA- and SPR-based epitope mapping techniques with HSP peptide 
overlapping epitopes and HSP intact protein were employed. 
 
3.3.1.1 Epitope mapping using linear peptides in direct ELISA 
 
The interactions of fourteen overlapping linear 20-mer peptides (Fig. 1), based on the 
144 amino acid long HSP, with 9 VHH antibodies were first studied using linear peptides as 
capture species (Fig. 2A, 2C). For each antibody binding peptides were found. Antibody A-
23 bound to peptides #3, #6 and #11, antibody A-50 bound to #1 and #11, whereas B-F10 
bound only to #9 (Fig. 2B).  The summary of interactions of all epitopes with all 9 VHH 
antibodies is given in Table 1. Overall it was found that as many as 7 out of 14 peptides were 
recognized by 8 out of 9 different VHH antibodies as summarized in Fig. 1 and Table 1. 
 
Table 1. Summary of interactions of 14 peptides derived from the HSP protein with 9 
different anti-HSP VHH antibodies [18] 
 
VHH  
Antibody 
Response to different epitopes (#1 to #14) of 16kDa HSP from tuberculosis 
#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 
A-23   X   X     X    
A-44     X      X    
A-50 X          X    
A-89    X       X    
B-A1    X       X    
B-B12               
B-D8   X            
B-F9   X            
B-F10         X      
 
The binding of antibodies can be grouped in three categories. Group 1 consists of 
antibodies binding to three different epitopes (A-23), group 2 those binding to two different 
epitopes (A-44, A-50, A-89 and B-A1), and group 3 those binding to a single epitope (B-D8, 
D-F9 and B-F10). Interestingly, all antibodies positively selected on purified antigen by a 
direct phage display selection procedure (represented here with prefix A) recognized peptide 
#11, whereas most of the ones negatively selected via a depletion strategy (prefix B)  
recognized other epitopes, which may therefore be more selective. To verify that the 
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observed interactions were not artefacts of the peptide immobilization method we also carried 
out a reverse analysis using two VHH antibodies (A-23, B-F10) with the highest binding 
affinity constants as capture species [18]. For this purpose the peptides #1, #3, #5, #6, #9, and 
#11 were biotin-tagged and assayed as in Fig. 2C. The results in Fig. 2D confirmed that A-23 
binds peptides #3 and #11, while binding to epitope #6 was at background level, and not 
conclusive. B-F10 was confirmed to only bind to peptide #9. 
 
Figure 2. Peptides (14 overlapping 20-mers) representing potential epitopes of the HSP 
protein mapped against different VHH antibodies in direct ELISA. Panel A - Scheme applied 
in B; Panel B - Results of direct ELISA with coated peptides; Panel C - Scheme applied in D; 
Panel D - Direct ELISA with VHH antibodies coated to the well 
 
3.3.1.2 Epitope mapping using HSP in sandwich ELISAs and SPR 
measurements 
 
If HSP would behave as a protein monomer then a sandwich ELISA using the same 
VHH for both capture and detection would not result in a signal, whereas the use of two VHH 
recognizing distinct epitopes that do not interfere sterically would yield a signal. To test this - 
sandwich ELISA with rHSP-tag protein captured by A-23-AVI was carried out using the two 
most potent and distinct VHH antibodies B-F10-VSV and A-23-VSV for detection. In Fig. 3, 
it is shown that rHSP-tag and M.tb.-HSP protein when captured by A-23 could be detected by 
both secondary antibodies i.e. A-23 as well as B-F10. The A-23 detection suggested that both 
recombinant HSP and M.tb.-HSP do not behave as monomers. For M.tb.-HSP, the signal was 
lower than for 2 µg/ml recombinant HSP protein, presumably due to the lower concentration 
of the HSP protein in the M.tb.-HSP. At lower concentrations, the VHH antibody B-F10 
yielded 3-4 times higher signals compared to A-23 for both the recombinant HSP protein as 
well as the HSP in M.tb.-HSP. The basis of this difference could be related to the difference 
in binding constants of the VHH antibodies (i.e. B-F10 (Kd = 0.4×10-9 M) is more efficient 
than A-23 (Kd = 2.4×10-9 M)), but also to the reported native higher order (dodecameric, 
[29]) protein structure in relation to the specific epitopes recognized. 
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Figure 3. Comparison of purified recombinant HSP protein with M.tb.-HSP in sandwich 
ELISA assays with antibody A-23 AVI as capture antibody 
 
To disentangle kinetic, conformational and steric effects, further analysis by 
“sandwich-SPR” was carried out. A-23 or B-F10 was used to capture recombinant HSP 
followed by either A-23 or B-F10 as detecting antibody (Fig. 4 and Table 2). With A-23 as 
capture antibody, B-F10 showed much higher binding to HSP (703RU) compared to A-23 
(172RU). This confirmed the peptide study that A-23 and B-F10 bind to distinct epitopes and 
would support a model of a protein monomer. However, with B-F10 as capture antibody, 
again B-F10 showed much higher binding (609RU) compared to A-23 (168RU). This 
contradicted a monomer model for recombinant HSP and called for a more complex 
multimeric model of HSP. 
 
Table 2. SPR assay results showing the observed response units (RU) for rHSP-tag (HSP) 
and the detection antibodies A-23 and B-F10. These responses are interpreted in terms of 
secondary binding efficiencies relative to different models of HSP oligomerization 
# 
Capture/ 
detection 
Antibody 
combinations 
HSP 
(RU) 
Detection 
Antibody 
(RU) 
Observed efficiency 
Monomer 
model 
Dimer 
model 
Trimer 
model 
Dodecamer 
model 
1 A-23 / HSP / A-23 2664 172  
not 
possible 15% 11% 8% 
2 B-F10 / HSP / A-23 2290 168  9% 17% 13% 9% 
3 A-23 / HSP / B-F10 2028 703  40% 82% 61% 45% 
4 B-F10 / HSP / B-F10 2020 609  
not 
possible 71% 53% 39% 
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Figure 4. Plots of “sandwich SPR” showing the binding kinetics of B-F10 or A-23 binding to 
HSP as a secondary antibody in a sandwich assay in which HSP was first captured by A-23 
or B-F10. Four different sandwich variations are shown: A-23-HSP-A-23 or -B-F10 (top 
panel) and B-F10-HSP-A-23 or -B-F10 (lower panel) 
 
3.3.2 Size exclusion chromatography (SEC) to determine the oligomeric 
nature of HSP 
 
In the literature, it is reported that the HSP protein exists either as monomer [30, 31], 
dimer [30, 31], trimer of trimers [31, 32] or dodecamer [29] depending upon the method of 
extraction from Mycobacterium or E. coli. To obtain an indication of the quaternary structure 
of recombinant and native HSP protein after standard isolation procedures, SEC was 
performed on four samples, i.e. (1) purified recombinant HSP with an AVI and HIS tag on 
the C-terminus (rHSP-tag) refolded from urea-dissolved inclusion bodies in E. coli, (2) 
French press generated lysate of native recombinant HSP protein without tags expressed in E. 
coli (rHSP), (3) heat inactivated French press generated lysate of native recombinant HSP 
protein without tags expressed in E. coli (Heated-rHSP), and (4) heat-inactivated M.tb. 
lysates generated by mechanical shear with zirconium beads also containing HSP (M.tb.-
HSP)[18]. In Fig. 5A the elution profiles obtained from each sample are super-imposed. 
rHSP-tag protein has a monomer size of 20.9 kDa due to the two (AVI and HIS) tags . On 
SEC, purified protein separated into two peaks with sizes corresponding to 14 ± 5 and 61 ± 
20 kDa. Unpurified rHSP with HSP as major component also showed two peaks at 301 ± 97 
kDa and 55 ± 18 kDa. After heating heated-rHSP, only the peak at 55 ± 18 kDa remained.  
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Figure 5. SEC for apparent molecular weight determination of HSP. Where figure A shows 
SEC plot of different HSP samples i.e. purified recombinant HSP with tag (rHSP-tag), 
unpurified recombinant native HSP (rHSP), heated unpurified recombinant native HSP 
(heated-rHSP) and M.tb. lysates (M.tb-HSP) while figure B shows the dot blot of interaction 
of 16 kDa protein present in these SEC fractions with antibody B-F10, where lane 4 & 5 
shows fractions of different HSP protein eluting at ~301 kDa, lane 7-9 shows fractions of 
different HSP protein eluting at ~55-61 kDa 
 
Unpurified heated M.tb.-HSP also showed only one peak at 55 ± 18 kDa. The 
presence of HSP protein in samples from these respective fractions was determined using dot 
blot analysis (Fig. 5B). Major peaks (fractions 7-9) eluting at ~55-61 kDa (33% error margin) 
all contained HSP protein reactive to A-23 and B-F10, but peak (fraction 10-11) eluting at 14 
± 5 kDa did not. Native rHSP protein peak (fraction 4-5) eluting at ~301 kDa also contained 
the HSP protein. In case of heated-rHSP the fraction 4-5 eluting at ~301 kDa contained much 
less HSP compared to non-heated rHSP. This shows that French press generated E. coli lysate 
of rHSP which avoids heating, mostly leaves rHSP in higher eluting (301 kDa) conformation 
whereas in the case of heated-rHSP it is mostly found to be eluting at ~55-61 kDa.  This is 
also evidence that indeed M.tb.-HSP, rHSP, heated-rHSP and rHSP-tag behave like 
multimers of different sizes and do not occur as monomers. 
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3.3.3 ESI-TOF-MS to determine oligomeric nature of HSP 
 
ESI-TOF-MS is a highly accurate method to determine the quaternary structure of 
complexes of proteins compared to SEC [33]. A nano electrospray ionization time-of-flight 
(nESI-TOF) analyzer was used for this mass spectrometric analysis of rHSP-tag under native 
conditions. The use of a volatile buffer (ammonium acetate) permitted the retention of non-
covalent interactions in the gas phase, such that accurate masses of protein complexes could 
be obtained. The sample of rHSP-tag that was analyzed is shown on an SDS PAGE gel (inset 
Fig. 6).  
 
Figure 6. Native ESI-TOF-MS spectrum of HSP confirming absence of oligomers 
greater than the dimer after urea-based isolation. Sample complexity at low m/z is due to 
proteolytic loss of tags prior to purification. The various HSP species are indicated in the 
spectrum: monomer without tag (light blue circle), monomer with tag (dark blue circle), 
dimer formed from monomers with tags (double dark blue circles), and dimer formed from 
mixed monomers (double circles, light and dark blue). Other signals in the spectrum stem 
from contaminants, including the released tags. Deviations of calculated and measured mass 
values are by exopeptidases pruning the proteins. Denaturing SDS-PAGE coomassie stained 
gel (inset) shows two prominent bands at 21 and 17 kDa size corresponding to monomers 
with and without tags 
 
A dominant band of 21 kDa (rHSP-tag) and a less intense band of 17 kDa (rHSP 
without tag) were observed plus less defined low molecular weight molecules. The nESI-
TOF mass spectrum (Fig. 6) shows the presence of these two monomer masses, in addition to 
peaks corresponding to homo- and hetero-dimers of the two monomers. Interestingly, the 
homodimer of rHSP without tag was not found, presumably because it was not purified on 
the His-tag column. The small differences between calculated and observed molecular masses 
could be due to proteolytic trimming of the protein. The two monomeric species we assume 
to be derived from the dimers, but to be less stable under the conditions of the ammonium 
acetate buffer in combination with the nESI-TOF conditions. No oligomers larger than the 
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dimer were observed, confirming that standard HSP isolation procedures, where HSP is 
refolded from urea-dissolved inclusion bodies in E. coli, reduces the HSP from the native 
dodecameric form to a dimeric form. 
 
3.4 Discussion 
 
In this study, the binding of a set of different VHH antibodies to the 16 kDa HSP was 
probed with the help of different techniques (ELISA, SPR, and SEC) using both peptides and 
whole protein. The results demonstrated that after mechanical release from heat-killed 
bacteria HSP behaves as a dimer. Optimal combinations of antibodies were selected for the 
development of diagnostic sandwich assays.  
 
TB is a contagious disease so patient samples are usually heat-inactivated at 80°C for 
30 mins, before performing any diagnostic test. The heat-killing step was also used in the 
original procedure to generate M.tb. specific antibodies by injecting llamas with heat-killed 
lysates of M.tb. [18]. However, such procedures normally tend to effectively denature most 
proteins, so that the immunization procedure was likely selective for heat-tolerant proteins. 
All selected VHH were reactive only with HSP as demonstrated by Trilling et al. [18]. This 
bias for binding of the 16 kDa HSP may, therefore, be the result of the standard heating 
practice. The heat tolerance adds to HSP being a robust protein marker [18].  Knowledge of 
the exact conformation of native HSP after applying denaturing conditions by this procedure 
is necessary for the development of reliable immunological diagnostic procedures that are 
strongly dependent on protein conformation in specific sandwich assays. 
 
Previous studies have shown immune-response to epitopes #3, #8, #10 and #12 with 
human T cells [34], epitope #3, #4, #6, #7, #8 and #13 for mouse Mabs, and epitopes #8, and 
#9 for human B cells [22]. We show using ELISA based on llama monoclonals instead of 
sera that 7 out of 14 epitopes were recognized by 8 out of 9 different llama VHH antibodies, 
and that epitopes #3, #4, #6, #11 and #13 were the epitopes recognized most. 
Immunodominance of epitopes #3, #4, #6 and #13 was shown previously for human sera after 
natural infection, but epitope #11 emerged as a new target in llama immunizations performed 
with heated lysates as described above by Trilling et al. [18]. Epitope #11 was the most 
frequently recognized epitope, showing interactions with five different antibodies, although 
frequencies of phage display selected antibodies may have no direct relationship to 
dominance of these antibodies in llama serum. Antibodies like B-D8, B-F9, B-F10 that bound 
to only one peptide, indicated that their recognition sites lie in the centre of the peptide, 
which in the 3D structure was either a loop or the coil region of the protein (Fig. S1). The 
overlapping adjacent epitopes may lack the full binding surface as it only represents half of 
the loop or coil. Several antibodies recognized more than one epitope. Interaction with 
multiple epitope domains of HSP could be due to a complex recognition site composed of 
several proximal peptide loops.  
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In the literature, for HSP, monomer [30], dimer [31], trimer [32], trimer of trimers 
(nonamers) [32] or dodecamer structures [29] have been described. The monomer and dimer 
configurations were based on reverse-phase high-performance liquid chromatography 
(HPLC), and on HSP protein purified by gel filtration chromatography [30, 31]. Trimer and 
nonamer configurations were based on cryo-electron microscopy [32], whereas the 
dodecamer configuration was deduced from SEC analysis [29]. These determinations were 
either based on native or denatured proteins, but for native protein only the SEC analysis has 
been reliable for size determination. Our SEC analysis initially suggested that HSP (16 kDa) 
occurred both as a trimer (16 × 3 i.e. 48 kDa) and a hexamer of trimers (18-mer 16 × 18 i.e. 
288 kDa) with observed sizes of 55 kDa and 301 kDa. However, within the SEC margin of 
error, HSP could also be a dimer and a hexamer of dimers (dodecamer) as reported before 
[29] and with expected sizes of 32 kDa and 192 kDa respectively. The slightly larger 
observed size (61 kDa) of the putative dimer of rHSP-tag compared to the putative dimers of 
the native rHSP, heated-rHSP and M.tb.-HSP proteins with a size of 55 kDa is consistent 
with the presence of the tags (2 × 5 kDa). To resolve the issue we analyzed the oligomeric 
structure by ESI-TOF-MS and concluded that the rHSP-tag sample contains dimers, but not 
trimers. 
 
In our sandwich ELISA and SPR experiments the immunological reactivity of HSP in 
SPR did not fit a monomer model, whereas a dimer model resulted in the best fit of our data. 
This can be seen from Table 2 where we calculated the observed efficiency of binding of the 
secondary, “sandwich” antibody A-23 and B-F10 relative to the theoretical maximum 
efficiency in relation to different possible configurations of HSP as a monomer, dimer, trimer 
or dodecamer using a the following two formulas: 
 
 
 
 
 
 
Where N represents the degree of multimerization. N-1 is used because the HSP antigen is 
assumed to be captured first by one antibody. 
 
If HSP were a monomer, A-23-HSP-A-23 or B-F10-HSP-B-F10 sandwiching would 
not be possible. B-F10-HSP-B-F10 (609RU), for which only one epitope was known, showed 
strong secondary binding, however. If the HSP would be a dodecamer then in theory each of 
the 12 captured HSP units might bind one secondary antibody each except for the anchoring 
unit. Given the dodecamer model for A-23-HSP-B-F10 we only observe 45% actual 
secondary binding, but given the dimer model 82% secondary binding is observed.  
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An unexpected result of the SPR experiments was that, in contrast to B-F10, A-23 
would not bind efficiently to A-23- or B-F10-captured HSP. We think that this was not 
related to the affinity of A-23 for HSP, because A-23 captured similar amounts of HSP from 
the solution as B-F10 in the same time period. Rather we think that there are steric reasons 
why A-23 and B-F10 are behaving so differently. To understand this steric interference it was 
necessary to map the information on the epitopes recognized by both antibodies i.e. A-23 and 
B-F10 on to the proposed 3D structure model of HSP (Fig. 7) [29]. To B-F10 only epitope #9 
would bind, whereas to A-23 two peptides #3 and #11 were consistently binding. Epitope #3 
sites for A-23 are not part of the 3D model, as the dodecameric structure deduced by 
Kennaway et al. does not show its arrangement [29]. We found that the dodecameric 
structure proposed for HSP by Kennaway et al. was built up from 6 dimers, and that the 
formation of the higher multimeric structure is dependent on interactions of all C-termini 
with adjacent protein dimers. Dimers are, therefore, the basic conformational unit of HSP, 
which might survive heat denaturation. Interestingly then, in the dimer 3D model the two 
positions of epitope #11 of antibody A-23 appear to be in the same plane, whereas the two 
positions of epitope #9 of antibody B-F10 are diagonally arranged to each other in opposite 
planes (Fig. 7). 
 
 
Figure 7. Model showing the arrangement of dimer structure of HSP protein along with the 
representation of possible sites of VHH antibodies B-F10 and A-23 
 
Based on the accumulated evidence from SEC, ESI-TOF-MS, SPR, and the 3D 
structure of the HSP protein, a model is proposed which shows schematically how B-F10 and 
A-23 bind to the HSP dimer (Fig. 8). As per this dimer model, all binding sites for A-23 are 
in the same plane, and thus, upon capture by antibody A-23, the other A-23 binding site is 
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blocked. Binding of VHH antibody B-F10 is still possible as that binding site is perpendicular 
to the site of A-23, in a different plane. By contrast, if antibody B-F10 is used for capturing, 
the binding sites of B-F10 are diagonally arranged in opposite planes, allowing strong 
binding, while apparently A-23 binding sites remain inaccessible. 
 
 
Figure 8. Models explaining the blocked detection by A-23 antibodies. The diagrams show 
the capture of HSP dimer with VHH antibodies B-F10 and A-23 and successful detection with 
B-F10 panels A-B) and failed detection with A-23 (panels C-D) 
 
In conclusion, the different VHH antibodies showed specific binding to many 
different epitopes of the 16 kDa HSP. The VHH’s B-F10 and A-23 were the best binders of 
HSP and are complementary to each other as they recognize non-overlapping epitopes on the 
HSP dimer. ESI-TOF-MS and SEC in combination with immuno-dot blot analysis showed 
that although the protein exists as a dodecamer in native state, the HSP is a dimer both as 
recombinant AVI-HIS-tagged protein (rHSP-tag) and in heat-inactivated M.tb. lysates (M.tb.-
HSP and heated-rHSP). Based on these findings, assays for protein-based diagnosis of 
tuberculosis could be developed. High concentrations of this non-secreted can be obtained by 
first concentrating the M.tb. cells from liquefied sputum samples using magnetic TB-Beads 
[35], followed by controlled lysis of the bacteria using mechanical or ultrasonic [36] lysis 
methods. 
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Abstract 
 
Tuberculosis (TB) is a contagious airborne disease, for which diagnosis is challenging 
due to several limitations with respect to handling, cost, sensitivity and reliability especially 
in resource poor settings. In the present study we describe the principle of a two-step capture 
and optical detection procedure of identifying Mycobacterium tuberculosis (M.tb.). First up-
concentrating of mycobacteria with PolyDADMAC functionalized microsieves is shown. In a 
second step direct fluorescent labelling of whole mycobacteria is possible. Alternatively the 
sample can be lysed for further assay detection. Here we show the presence of the 16 kDa 
heat shock protein (HSP) (in this report originating from E. coli.) on a second microsieve. 
The detection was not quantitative as the fluorescent labelling method seemed to induce the 
agglutination of the antigen, which was confirmed via dynamic light scattering study. 
However, the combination of up-concentrating M.tb. bacteria from sputum on microsieves 
and subsequent fluorescence assisted microsieve-based detection of HSP may overcome 
sensitivity issues relating to low bacterial counts and dilute antigen concentrations. Thus, the 
method may allow earlier detection of M.tb. infections in sputum and cultures from patients 
in resource-poor settings.  
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4.1 Introduction 
 
M. tuberculosis (M.tb.) is a gram-positive bacterium causing tuberculosis (TB), which 
is one of the leading causes of global mortality (1.4 million people in 2011) [1]. TB is a 
contagious airborne disease usually spreading from person to person with every year around 
8-9 million new cases reported. The WHO 2012 annual report states that one third of the 
world population has TB either in active or dormant state [2]. The TB bacterium can remain 
inactive or in dormant state for years without causing symptoms or spreading to other 
subjects, but as soon as the immune system of the host subject becomes weakened, the 
bacterium becomes active and will infect mainly the lungs along with other parts of the body 
[3, 4]. TB cases are also aggravated by sicknesses or illnesses that decrease body immunity 
such as HIV, which is prevalent in resource poor countries [5]. 
 
The diagnosis of TB is conventionally done using the skin Mantoux screening test or 
by direct acid-fast bacterium testing of sputum smears. The latter may face difficulties in 
sample collection especially in non-pulmonary TB cases [6, 7]. Plating methods are 
dependent on the slow growth of the TB bacterium and take around 2-6 weeks [8-11]. Other 
methods like DNA-based diagnostic procedures are usually very costly as they require an 
advanced laboratory infrastructure along with skilled personnel [8]. Early detection of TB i.e. 
either in dormant state or early active stage could enable an earlier treatment with better 
prognosis or lower epidemiological risks. Though treatment of active TB can be done 
utilizing one or a combination of several drugs, including rifampicin (Rifadin), ethambutol 
(Myambutol), pyrazinamide, and streptomycin, the development of drug resistant strains is 
making treatment of TB much more challenging [12-16]. Diagnostic assays utilizing 
antibodies have been implemented successfully for various infection diseases [17-19], but in 
the case of TB not much success was achieved over several decades [20]. To date, no 
commercial TB immunodiagnostic test is both sufficiently specific and sensitive [21]. Thus, 
there is an urgent need for rapid, inexpensive, reliable, technically simple and robust methods 
for the detection of M.tb. especially in resource poor settings [5, 22]. 
 
Flow-through assays are mature techniques, where the test principle is based on 
overcoming diffusion limitations by flowing of the analyte through a porous surface, pre-
immobilized with capture molecules specific for the analyte. Captured analytes on the porous 
surface, are then in a second step detected by optical or electrochemical techniques. Flow-
through assays are usually very fast and capable of detection of multiple analytes in one test 
[23].  Though flow-through assays have been around for a long time, very little has been done 
towards their application in the detection of TB. An attempt was made by Reither et al. in 
2010 to evaluate a novel flow-through assay i.e. Diagnos TB AG developed by Biomed 
Industries, Parwanoo, India, for the detection of pulmonary TB. The assay involved the use of 
four mycobacterial antigens including lipoarabinomannan (LAM) and the 30 kDa antigen 
[24]. The assay was a three-step assay, where the first step involved the inactivation and lysis 
of M.tb. cells, the second step the formation of antibody-antigen complexes, and the final step 
red-pink coloration of the membrane in case of positive reaction due to reaction of antibody-
antigen complex with protein A conjugate [24]. Application of the test to real cases was 
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problematic for the following reasons: (1) the test procedure was dependent on sputum 
viscosity and involved a time consuming mechanical homogenisation step through pipetting, 
(2) the visual interpretation of the colours in case of a positive test was variable between 
different researchers and (3) heterogeneous colour development was often observed but 
difficult to interpret. Thus, the test was evaluated as highly non-specific and not fit for point 
of care assays [24]. In our opinion, the flaws that were identified in the above method could 
easily be rectified by utilizing chemical homogenisation of the sputum and using a more 
advanced fluorescent detection method. 
 
The objective of the present work was to demonstrate the elements that could be part 
of a new detection method combining capture-based up-concentration of bacteria and 
fluorescent detection of subsequently released antigens after bacterial lysis captured on a 
second microsieve. The method potentially overcomes the limitations of the other method by 
up-concentrating bacterial cells first from chemically homogenized sputum using a 
microsieve. The concentrated antigens released from these bacteria upon lysis may be 
detected more reliably using fluorescence. 
 
 
4.2 Materials and Methods 
 
The 2-Epoxy-9-decene (96%), poly (diallyldimethylammonium chloride), high 
molecular weight (PolyDADMAC) 20 wt.% in water solution, acridine orange (powder 
phase) and acetone (semiconductor grade) were purchased from Sigma-Aldrich. 1, 2-Epoxy-
9-decene was purified by vacuum distillation; the obtained purity was >99% as determined 
by GC-MS. Ultrapure water from a Barnstead water purification system with a resistivity of 
18.3 MΩ.cm was used. Protein printing buffer solution (PPB) 2× was purchased from Arrayit 
corporation, USA. Biotinylated VHH antibodies were produced as described by Trilling et al. 
[26] Phosphate-buffered saline (PBS) solutions (pH 7.4), (Bovine serum albumin) (10 mg/ml) 
as blocking solution were used in biological experiments. Micro-engineered membranes 
(microsieves) made of Si3N4 thin films standing on silicon supports with circular pores of 
various well-defined sizes (0.45 µm and 3.5 µm) were provided by Aquamarijn Micro 
Filtration B.V., The Netherlands.  
 
4.2.1 Up-concentration experiments on the microsieve 
 
Microsieves were first coated with PolyDADMAC with the following procedure. 
Si3N4 microsieves with pore size of 3.5 µm were rinsed with acetone for 15 min, followed by 
piranha treatment for 15 min and washed 3 times with excess of water. Subsequently the 
samples were dipped into a solution of 2% (w/w) PolyDADMAC in water for 1 min. Any 
excess of the solution was passed through the microsieves. The microsieves were 
subsequently dried overnight under vacuum and subsequently rinsed thrice with an excess of 
water. PolyDADMAC-coated 3.5 µm microsieves were mounted into plastic filtration 
holders. Mycobacterium smegmatis (M. smeg.) was grown in Middlebrook 7H9 medium 
supplemented with 10% OADC, inactivated and next stained with acridine orange. A 100 µl 
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sample of stained M. smeg. suspension in water (106 bacteria/ml) was filtered through the 
microsieves at a flow rate of 50 µl/min, and subsequently rinsed with 1 ml of water at a flow 
rate of 500 µl/min. 
 
4.2.2 HSP-based detection of M.tb. with microsieves 
 
Concentrated bacteria loaded on microsieves can be characterized as mycobacteria 
using M.tb. specific antibodies. For this purpose we used the cellular 16 kDa heat shock 
protein (HSP) which can be released from mycobacteria by mechanical lysis methods like 
bead beating, sonication or urea lysis [25-28]. The schematic for this method is described in 
Fig. 1. We functionalized biotinylated llama VHH antibody for HSP on a second microsieve 
with a pore size of 0.45 µm. The functionalization of the microsieve was achieved in three 
steps, first with an epoxide layer, next with a streptavidin (SA) layer over the expoxy layer 
and finally with biotinylated llama VHH antibody coating. The Si3N4 microsieves with a pore 
size of 0.45 µm were provided with an epoxide layer after photochemical (λ = 254 nm) 
attachment of 1, 2-epoxy-9-decene as described by Nguyen et al. [29]. The epoxide-coated 
Si3N4 microsieves were next incubated with SA in PPB (1.0 mg/ml) for 15 min at room 
temperature followed by overnight incubation at 4oC. SA-coated microsieves were rinsed 
with 1 ml of PBS (pH 7.4) [30]. Unreacted epoxide groups on SA-coated microsieves were 
passivated using BSA solution (10 mg/ml) for 50 min. Subsequently, the microsieves were 
coated with biotinylated primary antibody VHH-A-23 antibody solution (5µg/ml) or antibody 
M200 (negative control) solution (5 µg/ml) respectively before the capture of HSP. 
 
 
Figure 1: Schematic of the microsieve sandwich immunoassay which is built up step by step 
to first capture the HSP molecule and then the detection antibody VHH-B-F10 
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All primary capture antibody coated microsieves were blocked using a mixture (1:1) 
of biotin (5 µg/ml) and BSA (10 mg/ml) for 40 min to block unreacted species, and 
subsequently rinsed with 1 ml of PBS. A 50 µL volume of HSP solution at different 
concentrations (5 µg/ml, 2.5 µg/ml, 1 µg/ml, 100 ng/ml, 10 ng/ml, 1 ng/ml) was subsequently 
incubated on top of the microsieves for 5 min and filtered through the microsieves. As 
negative controls, one microsieve was coated with biotinylated primary control antibody 
M200 (does not bind with HSP) followed by incubation with 50 µl of HSP solution at a 
concentration of 5 µg/ml. The samples were rinsed with 1 ml of PBS and then blocked with 
BSA solution for 40 min. 
 
4.2.3 Staining procedure to visualize the HSP 
 
In order to visualize the captured HSP, the samples were first incubated with 
biotinylated VHH-B-F10 antibody solution (5 µg/ml) for 5 min, followed by first rinsing with 
1 ml of PBS and then incubating with FITC-SA (5 µg/ml) for 10 min. Finally, all samples 
were rinsed with 1 ml of PBS and dried briefly with nitrogen gas before observation by 
fluorescence microscopy (excitation at 470 nm and emission at 528 nm).  
 
4.2.4 Dynamic light scattering (DLS) 
 
To better understand the results obtained via the capture and detection of HSP in the 
above sandwich assay, DLS measurements were performed of the agglutination reaction 
induced by mixing the complex of SA and biotinylated VHH antibody B-F-10 with HSP 
protein. The hydrodynamic radius (Rh) was measured using a nano-zetasizer (Nano-ZS), 
model: ZEN 3600, Malvern Instruments, Worcestershire, UK. The instrument was equipped 
with 633 nm laser and the samples were put in a 40 μl (minimum) quartz cuvette with 1 cm 
path length. The measurements were performed at 25oC in the automatic mode, in which the 
attenuator and the measurement position were selected automatically with the incident angle 
for laser to be at 90o. For DLS measurement an equimolar concentration of SA and VHH 
antibody B-F10 was incubated together for 10 min to obtain a SA-B-F10 complex that was 
further utilized to perform the experiments. A solution of 25 µl of SA-B-F10 complex was 
mixed with 25 µl of HSP solution at varied concentrations (5µg/ml, 2.5µg/ml, 1µg/ml, 100 
ng/ml, 10 ng/ml) and assayed after a 5 sec time delay of between adding and measuring. Both 
the VHH and HSP solutions were prepared by dilution from their respective stock solutions 
in 1 × PBS pH 7.5 to obtain the desired concentration for the experiment. The intensity 
fluctuations in the scattered light were measured at 173o for 25 sec. Ten such scans were 
averaged to obtain the correlation curve. Next, intensity based size distributions were 
calculated using the standard software of Malvern. The Rh was calculated in the Malvern 
software from the calculated diffusion coefficients and using the Stoke-Einstein relation. The 
diffusion coefficients were calculated from the measured characteristic decay times in the 
curves of auto-correlation coefficient versus time. Solutions of only SA-bound biotinylated 
VHH antibodies or HSP alone were measured as controls in order to exclude any 
agglutination arising from these samples themselves. 
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4.3 Results and Discussion 
 
4.3.1 Concentrating M. smeg. on microsieves 
 
Sputum is the most obvious sample for the detection of TB. Due to the high viscosity 
and stickiness of sputum, it is challenging to extract bacteria for further analysis, however. 
Also, a relatively low bacterium count is an issue for the early detection of TB. Concentrating 
the bacteria on a sieve could be a solution if known procedures of liquefaction such as salt 
solutions or household bleach will allow filtering of M. smeg. cells [31, 32]. PolyDADMAC-
coated microsieves were utilized in our study for up-concentrating mycobacteria of the strain 
smegmatis suspended in PBS buffer. Fig. 2A and 2B show the fluorescence image of acridine 
orange pre-stained M. smeg. cells on 3.5 µm PolyDADMAC-coated microsieves, whereas on 
control microsieves (Fig. 2C and 2D) with no PolyDADMAC coating, stained 
Mycobacterium cells pass through the 3.5 µm large pores. M. smeg. cells concentrated in this 
way may easily be lysed using standard procedures such as urea lysis, sonication or bead 
beating [25-28] to obtain lysates with cellular internal protein. 
 
 
Figure 2. Fluorescense microscopy images of Mycobacteria stained by acridine orange after 
capture on PolyDADMAC-coated microsieves with pore size 3.5 µm. Panel A shows the 
result for PolyDADMAC coated sieves under 5× magnification; panel B for 20×; panels C 
and D the experiment of panel A and B but with uncoated microsieves 
 
 
A 
C D 
B 
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4.3.2 Fluorescence based detection of HSP on microsieves by immunoassay 
 
Immunoassays have the potential to provide fast, simple and reliable detection 
methods, though in relation to TB not much success was achieved for several decades. Tested 
antibodies against whole M.tb. cells were either non-specific recognizing all Mycobacterium 
sp. or directed against secreted antigens that were too dilute in sputum test samples to provide 
a reliable diagnosis [25]. We therefore propose that cell internal proteins may be the better 
choice for these kinds of immunoassays as they can be pre-concentrated by concentrating the 
bacteria first. 
 
 
Figure 3: Fluorescent images of FITC-SA-B-F10 stained HSP captured by 0.45 µm pore-size 
microsieves coated with primary antibody VHH-A-23 antibody (test sample) or M200 
antibody (negative control) with variable concentrations of HSP in sandwich assay. The sub 
figures show the test results of HSP concentration of 5 µg/ml (A), 2.5 µg/ml (B), 1 µg/ml (C), 
100 ng/ml (D), 10 ng/ml (E), 1 ng/ml (F) while figure G shows the result for the negative 
control with primary antibody M200 (exposure times and CCD gain are the same for all 
images) 
 
In our previous work we selected the most optimal antibody pair against the most 
dominant antigen, HSP, of M.tb. [25]. Fig. 3 shows the results obtained using fluorescence 
based detection of HSP protein in a flow-through based system by performing a sandwich 
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immunoassay on microsieve surfaces with pore sizes of 0.45 µm. In Fig. 3A-G, the results of 
a range of applied concentrations of HSP i.e. 5 µg/ml, 2.5 µg/ml, 1 µg/ml, 100 ng/ml, 10 
ng/ml, 1 ng/ml are shown. For all concentrations - we surprisingly saw only the presence of 
aggregates. We suggest that those may be formed by an agglutination reaction as depicted in 
Fig. 4. Figure 3G is a negative control where primary antibody M200 was used that does not 
bind with HSP. We did not see significant amounts of aggregates in a range of replicates of 
that control unlike with the HSP coated sieves. The aggregates obtained in Fig. 3F, and to a 
lesser degree also visible in Fig. 3A, 3C, 3D and 3E, may possibly be fractal aggregations of 
the test proteins. They might be formed when SA bound biotinylated VHH antibody B-F-10 
comes in contact with the HSP protein dimer although this would require first a release of the 
HSP dimer from the capture antibody VHH-A-23. To verify that this might be happening 
DLS measurements were done. 
 
Figure 4: Schematics depicting the formation of aggregates due to agglutination between SA-
F10 complex and HSP antigen 
 
4.3.3 DLS-based agglutination analysis 
 
In order to understand the agglutination or aggregation observed when SA bound 
biotinylated VHH antibody B-F-10 contacts HSP protein especially at lower concentrations 
of HSP, DLS was utilized. In Fig. 5, the results of DLS studies are shown along with the size 
patterns of agglutinated particles with increasing concentration of the HSP antigen. The 
control experiments ran with only HSP or SA-F10 complex excluded the possible occurrence 
of an agglutination reaction with either molecular species (Fig. 5). With increasing 
concentrations of the antigen, HSP formed polydisperse agglutinated particles. The repeated 
peaks in the graphs of Fig. 5 suggest the growth and subsequent precipitation of agglutinating 
particles. After attaining a maximum height the particles settled down by gravity.  
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Figure 5: DLS plot where intensity is plotted against time showing fractal aggregation for 
different concentrations of HSP when incubated with antibody VHH-F-10 complexed to SA. 
HSP and SA alone give straight lines and in combination yield a very low response. Addition 
of HSP generates intensity fluxes 
 
HSP is known to exist as a homodimer after isolation using a urea lysis procedure 
resulting in two binding sites for each antibody or a valency of two [25]. Therefore, upon 
exposure to VHH antibodies that are bound to a SA molecule with a valency of 4, the 
molecules will induce a chaotic 3D complex formation. This complex formation leads to 
particles of different sizes and shapes in the measured samples. At a critical lower 
concentration of antigen HSP, this complex formation would lead to larger aggregates 
compared to both higher and lower concentrations of HSP (illustrated in Fig. 6). Indeed, with 
the concentration of SA-F10 complex fixed, but with varying concentrations of antigen HSP 
(also viewing other experiments), it appeared that more small aggregates were formed at 
higher concentrations (like 5 µg/ml and 1 µg/ml, except 2.5 µg/ml in this Fig. 3),. Possibly, 
the aggregates formed at higher concentration were also so small that most passed through 
the microsieve, while at lower titres the aggregates were large enough to be retained. 
 
 
Figure 6: Schematics depicting aggregate formation of the detection complex due to 
agglutination when HSP comes in contact with SA-F10 complex. A: shows the dimer 
formation when 1 HSP unit is added, B: shows clump formation where 11 HSP units were 
added while C: shows monomer formation where 36 HSP units were added 
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4.4 Conclusion 
 
Over the last few decades, a lot has been done to develop fast and effective assays for 
cheap, robust and reliable detection of TB under field conditions, with a main focus on 
measuring the level of anti-M.tb. antibodies in the serum, identifying M.tb. cells in sputum 
(by microscopy or culturing) or detecting biomarkers in urine [6, 33]. Nucleic acid 
amplification based techniques are fast alternatives, but are complex, expensive and require 
skilled personnel with high quality standards [34], whereas conventional assays are often not 
sensitive enough or too time-consuming [33, 35-37].  
 
With additional work, the fluorescence assisted microsieve based platform described 
here may be developed into a potentially fast, simple and reliable assay. The up-concentration 
techniques demonstrated here might be useful in obtaining high concentrations of M.tb. cells 
from sputum samples. Up-concentrated cells would greatly enhance the sensitivity of the 
suggested assay or any other assay that tries to identify M.tb. and quantify the bacterial count. 
The issue which still needs to be addressed is to develop a simple cell lysis protocol to obtain 
a concentrated protein extract. This might be de done utilizing mechanical or ultrasonic [38] 
lysis methods that preserve the proteins intact and allow subsequent immunoassays. The 
dominant antigen, 16 kDa HSP, is a good target protein to identify M.tb. [25]. However, the 
agglutination reaction that seems to occur makes it very difficult to obtain quantitative and 
reproducible data on the quantity of bacteria in the sputum. Possibly protocols can be 
improved in the future to prevent the occurrence of the agglutination reactions by a better 
primary capture of the HSP antigen on the sieves first and by using a detection antibody with 
a valency of one. 
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Abstract 
 
 
Most current diagnostic assays for tuberculosis have limitations in terms of 
reliabilities, sensitivities, costs, ease of use or speed, especially limiting implementation in 
resource-poor areas. In this study we describe the development of a fast, simple, sensitive 
lateral flow immunoassay (LFIA) allowing visual identification of the Mycobacterium 
tuberculosis (M.tb.) antigen. The LFIA employs variable heavy chain (VHH) llama 
antibodies to identify the 16 kDa heat shock protein (HSP), an immuno-dominant antigen. 
Recombinant HSP protein was produced and purified from E. coli. The assay detected a 
lower limit of 0.25µg/ml of purified recombinant HSP antigen. In combination with methods 
to up-concentrate M.tb. bacteria from sputum LFIA of HSP may be a simple and affordable 
method to detect M.tb. infections in sputum and identify M.tb. in cultures from patients in 
resource-poor settings.  
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5.1 Introduction 
 
Despite many efforts, tuberculosis (TB) remains one of the major unsolved global 
health problems with ~9.4 million new cases every year and an estimated global mortality of 
1.4 million people in 2010 [1]. The situation has deteriorated in several parts of the world 
mainly due to co-infection with human immunodeficiency virus (HIV), and the subsequently 
acquired immune deficiency syndrome (AIDS), weakening body immunity against TB [2, 3]. 
Furthermore, the growing problem of multiple drug resistance aggravates the situation 
especially in resource-poor countries, where implementation of modern methods to control 
the TB epidemic is lacking [4]. 
 
Initial detection of new cases of TB is mainly based on microscopic inspection of 
sputum smears for acid-fast bacterium. This method provides high detection rates for patients 
with active TB, but depends on skilled personnel and is too labour intensive [4]. In terms of 
sensitivity culture techniques are the gold standard for detection of active TB, with the 
drawback that they take 2-6 weeks to set a diagnosis [5-8]. Culture plating is also the main 
method for identifying multi-drug resistant (MDR) TB. An ideal TB test for resource-poor 
areas should be rapid, simple, reliable, low-cost, specific and sensitive. 
 
Nucleic acid amplification tests (NAATs) are a relatively new strategy in active TB 
detection [9-11]. This technique can amplify even small amounts of genetic material from TB 
bacteria. The sample used still has to contain a certain minimum (>100/ml) number of TB 
bacterium that is not always possible. Often by culturing, the number of bacterium is 
increased to improve the sensitivity of the test before carrying out PCR [12].  NAAT 
techniques are also used to identify MDR TB strain mutations causing drug resistance [13]. 
NAATs require expensive and labour intensive readout systems, like PCR, that are only 
accessible in well-equipped laboratories [14], although a NAAT coupled lateral flow-based 
readout have recently become available for malaria diagnosis [15]. 
 
Antibody based diagnostic assays have been successful for several other infectious 
diseases [16-18] but in case of TB diagnosis, no significant success has been achieved for 
several decades [19]. The commercially available antigen based kits are often used to test the 
supernatants of cultured bacteria and are not suitable for sputum analysis [12]. Further studies 
on developing these assays for the diagnosis of TB are in progress due to its potential as a 
fast, simple and reliable detection method. 
 
The continuous search for simplified, portable, rapid, and sensitive detection assays 
with immediate “on-the-spot” interpretation for diagnosis of infectious diseases has led to the 
development of biosensors as well as lateral flow immuno assay (LFIA) platforms [19, 20]. 
These platforms are especially relevant in the context of their adaptability to resource-poor 
settings, where a sophisticated laboratory infrastructure and highly trained personnel are not 
available [21, 22]. LFIA is a rapid (10-20 min), one step, and immuno-chromatographic test. 
Detection of an antigen is done by sandwiching this antigen between capture antibody 
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(ligand) on/in the nitrocellulose (NC) membrane and detection antibody (ligand) immobilised 
onto carbon nanoparticles (CNPs). 
 
This study describes the development of an LFIA for the detection of the 16 kDa heat 
shock protein (HSP), a species-specific dominant antigen present in TB-causing 
Mycobacterium sp. [23]. It employs VHH (variable heavy chain) llama antibodies which are 
known to be very stable under harsh conditions. The utility of the method for the diagnosis of 
infectious M.tb. in patients is discussed. 
 
5.2 Materials and Methods 
 
5.2.1 Chemicals 
 
The100 mM Borate Buffer (100 mM BB) pH 8.8 was prepared by mixing 100 mM 
solutions of H3BO3 (Merck,Darmstadt, Germany) and Na2B4O7.10H2O (Sigma-Aldrich 
Chemie BV, Zwijndrecht, Netherlands). BB buffer, Bovine serum albumin (BSA, Sigma-
Aldrich Chemie BV, Zwijndrecht, Netherlands) and Tween 20 (Merck, Amsterdam, The 
Netherlands) were used to prepare Washing Buffer (WB) with 5 mM BB and 1% (w/v) BSA; 
Storage Buffer (SB) with 100 mM BB and 1% (w/v) BSA); Running Buffer (RB) with 100 
mM BB, 1% (w/v) BSA, and 0.05% (v/v) Tween 20). 
 
5.2.2 Biomolecules 
 
VHHs raised against the HSP protein of M.tb. as described by Trilling et al. [23] were 
produced in E. coli BL-21 wild type strain and purified as described [24]. The highest affinity 
VHH antibodies A-23 and B-F-10 recognizing non-overlapping epitopes were selected for 
this study [23]. Both A-23 and B-F-10 were either produced with a VSV-tag or AVI-biotin 
tag. Rabbit anti-VSV-tag antiserum (Abcam, Cambridge, UK) was used to capture the 
antibody on the NC strip. NeutrAvidin (NA) biotin binding protein was purchased from 
Pierce, Rockford, IL, USA. Goat-anti-Mouse-biotin was purchased from Dako (Dako 
Netherlands BV, Heverlee, Belgium). Recombinant HSP target protein of M.tb. with AVI- 
and HIS-tags was also produced in E. coli and purified as described by Trilling et al. [23].  
 
5.2.3 Preparation of nitrocellulose LFIA strips 
 
LFIA strips were manufactured as described by Posthuma-Trumpie et al. [25] using 
NC membranes cut to a length of 20 cm (HF135, MilliPore, Amsterdam, Netherlands or 
CN140 NC membranes with backing, Sartorius Stedim, Göttingen, Germany). The NC 
membranes were fixed on a plastic backing along with a cellulose absorbent pad (Schleicher 
and Schuell,’s-Hertogenbosch, The Netherlands). Capture anti-VSV antibody was diluted in 
5 mM BB after buffer exchange using Zeba spin columns (Pierce, Rockford, IL, USA). The 
antibody concentration was measured using a Nanodrop 2000 spectrophotometer (Thermo 
Scientific, EttenLeur, Netherlands). Dilutions were made in 5 mM BB to meet the following 
requirements 500, 250 and 125 µg/ml. Alternatively, NA was sprayed as test line in 
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concentrations of 1000, 500, 250, 125 µg/ml. A Linomat IV TLC dispenser (Camag, Berlin, 
Germany) was used to dispense the specific antibody (test line, TL) and the biotinylated 
antibody (control line, CL) on the NC membrane at a dose of 1 μL/5 mm. Distance between 
lines was 3 mm. The NC membranes were dried overnight at 37 ºC. Finally, strips were cut at 
a width of 5 mm using a Bio-Dot Cutter CM4000 (Irvine, California, USA), used 
immediately, or packaged in aluminium pouches (with a silica desiccation pad), sealed and 
stored at room temperature until use. 
 
5.2.4 Preparation of CNPs 
 
CNPs with adsorbed NA (CNP-NA) were prepared as described by Posthuma-
Trumpie et al. [26]. Briefly, 10 mg of carbon (Spezial Schwartz 4, Degussa AG, Frankfurt, 
Germany) was suspended in 1 ml of MilliQ water and sonicated for 5 min (Branson Model 
250 Sonifier, Danbury, Connecticut, USA). The resulting 1% (w/v) carbon suspension was 5-
fold diluted in 5 mM BB and sonicated for 5 min. Next, 350 μg NA was added to 1 ml of the 
diluted carbon suspension and stirred for 3 h at room temperature. This suspension was first 
centrifuged at 13.636 × g for 15 min; the supernatant was removed and the pellet was washed 
with WB to remove unbound protein. To achieve this, 1 ml of WB was added to the pellet, 
thoroughly mixed and the mixture was centrifuged at 13.636 × g for 15 min. Subsequently, 
the supernatant was removed and the pellet was re-suspended in 1 ml WB. This process was 
repeated twice. After the final wash, the pellet was re-suspended in 1 ml SB. The resulting 
suspension contained 0.2 % (w/v) carbon conjugate CNP-NA. Alternatively, 350 μg of anti-
VSV in 5 mM BB was adsorbed on the carbon using the same procedure as described above 
and resulting in CNP-VSV. 
 
5.2.5 Execution of the test 
 
The LFIA sandwich assay carried out in this study involved spraying of anchoring 
protein, binding of capture/detection VHH antibody and detection of HSP target protein. The 
schematics of these steps are shown in Fig. 1 where first the LFIA strip was coated with anti-
VSV or NA protein to capture primary VHH antibody with VSV-tag or biotin tag, 
respectively. The two VHHs bind the HSP target protein at two different epitopes [24]. 
Hence, the VHH-HSP-VHH complex can be sandwiched between complementary secondary 
anti-VSV antibody and NA. Both anti-VSV antibody and NA can serve as the capture (bound 
to the membrane) and the detection ligand (bound to the CNPs).  
 
The test was executed by vertically inserting an anti-VSV or NA coated LFIA strip in 
wells of a low protein binding 96-wells microplate containing a thoroughly mixed solution of 
25 μl of capture VHH with VSV or biotin-tag, 25 μl of HSP target protein dilution, 25 μl of 
detection VHH with biotin or VSV-tag (all proteins diluted in RB) and 25 μl of RB 
containing 1 μl of CNP suspension coated with either anti-VSV or NA protein. After running 
and drying, the strips were inspected visually or, for documentation purposes, were scanned. 
Here an Epson Perfection V600 scanner was used, and the pixel gray volumes (PGV) were 
obtained using image analysis software (Total Lab, Nonlinear Dynamics, Newcastle upon 
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Tyne, UK). Blank correction was performed with an identical non-modified line right below 
the test line. Pixel grey volume of the blank was subtracted from the result obtained for the 
test line. 
  
 
Figure 1: Schematic representation of the final LFIA assay sandwich. In each case the 
anchoring protein on the LFIA strip captures a CNP complex of HSP and two different VHHs 
by the complementary tag. Panel A: Anti-VSV captures the VHH A-23 with VSV tag and 
associated complex. Panel B: NA captures the VHH A-23 with biotin tag and associated 
complex. Panel C: Anti-VSV captures the VHH B-F-10 with VSV tag and associated complex. 
Panel D: NA captures the VHH B-F-10 with biotin tag and associated complex. The binding 
model of VHH with HSP is based on Srivastava et al. [24] 
 
 
5.2.6 Determination of a suitable anchoring protein 
 
To determine the best anchoring protein, both anti-VSV and NA were tested on the 
LFIA strips. For this, either anti-VSV at concentrations of 125, 250 and 500 µg/ml or NA at 
concentrations of 125, 250, 500 and 1000 µg/ml was sprayed on LFIA strips and dried 
overnight. An amount of 2µg/ml capture and detection VHH antibodies in the combinations 
as described in the scheme of Fig. 1 with either VSV or biotin tag (depending upon the 
A B
C D 
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anchoring protein) was used and mixed with serial dilutions of HSP ranging from 2µg/ml to 
0.25µg/ml to execute the test. After running and drying the LFIA strips from both 
experiments, the strips were scanned and analysed as described above. 
 
5.2.7 Determination of suitable capture and detection VHH antibodies 
 
LFIA strips with an anti-VSV concentration of 250 µg/ml were treated with different 
concentrations and ratios of capture and detection VHH antibodies: both antibodies were 
tested at either the same (1, 2 or 4 µg/ml) or a different concentration (2 µg/ml capture and 1 
µg/ml detection antibody). Antibodies were combined with serial two-fold dilutions of 16 
kDa target protein (2 - 0.25 µg/ml). LFIA strips were analysed as described above. Next, 
whole cell lysate from cultured Mycobacterium was tested with 4 µg/ml of both capture and 
detection VHH. In this experiment - a fixed concentration of 2 µg/ml of whole cell protein 
lysate from M.tb. and M. smeg. (a control non-TB causing strain Mycobacterium smegmatis) 
were tested. In order to check whether sequential addition of the two VHH antibodies was 
preferable over simultaneous mixing, an experiment was done adding the antibody A-23 with 
VSV tag first followed by HSP, biotinylated antibody B-F-10 and the CNP-NA (Fig. 1A), or 
in reverse adding biotinylated antibody B-F-10 first followed by the HSP protein, antibody 
A-23 with VSV tag and the CNP-NA (Fig. 1A). LFIA strips sprayed with 250 µg/ml of anti-
VSV were inserted into wells containing these samples and analysed as described above. 
 
 
5.3 Results and Discussion 
 
5.3.1 Determination of a suitable anchoring protein 
 
For adequate performance of the LFIA test, it was crucial to first identify a suitable 
anchoring protein concentration to give a sensitive response in the sandwich assay. For this, 
LFIA strips were sprayed with either anti-VSV or NA at various concentrations. Anti-VSV 
coated LFIA strips gave a higher response than NA sprayed LFIA strips (Fig. 2). This 
difference in signal may possibly carry a relationship to the relative purity of the samples or 
to the fact that NA molecules have four binding sites for the biotinylated VHH antibody, 
whereas anti-VSV has only two binding sites for the VHH carrying a VSV tags. Overall, anti-
VSV was preferred, because the efficiency of binding HSP-CNPs was greatest and the 
linearity of the response was good. The most linear response to increasing HSP 
concentrations and lowest background signal was obtained for the 250 µg/ml anti-VSV 
anchoring antibody concentration, and, therefore, this concentration was chosen for all next 
experiments.  
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Figure 2: LFIA assay responses to different concentrations 16 kDa HSP M.tb. antigen with 
anti-VSV (A) as in Figure 1A or NA (B) as in Figure 1B as capture protein 
 
5.3.2 Determination of the suitable capture and detection antibodies 
 
Next, the optimal ratio of the VHH capture and detection antibodies was determined. 
To evaluate this, an experiment was set up, where either the same concentrations of capture 
and detection VHH were used, or where the capture VHH concentration was twice higher 
according to diagram Fig. 1A. Fig. 3 shows that at low HSP concentrations a 2:1 ratio of 
capture: detection VHH was twice more effective at detecting HSP. The detection VHH at 1 
µg/ml was limiting detections above 0.5 µg/ml HSP, however, because a 1:1 ratio at 1 µg/ml 
of both VHHs would ultimately lead to the same detection sensitivity at 2 µg/ml HSP. 
Doubling both VHH antibodies to 2 µg/ml only yielded a small increase in total signal, 
suggesting that the 2:1 ratio of capture: detection VHH is more optimal. This can be 
understood from Fig. 1A where it is sterically possible for the HSP-CNP complex to be 
captured by two molecules of VHH-A23 which may be critical for this antibody which is 
weaker than VHH-BF10. For best sensitivity and a greater linear response concentrations of 4 
and 2 µg/ml capture and detection VHH (or even higher concentrations at that ratio) may be 
the best compromise, but a 1:1 ratio was chosen in the remaining experiments because of the 
good linear response in Fig. 3.  
 
The optimal concentration and combination of VHH antibodies A-23 or B-F-10 as 
either capture or detection antibody, was tested by comparing the detection efficiency of the 
recombinant 16 kDa HSP protein (Fig. 4). At a concentration of 4 µg/ml VHH signals 
obtained were similar irrespective of the combination of capture or detection VHH. At lower 
concentrations it was more effective if the B-F-10 VSV-tag was used as capture antibody 
(Fig. 4B). In that configuration 2 µg/ml gave the best linear signal. 
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Figure 3: LFIA assay results in relation to different combinations of capture and detection 
VHH antibodies. Anti-VSV was sprayed on the LFIA strip at 250µg/ml. Capture VHH was A-
23 with VSV tag, detection VHH was biotinylated B-F-10 as in Figure 1A 
 
 
 
Figure 4: Tests of the effect of exchanging capture and detection antibodies at different 
concentrations on anti-VSV sprayed LFIA strips. Panel A: LFIA assay response with VHH A-
23 with VSV-tag as capture and biotinylated B-F-10 as detection antibody as in Figure 1A. 
Panel B: LFIA assay response with VHH B-F-10 with VSV-tag as capture and biotinylated A-
23 as detection antibody as in Figure 1C 
 
For whole cell lysate from cultured Mycobacterium, we confirmed that also here the 
best response was obtained when VHH B-F-10 was used as capture antibody. Fig. 5 shows a 
comparison of signals obtained for both situations and compared to the low signal from the 
non-tuberculosis causing strain M. smeg. Remarkably the signal strength of the crude lysates 
was double that of the purified recombinant HSP samples at the same protein concentration. 
This was unexpected but the reason could be that recombinant HSP with protein tags for 
purification may have a different and less accessible conformation for VHH binding 
compared to the native protein. 
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Figure 5: Tests of the effect of exchanging capture and detection antibodies on M. smegmatis 
and M. tuberculosis samples using anti-VSV sprayed LFIA strips. VHH were used at 4µg/ml. 
Treatment A: VHH A-23 with VSV tag was used for capture and biotinylated VHH B-F-10 
was used as detection antibody. Treatment B: VHH B-F-10 with VSV tag was used as capture 
and biotinylated A-23 was used as detection antibody 
 
To evaluate the effect of sequential rather than simultaneous addition of the two VHH 
antibodies i.e. A-23 and B-F-10 to wells containing 16 kDa HSP and CNP-NA, it was 
observed that when antibody A23-biotin was incubated first with the 16 kDa HSP protein and 
CNP-NA a higher signal was obtained compared to incubating B-F-10-VSV first (Fig. 6). 
These results are in agreement with the results obtained by Srivastava et al. [24] on a surface 
plasmon resonance (SPR) platform. There, we also showed that the capture of the HSP dimer 
on a surface (SPR chip there, CNP here) is best done first with VHH A-23 which has both 
epitopes facing to the capture surface (Fig. 1C), leaving room for subsequent binding of the 
16 kDa HSP by B-F-10. Quite possibly if B-F-10 is added first, a coagulation reaction occurs 
removing a lot of HSP dimer from effectively binding to CNPs. 
 
 
Figure 6: LFIA assay response obtained with anti-VSV sprayed LFIA strips when either A23-
VSV or B-F-10-VSV was pre-incubated first with 16 kDa HSP protein, followed by the 
capture VHH (biotinylated A-23 or B-F-10) and CNP-NA of the running mix 
 Lateral flow immunoassay for tuberculosis detection 
 
75 
5.3.3 Sensitivity of HSP detection in sandwich LFIA 
 
The exact amount of 16 kDa HSP protein present in the whole cell lysate was not 
known. For this reason, recombinantly produced and purified 16 kDa HSP protein in E. coli 
was utilized to demonstrate the sensitivity of the system. Fig. 7 shows the LFIA response at 
concentration series of 4, 2, 1, 0.5 and 0.25 µg/ml of recombinant 16 kDa HSP. The lowest 
concentration of 0.25 µg/ml was clearly detected above background in repeated tests. Tests 
used only 25 µl of sample. A concentration of 0.25µg/ml 16 kDa HSP dimer, therefore, 
corresponds to an actual protein quantity of 6.25 ng and a concentration of approximately 6 
nM just 10-fold above the dissociation constants of these antibodies for HSP. Thus, we 
conclude this assay to be highly sensitive and potentially effective as a tool to identify M.tb. 
  
 
Figure 7: LFIA assay response of an anti-VSV sprayed LFIA strip with A23-biotin as 
detection and B-F-10-VSV as capture antibody for detection of 4 to 0.25 µg/ml 16 kDa HSP 
 
5.4 Conclusion 
 
A lot of work has been done over the last few decades to develop fast and effective 
assays for the detection of TB under field conditions that are cheap and robust. These assays 
mainly focus on detection of TB by measuring the serum response to HSP antigens, 
identifying M.tb. cells in sputum or detecting biomarkers in urine [27, 28]. Conventional 
assays, such as radiometric immunoassays, flow cytometry, rapid cultivation techniques or 
sputum cultures for acid-fast bacterium are often not sensitive enough or too time-consuming 
[28-31]. Techniques like nucleic acid amplification are fast and sensitive, but they are 
complex, expensive and require skilled personnel with high quality standards [5].  
 
The LFIA based platform described here may present a useful alternative by 
providing an affordable, fast, simple, sensitive and instrument-independent solution for the 
visualization and identification of 16 kDa HSP protein from lysed M.tb. The method 
identifies a dominant antigen, i.e. the 16 kDa HSP, which is a cell internal protein associated 
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with the membrane and also known to be a major contributor to the pathogenicity of the TB 
causing Mycobacterium strain. The 16 kDa HSP is produced extensively during the latent 
phase, and helps the bacterium to survive inside macrophages during latency [24]. The lower 
limit of detection for LFIA was 0.25µg/ml (6nM) of HSP antigen in 25µl solution. Initially 
with fresh antibodies and antigen (both recombinant and from M.tb.), the results obtained in 
first series of experiments were reproducible but for the second and third series of 
experiments the signal deteriorated and were also not reproducible. The main issue which still 
needs to be addressed is to make the method practical for the detection of M.tb. in sputum 
samples is the pre-concentration of M.tb. cells from sputum and a simple cell lysis protocol to 
obtain a concentrated protein extract. Pre-concentration of M.tb. cells from liquefied sputum 
samples could, for example, be done using magnetic TB-Beads [32] or the up-concentration 
method described in former chapter, followed by controlled lysis of the bacteria using 
mechanical or ultrasonic [33] lysis methods.  
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Abstract 
 
Biosensors allow label-free measurement of targets or analytes with ample 
opportunities for multiplexing and miniaturisation relevant for point-of-care assays. 
Integration of microfluidics brings the added feature of sequential measurements allowing 
high throughput screening. Here, we report the realization of a compact modular biosensing 
system capable of carrying out nanowire based FET detections within a microfluidic flow 
cell. The flow cell is re-sealable on the sensing area of the biosensor chip allowing the 
attachment of biological capture molecules prior to analysis. The nanowire chips have a size 
of 10 × 15 mm with 10 outer electrode connections. The module incorporates a printed circuit 
board soldered with spring probes in contact with the sensing device platform and allows 
switching between AC impedance and DC conductivity measurements. The flow system is 
coupled to a set of syringe pumps with valves that allow for automated injection of defined 
volumes of analyte at a constant flow of buffer. We demonstrate that the nanowire DC 
conductivity responds predictably to sequential injections of different iso-ionic pH solutions, 
and that the sequential binding of proteins (streptavidin, antibody, protein ligand) to the 
surface can be followed in real time with AC impedance spectroscopy of the nanowire. 
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6.1 Introduction 
 
Clinical analyses based on point-of-care diagnostics require dynamic, rapid and 
reliable read outs to diagnose diseases without compromising on sensitivity [1]. For this 
purpose diagnostics based on micro- and nanosystems are being developed which include the 
use electronic, optical, and mechanical (piezo) actuation principles [2-8] to replace automated 
analytic systems using classical microtiter plate-based assays [9]. Most current diagnostic 
assays typically rely on optical spectroscopy, mass spectroscopy, gel electrophoresis or other 
molecular diagnostic assays which are inherently complex, expensive and often low-
throughput due to static or no flow sampling methods [10]. Though these techniques are 
specific and highly sensitive, they are challenging to miniaturize. 
 
Electrical detection techniques can detect analytes with similar sensitivity to optical 
techniques [11]. They are different from other bioanalytical systems in the sense that they 
could provide a direct conversion of a biophysical or biochemical event to an electronic 
signal, which are detected in real time thereby facilitating rapid and convenient sensing 
assays [12]. Nanowire (NW) based sensors are electrical sensors which are potentially 
powerful tools to achieve ultra-sensitive reversible assays due to their large surface to volume 
ratio and semiconductor properties. They enable the direct electrical detection of changes in 
the charge density on or near the sensor surface [13]. Since the initial report in 1999 [14, 15] 
there has been an increased interest towards utilizing NW-based sensors to study the capture 
of biological entities such as DNA, proteins, viruses, bacteria and cells [16-23]. Biological 
sensing layers coated on specific NWs can be used as bio-detection platforms to detect 
captured species in the immediate vicinity of the NW [24]. Both metallic and semiconducting 
NWs have been used for biological sensing. However, the electronic properties of 
semiconducting NWs enable a better signal-to-noise ratio and thus a higher sensitivity. A 
direct electrical readout is also favourable, which is highly attractive for many applications in 
life sciences and medicine [16, 25, 26]. Due to advances in nanotechnology, NW-devices can 
also be readily integrated into miniaturized systems thus facilitating the use of above-stated 
characteristics, which - in turn - would avoid the tedious and time-consuming process of 
labelling chemistry [11, 25, 26]. Lieber and co-workers were the first to make 
semiconducting NWs in a field effect transistor (FET) configuration using a bottom-up 
approach [13-15]. Due to the presence of a thin layer of oxide on top of the NWs, initial 
experiments were focused on pH, ion sensing, and also the detection of charged biological 
macromolecules in aqueous solutions including proteins and DNA [13]. This was done with a 
so-called backgate electrode configuration, without a reference (front or solution gate) 
electrode. 
 
Ion-sensitive field-effect transistors (ISFETs) are field-effect transistors devices that 
are designed for sensitive measurement of changes of specific ion concentrations in solution, 
through monitoring of the current through the transistor in combination with an ion selective 
coating. ISFETs were aimed for electrophysiology measurements where local ion 
concentrations as well as their potentials could be measured. For pH/ion sensing, Bergveld 
determined that planar ISFETs, displaying a typical Nernst limit behaviour, have a maximum 
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sensitivity limit of 59 mV/pH [27]. However, more recently, Knopfmacher [28] and Go et al. 
[29] have shown that dual-gated NW-based ISFETs can go beyond the Nernst limit, thereby 
amplifying small signals that are typical for (bio)chemical sensing at the nanoscale [27, 30]. 
Thus, NWs were evaluated under ISFET configurations with conventional planar ISFETs as 
benchmarks [31]. For biosensors, the most commonly used insulating surfaces are SiO2 and 
Si3N4, which have been well studied due to their CMOS compatibility although other surfaces 
such as ZnO, In2O3, Ta2O3, GaN, etc. have been explored as well [32-35]. With the 
development and integration of new device concepts, optimization of the nanosensor devices 
and their properties is still going on [25]. 
 
The sensor performance is critically dependent on the binding efficiency of ligands 
(biological agents such as antibodies) to the sensor surface. Control of surface (bio)chemistry 
is, therefore, a critical first step. The sensor performance also depends on the binding of the 
chemical species and the orientation of the biological agents. The chemistry needs to be tuned 
to ensure minimal distance between the NWs with the biological sensing entities [36, 37] in 
the order of a few nm. Binding on surfaces can be influenced by a number of factors that 
could enhance molecular binding to surfaces through electrostatic, covalent or simply 
physical interactions [37-39]. Microfabricated electronic devices have surfaces and interfaces 
that could easily be tuned by adopting different surface modification strategies [40]. The need 
to develop point-of-care diagnostics leads to high demands to increase the throughput, reduce 
the size and concentration of samples, and lower the cost without compromising on 
sensitivity. Implementation of microfluidics provides an excellent solution to these needs. 
Microfluidics allows the user to control assay time by means of flow rate, mixing, 
multiplexing and parallel assay designs. Furthermore the assay analysis in such systems is 
improved as the ligand kinetics is visualized in both on and off rates for ligand binding for 
example. During the past decade, there has been a strong trend to realize compact 
microfluidic NW-based biosensing platforms which can monitor specific analytes in a 
continuous flow format [41-44]. These platforms are still under development and differ in 
their designs to carry out reliable measurements.  
 
 In this report, we describe our own design of a compact, modular, microfluidic 
biosensing platform and its capability for carrying out NW-based electrical detections inside 
a re-sealable flow cell. The system is coupled to a set of syringes with valves and syringe 
pump which allows automated injection of defined volumes of analyte solution and a 
constant flow of buffer. We demonstrate its application for pH measurements and protein 
interactions using silicon NW FETs. 
 
6.2 Experimental  
 
6.2.1   Materials 
 
All chemicals used in the present study were of analytical grade and supplied by 
Sigma Aldrich. They were used as received. The solutions were prepared using demineralized 
water (resistivity 18.2 MΩ-cm) obtained using Pure lab Ultra from Elga Lab solutions. The 
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buffers for pH experiments (pH 4 to pH 7) were prepared using 0.1 M citric acid/0.2 M 
dibasic sodium phosphate solutions with an ionic strength of 100 mM [45]. A 2% Hellmanex 
II solution in demineralized water was used for cleaning of new as well as used substrates. 
Also a 2% HF was utilised for cleaning and surface activation of the new as well as used 
substrates prior to surface functionalization. 
 
6.2.2 NW FET devices  
 
The p-type, {100} surfaces SiNW (silicon nanowire) FET array devices were 
fabricated in the class 100 cleanroom (Dimes, Delft University of Technology, The 
Netherlands) on 4-inch SOI wafers from which SiNWs were patterned via plane dependent 
etching using photoresist developer which are conventional wafer-scale process without the 
use of e-beam nanolithography. The width of the SiNWs varied between 100-300 nm while 
their lengths were 7, 10, 30 and 50 μm depending on application [46, 47]. For both pH and 
protein sensing, SiNWs with length of 30 μm, height of 300 nm and a width of 300 nm were 
utilized. 
 
6.2.3 Surface modification procedures  
 
For surface modification, the sensing device was subjected to cleaning via dipping in 
2% Hellmanex II solution for 30 sec followed by surface activation with a 2% HF solution 
for 3 sec. The clean sensing device now obtained was then modified with APTES, which was 
coated overnight in a desiccator via a chemical vapour deposition method [48]. 
  
6.2.4 Biosensing measurement setup 
 
The sensing module along with the sensing chip was coupled to an automated fluid 
syringe injection pump Chemyx Fusion200 and through BNC connectors to the electronic 
measurement system, i.e. Autolab PGSTAT302N and/or Keithley 2612A. For pH 
experiments only the dual channel Keithley 2612A was used, where one channel, i.e. source 
measure unit (SMU), was utilized to monitor the time-dependent response of different pH 
buffers, while the second channel/SMU was used to provide the back gate. For the protein 
binding and antibody-antigen interactions, the Autolab PGSTAT302N was used to provide 
frequency-dependent AC excitation and monitoring of the time-dependent response, while a 
Keithley 2612A was utilized for providing the back gate. Data acquisition and automated 
control of instruments for Autolab PGSTAT302N were carried out using Nova software (V-
10.1). Fig. 1 shows the connection scheme of the biosensing platform hosting the biosensing 
module, the syringe pump with different microfluidics connections and the measurement 
instruments. A syringe pump that supplied a constant flow of buffer controlled the 
microfluidics. Injection of ligands was done using an injection valve. An opening in the 
sensing module right above the sensing area enables optical access to physico-chemical 
events on the sensing platform. 
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Prior to the insertion of the flow cell into the flow cell holder (detailed description in 
section 3.1), the inlet and the outlet of the flow cell channels were manually filled with 
working buffer to prevent the trapping of air bubbles in the channels during the assembly. 
The re-sealable flow cell of volume ~10 µl was created by a silicone ring gasket of 4 mm 
inner diameter and 1 mm height, which created a closed gasket when it was pressed on the 
sensing device with screws of the flow cell holder. For the sequential injection of a series of 
defined samples, a 3-way injection valve system was used which allows the injection of 
predefined volumes of analyte/ligand-spiked buffer over the sensing chip using a piece of 
capillary tubing of defined length. Characterizations of FET SiNW devices were done under 
DC mode (I-V sweeps), whereas impedance measurements were done in AC mode for time-
dependent measurements. An excitation voltage of 10 to 100 mV and frequencies up to 1 kHz 
were used for these measurements. 
 
Figure 1: Schematics of the biosensing measurement platform with the syringe pump along 
with the connection scheme of the biosensing module, hosting the sensing chips. The 
schematics of sensing platform are shown in more detail in the section 3.1 
 
6.2.5 pH sensing 
 
To evaluate the performance of the NW FET sensing module, pH measurements were 
performed on non-functionalized SiNW chips with NWs of 30 µm in length, 300 nm in 
height and 300 nm in width [46, 47]. A continuous flow of 10 µl/min of 0.1 M citric acid/0.2 
M dibasic sodium phosphate buffer at pH 7 and an ionic strength of 100 mM was applied to 
the chip. Simultaneous injections of citrate-phosphate buffers of pH 4 or pH 5 for 4 min over 
continuous flow of pH 7 with an ionic strength of 100 mM were carried out at intervals of 8 
min using 4-way valves. Effects of flow rate were studied with a 100 mM citrate-phosphate 
buffer (pH 4) at flow rates of 0, 5, 10, 15, 20, 25, 30, 40 and 50 µl/min. Drain currents were 
recorded online in all cases. The experiments were performed at gate-source voltage (Vgs) of -
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5 V and drain-source voltage (Vds) of 4 V. The SiNW is a p-type accumulation mode device, 
which means that there is already a measurable drain current at zero gate–source voltage. On 
applying a negative gate-source voltage the device will be brought in a higher conductive 
state.  
 
6.2.6 Protein sensing 
 
To demonstrate the biomolecular sensing properties of the NW FET, the step-by-step 
binding of various proteins to the surface was studied. To this end, the FET NW chip was 
first coated with APTES as described above, followed by a coupling reaction to a PEGylated 
biotin reagent EZ-Link NHS-PEG12-Biotin (EZ-link in short, obtained from Thermo Fischer 
Scientific, The Netherlands). In 0.1 × PBS pH 7.5, EZ-link reacted with the exposed amino 
groups present on the APTES-modified NW FET surface in 30 min [49]. Activated chips 
were then mounted in the sensing module and binding of 50 µl of 1 nM streptavidin dissolved 
in 0.1 × PBS pH 7.5 was measured. Then, 35 µl of 5 µg/ml, i.e. 300 nM biotinylated VHH 
llama antibody A-23 was applied [50, 51] in 0.1 × PBS pH 7.5. Then 65 µl 100 ng/ml, i.e. 2.5 
nM of mycobacterium tuberculosis specific 16 kDa antigen recombinantly produced in 
E.coli, in 0.1 × PBS pH 7.5 was applied [50]. The experiments were performed at a gate-
source voltage (Vgs) of -20 V and drain-source voltage (Vds) of -0.1 V, while the flow speed 
for all the experiments were kept constant at 10 µl/min. 
 
6.3 Results and discussion 
 
6.3.1 Construction of the sensing module 
 
The prototype biosensing module described here was a compact module that 
comprised of the following components: a borosilicate glass flow cell with gasket, silicon 
NW FET with 10 contact pads, a metal flowcell/chip holder and a printed circuit board (PCB) 
with solder mounted spring probes for connecting to the sensing device. These items were all 
assembled inside a die-cast aluminium metal alloy LM24 Faraday cage that excluded 
environmental noise from light and electromagnetic interference along with enabling easy 
connectivity to the signal readout systems. All components are described in more detail 
below. 
 
6.3.1.1 Microfluidic flow cell 
 
The top part of the flow cell measured 45 mm × 15 mm × 1.5 mm, but the gasket 
forming the actual flow cell with the NW FET was only 4 mm in diameter (10 µl in volume) 
(Fig. 2). The fluids were supplied to the inlets through plastic tubing with an inner diameter 
of 250 µm, while the outlet tubing had an internal diameter of 750 µm to prevent pressure 
build-up in the flow cell. The top part of the flow cell consisted of two borosilicate glass 
slides fused together by heating at high temperatures. The top part has an etched fluidic 
channel to lead the fluid inlet and outlet to the sensing area confined in a gasket of 5 mm in 
diameter and 1 mm in height. The bottom slide sealed the patterns of the top part and encased 
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the fluid inlet and outlet to the gasket covered area (Fig. 1). The gasket was either applied to 
the glass surface using a robotic glue dispenser before it was cured onto a soft elastic material 
or simply based on a standard natural rubber O-ring. The glass flow cells used here did not 
leak under a wide range of flow rates from 1 µl/min to 100 µl/min. 
 
 
Figure 2:  Schematic drawing of the construction of the glass flowcell: The top part of the 
flow cell is made from two fused borosilicate glass sheets (dark and light gray), of which the 
top one contains a series of holes (black circles) for connecting fluidics along with two 
etched channels open to the top and two openings for entry/exit to the O-ring compartment 
and the lower one only contains the two openings for entry/exit to the O-ring compartment 
(black circle inside the O-ring). The fused glass top part is pressed on the NW chip separated 
by the flexible O-ring seal thus creating the flow cell 
 
6.3.1.2 The flowcell/chip holder 
 
The flow cell and the electronic sensing device are placed inside a compact holder, 
consisting of two parts. The bottom part of the holder is made up of Teflon that contained 
slots for placement and alignment of the chip die and the flow cell. The top part is a stainless 
steel lid that consists of the inlet and outlet for fluidic interconnects to the glass flow cell; as 
well as a pin-based electrical spring contacts for connecting the contact pads of the sensing 
chip with the electrical measurement device. To obtain leakage-free flow cells, the top part of 
the holder is fastened with screws. The holder had dimensions of l × b × h: 8 cm × 5.5 cm × 
0.56 cm and slot dimensions for placing the flow cell of 4.5±0.03 cm × 1.5±0.03 cm × 0.39 
cm, and slot dimensions for placing the sensing device of 1.5±0.03 cm × 1 cm × 0.17 cm 
(Fig. 3). 
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Figure 3:  Schematics of flowcell/chip holder: sketch showing the Teflon/metal bottom plate 
where the chip is hosted under a glass flowcell and the top metal part along with the fluidic 
and electronic connections 
 
6.3.1.3 PCB module and the measurement box 
 
The PCB layout is a crucial part of the sensing module, allowing high-quality 
connectors and switching between AC/DC impedance spectroscopy and NW FET 
measurements. Switching between DC-based FET measurements and AC-based impedance 
measurements could be done by the switch indicated in brown in the PCB layout (Fig. 4). The 
PCB layout had an open window over the sensing chip to enable optical observations. Five 
soldered mounted spring contacts on either side of this window on the PCB enabled electrical 
connections to the contact pads of the sensing chip. In addition, the PCB sits in such a way on 
the flow cell holder, that the micro-fluidic connections are not hindered.  The sensing module 
and measurement setup were grounded via the PCB. 
 
In order to carry out AC-based impedance measurements between pins on either side 
of the optical window, jumpers are inserted in the respective red boxes between A and D or B 
and C to establish the connections to the desired pairs of pins where the electrode 
measurements can be performed. For DC-based FET measurements, connection to the source 
and drain were realized using BNC connectors to “drain high” and “source low”, with biasing 
using “gate high” and “gate low”. T-connectors were used to couple the “source low” and 
“gate low” BNC connections and to keep the entire module at ground potential. Additional 
sets of BNC sockets were provided for carrying out parallel reference measurements 
simultaneously. 
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Figure 4: Schematics of the PCB layout, used for connecting the NW chip with the readout 
electronics with two independent, two-point connection systems, i.e. between point A-D and 
B-C for parallel measurements. A set of two independent BNC connector is available at each 
point, i.e. A, B, C and D for connection to two adjacent devices, e.g. 1 and 2. (further 
described in 3.1.3) 
 
6.3.2 Platform characterization using NW FET pH sensing 
 
Lieber  and co-workers have previously shown how the solution pH affects source-
drain currents of functionalized and non-functionalized silicon NWs [13].The non-
functionalized SiOx surfaces are acidic in nature (pKa=4).  The charges induced on the NW 
surface are dependent on charge polarity of the oxide. At high pH, H+ ions are removed i.e. 
Si-OH deprotonates to give negatively charged SiOx- groups which attract the holes present in 
the p-doped silicon NW increasing the conductance through the NW. When the pH is 
decreased, the H+ concentration increases, neutralizing the SiOx- groups (to give SiOH, and 
repelling the (positive) majority charge carriers in the NW and causing the current to decrease. 
NW FET functionality and behaviour under flow in this platform was, therefore, first tested 
by pH measurements on non-functionalized silicon NWs covered with a layer of native 
silicon oxide. 
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Figure 5: The pH response of NW-based sensors. Panel A shows the response of different pH 
solutions ranging from pH7 to pH 4 on a NW, under a Vgs of -5 V and Vds of 4 V and a flow 
rate of 10 µl/min. The Vds is set relatively high to obtain an Ids with good signal to noise ratio. 
Panel B shows the response of sequential injections for 4 min of either pH 4 or pH 5 over a 
continuous flow of pH 7 and an interval of 8 min at a flow rate of 10 µl/min. NWs used in the 
experiment had the following dimensions: 30 µm in length 300 nm in thickness and 100-300 
nm in width 
 
Response profiles to citrate-phosphate solutions (ionic strength of 100 mM) of pH 4-7 
under continuous injection are shown in Fig. 5A. As expected, a decrease in drain current of 
the NW FETs was observed with decreasing pH and rather stable currents of 30-31 µA with 
only slight drift established within 3 min. The experiments were reproduced with 
simultaneous injection for 4 min of either pH 4 or 5 buffers over a continuous flow of pH 7 
and an interval of 8 min at a flow rate of 10 µl/min in order to verify the observed pH 
reversibility effects. Fig. 5B shows the time-dependent pH response of the devices under a 
flow rate of 10 µl/min over the non-functionalized SiNW FETs. At pH 7, a stable response 
was recorded. After 8 min, the device was switched to a 100 mM citrate-phosphate solution 
of pH 4 for 4 mins. A transient decrease in the order of 1 µA was observed upon re-injecting 
a buffered solution of pH 4. Similarly for pH 5, reproducible responses of a 0.5 µA current 
change were recorded. Over time there is a slight increase in the source-drain current Isd, 
which may be attributed due to a drift induced by the continuous flow of pH solution in the 
flowcell. The results obtained here for non-functionalized NWs can be quantitatively 
compared with the results obtained by Stern et al. who tested pH solutions ranging from pH 8 
to pH 6 on un-functionalized nanobars for two dimensions, i.e large (1000 nm in width and 
80 nm in thickness) and short (100 nm in width and 25 nm in thickness) nanobars. For large 
electrodes they observed a decrease in drain current of 700 nA and 190 nA for pH change 
from 8 to 7 and 7 to 6, respectively, whereas for short electrodes the decrease in drain current 
was 445 nA and 70 nA for a similar transition in pH. It can also be inferred that the change in 
drain current depends on the dimension on the electrode [52]. Although a direct comparison 
of our results with the results obtained by Stern et al. would be difficult due to different pH 
ranges measured, but the trends obtained for changes in drain current were in the same 
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direction [52]. Kim et al. reported the effects of flow velocity of ionic solutions on electrical 
currents through SiO2-covered SiNWs [53]. To check for such effects in our set-up a pH 4 
citrate-phosphate solution was injected at variable flow speeds from 5 to 50 µl/min. Although 
initial changes in the drain current were observed upon changing the flow, no overall change 
was observed (Fig. 6). Initial changes were presumably caused by the sudden change in flow 
rate causing a pressure wave with apparent transient electrical consequences. The previously 
observed effects of flow rate of ionic solutions on NW’s conductance (both p-type and n-type 
devices) [53], were claimed to be due to the formation of streaming potentials when excess 
counter ions are swept down a pressure-driven flow. We believe the difference between this 
work on our results may be due to the fact that the flow rate range probed by Kim et al. was 
60-900 µl/min with an ionic strength up to 1 mM, while we remained below 50 µl/min flow 
rate with an ionic strength of 100 mM. It could thus be inferred that the dependence on the 
flow rate reduced above 1 mM ionic concentrations. In more detail, from theory we know the 
value of the streaming potential is inversely related to the electrical conductance of the 
medium. Since the electrical conductance is proportional to the ionic strength we have an at 
least 100 times reduced value for the streaming potential than found by Kim et al. We 
understand therefore why the device did not show significant changes within the tested ionic 
and flow rate range. 
 
 
Figure 6: Flow rate induced effect on NW with a Vgs of -5 V and Vds of 4 V: effect of different 
flow rates ranging from no flow to 50 µl/min of a pH 4 buffer solution with an ionic strength 
of 100 mM, under a Vgs of -5 V and Vds of 4 V and an interval of at least 5 min after every 
injection 
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6.3.3 Biomolecular sensing using FETs 
 
To demonstrate the suitability of utilizing NW FETs in the present compact 
biosensing module for the detection of binding of proteins from solutions, an experiment was 
set up to test the binding of dissolved streptavidin in 0.1 × PBS solution on biotin-coated 
NWs, followed by the binding of biotinylated VHH llama antibody A-23, and its specific 
antigen, i.e. the 16 kDa recombinant heat-shock protein produced in E. coli  [50]. For this 
purpose, the NW FETs were pre-functionalised with APTES, followed by a PEG12-Biotin 
cross linker that reacts with the amino-groups present on the APTES coating. Fig. 7 shows 
the resulting binding response in terms of the measured impedance (inverse of the complex 
analogue of conductance). The change in impedance for 1 nM streptavidin in a 0.1 × PBS 
buffer solution was 50 kΩ, which was a change of about 1%. Elfstrom et al. did a similar 
experiment where they demonstrated the binding of 1 nM streptavidin to biotin-coated NW 
FETs and observed a decrease in the normalized current using p-type NWs with dimensions 
of 45 nm in thickness and 100 nm in width [49].  
 
 
Figure 7: Impedance vs time response plot upon binding of different proteins on NWs. 
The first streptavidin blue bar shows the time during which 1 nM streptavidin was present on 
a biotin functionalized NW. The green (antibody) bar shows the time during which 300 nM 
VHH antibody A-23 was present on an streptavidin-functionalized NW, while the blue 
(antigen) bar shows the duration for a 2.5 nM HSP antigen solution on the antibody 
functionalized NW. The flow speed for the experiment was kept constant at 10 µl/min 
 
Since the current is inversely related to impedance, it could be inferred that the 
binding of (negatively charged) streptavidin resulted in an increase of the absolute impedance 
in their case. A similar pattern was observed in our case as well as we also see an increase in 
impedance of the NW upon binding of 1 nM of negatively charged streptavidin at pH 7.5 (pI 
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~5.6). Although this is counterintuitive it can be rationalized as follows. The biotin-coated 
NW will be negatively charged at pH 7.5 and surrounded by small positive counter-ions 
(Na+). The negatively charged streptavidin molecule will also be surrounded by positive 
counter-ions. The streptavidin molecule however is quite large (50-60 kDa) and thus its cloud 
of counter-ions is more scattered (less dense) around the molecule. Also the isoelectric point 
of streptavidin is much higher than that of biotin, which means that the streptavidin molecule 
is less negatively charged than the biotin molecules attached to the NW. When the 
streptavidin with its counter-ions comes close to the NW, then the positive counter-ions of 
the streptavidin will also be attracted strongly by the negative groups of the biotin, herewith 
reducing the strength of the electrical double layer close the NW. The latter means that less 
negative charge of the biotin groups is felt inside the NW, and that some majority charge 
carriers (holes) in the NW will be repelled, resulting in higher impedance. Please note that the 
negatively charged streptavidin molecules are always in distance further away from the NW, 
and that its electric field gradient is effectively shielded by the Debye Length. With the 
binding of the biotinylated antibody A-23 having a molecular weight of 17 kDa and HSP 
antigen dimer of 40 kDa, we again see an increase in the impedance of 30 and 40 KΩ 
respectively. Both the antibody (pI ~ 5.9) and antigen (pI ~ 6.1) are negatively charged at pH 
7.5 thus this increase in impedance observed is reasonable based on the previous rationale. At 
around 1600 sec, there is first a small jump down and then a constant level of bound antigen. 
This pattern is similar to what we observe in SPR and could be attributed to the bulk response 
when buffer with HSP is exchanged for buffer without as well as slow unbinding of 
specifically bound antigen as also shown in Srivastava et al. using SPR (Chapter 3, Fig. 4). 
 
6.4 Conclusion 
 
In conclusion, we have demonstrated a flow-based sensing module for NW-based 
FET-based biomolecular electrical sensing. We have demonstrated pH-dependent sensitivity, 
detection of streptavidin and have provided some first evidence of a response to protein 
binding at flow rates of 10 µl/min. Unfortunately, due to a shortage of NW chips - additional 
experiments to corroborate this could not be carried out in the frame of this project. A 
limitation in the present prototype is the inability to do simultaneous measurement on more 
than one electrode, due to electrical interferences. In future, integrating an array of sensors 
enabling multichannel measurements with the aim of performing simultaneously multiple 
biomolecular sensing could be an extension to the present module. 
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Abstract 
 
Impedance spectroscopy of cell lines on interdigitated electrodes (IDEs) is an 
established method of monitoring receptor-specific cell shape changes in response to certain 
analytes. Normally, assays are done in multiwells making it a bulky, static and single use 
procedure. Here, we present a biosensor allowing sequential application of biological test 
samples with an automated microfluidic system. It is capable of monitoring relative changes 
in impedance using castellated IDEs of 250–500 µm diameters, covered with stable or 
reverse transfected HEK293 cells. Reversible activation of the Neurokinin 1 (NK1) receptor 
in stable cell lines was observed in response to a series of 5 minute exposures from 1 pM – 10 
nM of the specific ligand Substance P (SP) using impedance measurements at 10 mV and 15 
kHz. An optimal flow speed of 10 µl/min was chosen for the 10 µl flow cell. The EC50 of 
~10 pM was about 10 times lower than the EC50 based on measuring changes in the calcium 
ion concentration. The method was also shown to work with reverse transfected cells. 
Plasmid DNA encoding the NK1 gene was spotted onto the electrodes and pre-incubated with 
a transfection agent. The overlaid HEK 293 cells were subsequently transfected by the 
underlying DNA. After challenge with SP, the cells induced an activation response similar to 
the stable cell line. The microfluidic micro-electrode reverse transfection system opens up 
possibilities to perform parallel measurements on IDE arrays with distinct receptors per IDE 
in a single flow channel. The potential of the system for measuring host-derived biomarkers 
of patients is discussed. 
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7.1 Introduction 
 
The use of label-free sensing in cell-based screening is gaining increasing interest as a 
tool to enable the discovery of analytes specific for G protein-coupled receptors (GPCRs) in 
applications involving pharmaceutical drug screening [1, 2]. A strong potential exists to use 
these receptors as well for monitoring of food quality and safety, and disease diagnosis. 
However, the microtiter plate-based platforms tend to be too costly for these tasks [3, 4]. 
Responses of live cells expressing GPCRs to specific analytes are usually immediate, 
transient (1-5 min) and can be highly sensitive (nM–pM range). In comparison to 
conventional diagnostic methods for example PCR for DNA/RNA detection and ELISA for 
immunodetection, the activation of GPCRs identify a sample’s bioactivity, but not its 
identity. This can be an advantage when the potential ligand is unknown or diverse [5]. 
Broader application of GPCR-based assays for diagnostics will hinge on our ability to scale 
down the assays to save on handling and material costs and to integrate them with automated 
microfluidic formats allowing multiple sequential use and internal calibration [6]. 
 
GPCRs play important roles in sensory, physiological and disease-related signalling 
processes. As such they can be utilized for screening assays in both medical and food related 
industries. Collectively the ~800 receptors known in humans specifically recognize 
extracellular stimulants ranging from glycoproteins, cytokines, hormones, neurotransmitters, 
growth factors, to tastants and odorant molecules [7]. Once activated, the dissociating G 
proteins trigger one or more pathways that finally generate an intracellular response [8]. 
Generally, for measurement of GPCR activation assays, concentration dynamics of secondary 
messengers like Ca2+ and cAMP are studied in real time utilizing various fluorescent 
indicator dyes [9, 10]. Alternatively, field-effect transistors, impedance spectroscopy, light-
addressable potentiometry, patch clamp and piezoelectric methods have been used [11]. 
Impedance spectroscopy is a well-established technique for studying effects of biomolecules 
on a wide range of prokaryotic and eukaryotic cells [12]. The technique measures the 
combined resistive and capacitive changes due to morphological or mass redistribution 
changes of cells on electrodes [13]. 
 
Yu et al. (2006) showed for the first time that impedance measurements of cells 
transfected with different GPCRs allowed measurements of morphological changes; however, 
those were measured in terms of h rather than min [14]. Since then, the advent of dedicated 
instruments has opened a large research field, and dedicated assays were demonstrated to be 
similarly sensitive as label-based methods, but operate on a scale of minutes rather than 
seconds [1, 2]. In 2009 Meshki et al. demonstrated substance P (SP)-dependent activation of 
the Gα12/13 pathway using HEK293 cells expressing the NK1 receptor. The pathway causes 
apoptosis-independent cellular blebbing, and is mediated by the Rho/Rho-associated coiled-
coil kinase pathway [15]. The activation of this receptor has been associated with the 
transmission of stress signals and pain, the contraction of smooth muscles and inflammation 
[16]. The morphological changes of the cells after the activation of the Gα12/13 pathway could 
be monitored using impedance spectroscopy, and there have been similar demonstrations for 
other receptors and activation pathways [14, 17-19]. In general, it is thought that also 
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activation of Gαs, Gαi/o and Gαq/11 pathways can lead to changes in actin and myosin 
complexes of the membrane cortex that are essential for cell shape and locomotion [20]. 
 
At present there are four commercial electric cell-substrate impedance-sensing (ECIS) 
platforms available in the market (ECIS, xCELLigence (RT-CES), Bionas Discovery 2500, 
Cellkey). These systems have been utilized for a large variety of studies, including cell 
adhesion, proliferation, cytotoxicity, receptor-mediated signalling, barrier function and 
immune cell signalling [21, 22]. These systems utilize interdigitated electrodes (IDEs) of 
similar dimensions (i.e. electrode features of 30 µm and line gap of 50 µm) [23] in 8, 16, 96 
or 384 (RT-CES and Cellkey) well microplate formats. However, other IDE dimensions are 
needed to expose cells transiently and/or repeatedly to a ligand, including integration with 
microfluidic auto-samplers. These changes would make them amenable to automated internal 
calibration and create possibilities of screening or monitoring of biological targets with lower 
material and labor costs [6, 24, 25]. To also match the power for parallel measurements 
solutions are needed to generate and read cell arrays in flow cells. Some approaches have 
focused on top down dispensing methods of transfected cells into semi-open array structures 
[26]. A potentially more elegant and low cost solution can be found in reverse transfection of 
spotted plasmid DNA [27]. This method allows the formation of cell arrays by overlaying the 
DNA arrays with a single cell type. However, until now, the method has not been applied to 
IDE based methods or flowcells [27]. 
 
In this study, we aimed to demonstrate for GPCRs the possibility of doing sequential 
impedance measurements on stable cell lines and reverse transfected cells by monitoring 
impedance changes during serial injections of analyte in a microfluidic flow configuration. 
 
7.2 Materials and Methods 
 
7.2.1 Materials 
 
All chemicals were analytical grade and supplied by Sigma Aldrich, unless specified 
otherwise. The NK1 receptor gene construct NK1-T2ANC YC3.6 for stable and reverse 
transfection cell lines as well as the cell culture conditions were as described by Roelse et al. 
[28]. All solutions were prepared in demineralized water (conductivity 18.2 MΩ∙cm) 
obtained using Pure lab Ultra from Elga Lab solutions. 
 
7.2.2 IDE preparation  
 
The gold interdigitated electrodes IDEs were fabricated (Nanosens BV, Zutphen NL) 
using a standard micro-photolithography process on thermally oxidized silicon oxide/silicon 
substrates of 10 × 15 mm dimensions. Interdigitated chromium-gold patterns of 20 μm line 
width with castellated features of 40 μm length and a line spacing of 12 μm were printed on 
the silicon substrates as a series of 5 sensing electrodes with a unit-to-unit distance of 500 
μm, and electrode dimensions of 500 × 500 (central three) or 250 × 250 μm (terminal two) 
(Fig. 1A). Prior to use, the sensing chips were subjected to cleaning, surface activation and 
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modification procedures. New and used IDE sensor chips were cleaned with 2% Hellmanex 
II in MilliQ water followed by exposing the chips to a 2% HF solution for 10 sec and rinsing 
with de-mineralized water. For adherence of cells, surface functionalization of both gold and 
silicon oxide was required. First, the gold electrodes were surface functionalized via drop 
casting with 25 mM of cysteamine in ethanol for 30 min [29] followed by a modification of 
the SiO2 surface with APTES through chemical vapor deposition on the chip [30]. 
Subsequently, the gold arms connecting the sensing area with the contact pads were covered 
with a negative photoresist SR3170 PR. Finally, bovine fibronectin (100 µg/ml, Mw ~220 
kDa) was drop-casted, incubated for 30 min at 37ºC, and unbound fibronectin was rinsed off 
the chips with MilliQ water [29, 31].  
 
7.2.3 Flowcell set up 
 
A re-sealable and re-usable flow cell was designed to allow connection to a 
microfluidics system. The flow cell had dimensions of 4.5 cm × 1.5 cm × 0.15 cm. On the top 
of the borosilicate glass flowcell the in- and outlets were spaced 3.5 cm apart and on the 
downside 4 mm apart, connected by an internal microfluidic channel. A poly-silicone gasket 
of 5 mm in diameter and 1 mm in height yielded a compact encasing around the 5 IDEs and 
resulted in a flow cell volume of 10 µl. The fluids were supplied to the inlets through a 
Teflon connection tubing of inner diameter 250 µm while the outlet tubing had an internal 
diameter of 750 µm to prevent any pressure build-up and leakage from the flow cell. Cultured 
chips were placed in a tailor made stainless steel chip holder of dimensions of l × b × h: 8 cm 
× 5.5 cm × 0.56 cm with slot dimensions for placing the flow cell of 4.5±0.03 cm × 1.5±0.03 
cm × 0.39 cm, and with slot dimensions for placing the sensing device of 1.5±0.03 cm × 1 cm 
× 0.17 cm (Micronit Microfluidics BV, Enschede, NL). A printed circuit board (PCB) with 
solder-mounted spring probes for connection to the sensing device was assembled over the 
chip holder. This flow cell device was mounted inside a die-cast aluminium metal alloy 
LM24 Faraday cage to exclude environmental noise from light and external electromagnetic 
interference and enable easily accessible connections to the signal readout systems.  
 
7.2.4 IDE preparation with stable cell lines and reverse transfected cells 
 
The fibronectin coated IDE chips were seeded and incubated for 15 min with 0.5 ml 
of freshly harvested NK1 expressing stable HEK293 cell lines [28] by drop casting at either a 
density of 1×104 or 1×106 cells/ml, followed by the addition of 9.5 ml of freshly prepared 
DMEM medium in a dish of 5.5 cm in diameter. A uniform monolayer of cells with ~50% 
coverage for lower and ~80-100% for higher seeding density had formed after 48 h of 
incubation at 37ºC in a 5% CO2 environment. All subsequent experiments were performed at 
room temperature in HEPES assay buffer composed of 20 mM HEPES pH 7.4, 137 mM 
NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4 and 20 mM glucose. Serial injections of 
various freshly prepared dilutions of NK1 ligand SP (Bachem AG, Switzerland, product nr. 
H-1890, stock solution of 0.5 mM (0.67 mg/ml in 50% acetic acid) in HEPES assay buffer 
was carried out at a constant flow rate of 10 µl/min.  
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For reverse transfection experiments fibronectin-modified chips were used as 
described above. The 0.5 mm diameter sensing area of the IDE was spotted with 1 µl of 
DNA-gelatin mixture (1 µg of transfection grade NK1-T2ANC YC3.6 as described by Roelse 
et al. [28] with 1 µl of 1.5 M sucrose and 12 µl 1% gelatin in total of 30 µl MilliQ) using a 
micropipette, followed by drying for 1 h in a 50–60% humidity chamber. Spotted chips were 
stored in a dry box. For experiments, the chips were drop casted with 30 µl of effectene 
mixture (30 µl of buffer EC, 3.2 µl of enhancer and 5 µl of effectene reagent, all taken from 
the Qiagen effectene transfection kit) on top of the DNA spotted area and incubated for 10–
20 min at room temperature. The chips were then rinsed with DMEM medium and seeded 
with freshly harvested wild type HEK293 cells at a density of either 1×104 cells/ml (the 
multiple loop injections of 1 nM SP experiment) or 1×106 cells/ml (the multiple-loop 
injections of 1 pM to 100 pM SP experiment) and cultured in DMEM medium for 48 h in an 
incubator with 5% CO2 at 37ºC.  
 
7.2.5. Impedance measurements 
 
Impedance measurements were performed at a fixed voltage of 10 mV and a fixed 
frequency of 15 kHz as described previously [32] and cell responses were measured as a 
function of time using an Auto Lab PGSTAT302N with FRA2 module (Metrohm Autolab 
B.V., The Netherlands) at a frequency interval of 3 sec. The sensitivity of the instrument was 
in the range of ~0.1 Ω+2% – 1 Ω+0.3%. Before and after each series of measurements a 
frequency-impedance sweep of the cell covered electrode and the bare electrode was carried 
out in the range of 1 Hz to 1 MHz in order to quantify the impedance contributed by the cells 
covering the IDEs. 
 
7.3 Results 
 
7.3.1 Impedance characterization of cell covered IDEs 
 
To allow experiments in the flow cell the first requisite was proper adhesion of the 
cells to the gold electrodes under the shear of the applied flow rate. For this, IDE chips were 
given a surface modification using cysteamine, APTES and fibronectin to enhance cell 
adhesion under flow as described in Materials and Methods. Stable NK1 receptor expressing 
HEK 293 cells (1×106 cells/ml) were applied on the IDEs and after 2 days of culturing a 
nearly complete monolayer of cells was formed (Fig. 1B). After the flow cell was integrated 
into the stainless steel chip holder, a flow of 10 µl/min was applied. The absolute impedance 
response as a function of frequency sweep (Bode plot) was recorded for both cell-covered 
and cell-free IDEs in a set up as shown in Fig. 1A. Absolute impedance was found to increase 
in the range of 100 Hz to 1 MHz due to the coverage of cells on the electrodes. For time-
dependent measurements we chose to work at a frequency of 15 kHz where electrode surface-
related effects are dominant and the cells induced an additional impedance of around 2 kΩ for 
500 µm IDEs (Fig. 1C), and 2.5 kΩ for 250 µm IDEs. 
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Figure 1: Optical and electrical characterization of IDE electrode chips. A: Schematic 
representation of the sensing device. B: Microscopic image of a 250 µm IDE coated with 
NK1-HEK293 cells [28] showing ~80% coverage on the electrode between the yellow layers 
of photoresist after the measurement. C: A Bode impedance spectrum of an IDE of 500 µm 
with and without cell coverage in HEPES buffer or without liquid medium exposed to 
ambient air (dry blank) 
 
Prior to further analysis each electrode, covered with stable NK1 receptor expressing 
HEK293 cells, was first characterized with a Bode plot (Fig. 2A) and a Nyquist plot (Fig. 
2B). The Bode plot was generated under a 10 µl/min flow of HEPES medium. At around 1 
kHz, the phase shift of the Bode plot reached a maximum of around 70º, which was 
indicative of a quasi-capacitive behaviour originating from the nearly confluent cell layer on 
the electrode, which slowly decreased upon increasing frequency [33, 34]. In the sample 
analysed in Fig. 2B, the Nyquist plot shows quasi- parallel resistive-capacitive RC 
component behaviour for the central cell-covered electrodes (500 µm) (Fig. 2B and 2C) [34]. 
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7.3.2 Impedance responses of stable NK1 receptor-expressing HEK293 cells 
to SP  
 
 Based on the response obtained from impedance spectra of the Bode and Nyquist 
plots (Fig. 2), a single pair of 500 µm IDEs covered with stable NK1 receptor expressing 
cells was chosen to measure the specific cell response to activation by a series of injections of 
SP. Following literature and from Fig. 1, a frequency of 15 kHz and amplitude of 10 mV was 
chosen to record the induced changes in cell-electrode coverage [32, 35]. A 50 µl sample of 
SP was loop-injected at concentrations ranging from 1 pM to 10 nM. Samples were diluted in 
the same HEPES buffer also used for continuous flow. Due to the constant flow rate of 10 
µl/min - each 50 µl injection lasted 5 min and was always followed by a recovery period of at 
least 2–3 min.  
 
Figure 2: Optical and electrical characterization of a 500 µm IDE with stable NK1 HEK293 
cells. A: Bode plot of an IDE covered with NK1-HEK293 cells. The black line indicates the 
impedance, and the blue line shows the phase. B: Nyquist plot of the same IDE and C: optical 
microscope image with normal light of a cell covered microelectrode of 500 µm after the 
experiment. In red is the photoresist (SR3170 PR) shielding the connecting electrodes from 
the assay solution. The plots were obtained from the central 500 µm electrode. 
 
In detail, Fig. 3A shows the combined signals obtained from stable NK1 receptor 
expressing covered electrodes during and after exposure to 1 pM to 10 nM SP as a function 
of time. Subplots of Fig. 3B-3F show the same for individual SP concentrations compared to 
the blank measurement. The overall sample resistance of the sensing area coated with cells 
was around ~5 kΩ with a contribution from cells of ~2 kΩ. As a control for non-specific 
buffer effects or drifts from switching the valve, blank injections were done by injecting only 
buffer on stable NK1 receptor expressing cells (Fig. 3).  
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Figure 3: Impedance change of a 500 µm IDE covered with an stable NK1 receptor 
expressing cell line in response to 300 sec injections of different concentrations of ligand SP. 
Panel A: the combined data of impedance response to different concentrations of ligand 
doses ranging from 1 pM to 10 nM on interdigitated electrodes covered with stable NK1 
receptor expressing cells. Panels 3B-3F: the changes in impedance for individual ligand dose 
concentrations. The intervals in light blue background color represent the period that SP was 
contacting the cells, while areas in white represent recovery periods with buffer flow without 
ligand. The notation 1–10 in the ligand of the plot represents the sequence of injection. 
Assay-independent drift was corrected in all cases by subtracting a linear slope coefficient of 
a line drawn between t = 0 and the highest recovery point between t = 400–500 s post 
injection (t = 300 s for the blank). 
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As a negative control to verify that the signals obtained were due to GPCR activation 
only and not due to changing concentrations of SP, different concentrations of SP were tested 
on wild type HEK293 cells (Fig. 4). The baseline noise level was below ~2 Ω for this sample. 
The system could detect cell morphological changes after challenges with concentrations of 
SP down to 1 pM even when the electrodes were fully covered with cells. An average 
impedance change of around 14 Ω was observed for 1 pM concentrations, whereas the higher 
concentrations (10 pM, 100 pM, 1 nM and 10 nM) showed average changes of 60, 89, 94 and 
87 Ω, respectively. Impedance changes associated with the mechanical injection process were 
found to be negligible. Every injection of SP followed a typical response pattern, with a 
maximum response being reached typically 100–200 sec after injection, followed by 
decreasing impedance and a recovery period after removal of SP of again 100–200 sec. The 
activation and recovery slopes of the curves were very similar, independent of the ligand 
concentration, but the response valleys were deeper at higher ligand concentrations. There 
was some uncontrolled variation in both the onset (e.g. Fig. 3F) of the strong response and 
also in the response duration (e.g. Fig. 3E vs. the rest). Also the tenth injection of 10 nM SP, 
showed a lower response compared to the ninth injection of the same concentration of SP. 
This could be due to saturation of the receptor as described by Roelse et al. 2013 [28]. 
 
Figure 4.Transient response of wild type HEK293 cell lines coated IDEs (500 µm) to the SP 
ligand (1 pM-10 nM). Assay-independent drift was corrected as in Figure 3. 
 
7.3.3 Impedance responses to SP on NK1-expressing reverse transfected 
wild type HEK293 cells 
 
Arrays of electrodes in a single flow cell can be individually transfected with different 
receptors by means of reverse transfection. HEK293 cells, reverse transfected with NK1 
plasmid DNA on 500 µm electrodes, were first characterized with Bode (Fig. 5A) and 
Nyquist (Fig. 5B) plots when full cell coverage was reached after 48 h. These plots were 
generated under a 10 µl/min flow of HEPES medium and the phase response was plotted for 
reference purposes. Two-phase shifts at 1–15 kHz, and 0.1–1 Hz were evident in the Bode 
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plot (Fig. 5A) suggesting two independent electrical Resistance-Capacitance circuits (RC 
circuit). This is also evident in the Nyquist plot (Fig. 5B) where two corresponding 
semicircular regions are observed. The large semi-circle corresponds to a low frequency RC-
circuit formed by the internal IDE electrical capacity and an electrical resistance, originating 
from the transport/diffusion of ions via the bulk liquid towards the electrodes. The small 
semi-circle corresponds to a second RC-circuit formed by the electrical capacity of the cell-
envelopes and the electrical conductance within the cells and of the exo-ions towards the 
electrodes. Both RC circuits are present in parallel (cf. extended Randle equivalent circuit) 
and at 15 kHz mainly the presence of the second RC-circuit are probed, herewith recording 
sensitive changes in the electrical capacity of the cell-envelopes. 
 
 
Figure 5: Optical and electrical characterization of IDE (500 µm) electrode chip used for 
the experiments with reverse transfected HEK293 cells expressing NK1 receptor. A: Bode 
plot from an electrode covered with reverse transfected HEK293 cells expressing NK1 
receptors. B: Nyquist plot from a cell-covered electrode and C: optical image of cell-covered 
electrodes of 500 µm. In red is the photoresist (SR3170 PR) covering the thick connecting 
electrodes. 
 
To test the compatibility of the process of reverse transfection with impedance 
measurements, two distinct experiments were performed. First, doses of 1 nM SP were 
repeatedly passed over reverse transfected cells with chips seeded at a lower cell density 
(1×104 cells/ml), and after that, doses ranging from 1–100 pM SP were tested on a different 
chip seeded at high cell density (1×106 cells/ml). Fig. 6A shows the combined signal obtained 
from reverse transfected cell-covered electrodes exposed to repeated 1 nM SP injections. An 
average maximum response amplitude of ~18 Ω was obtained which was 2–3 Ω less than the 
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signal obtained for 1 nM with stable transfected NK1 cell lines seeded at the same cell 
density of 1×104 cells/ml (data not shown), but ~76 Ω less compared to electrodes seeded 
with 100 times more cells. Transient response curves were different from the shapes obtained 
with stable cell lines as the deepest point of the curve was usually reached after removal of 
SP. The apparent decrease in the signal response (slope and depth) in the later two injections 
(-5 and -6) may be attributed to temporary desensitization of the NK1 receptor cells due to 
receptor recycling of SP-activated receptors [28]. 
 
In the second experiment a different single pair of IDE electrodes covered with NK1 
reverse transfected HEK293 was selected to measure the signal responses to doses ranging 
from 1 to 100 pM SP. The overall sample resistance for all the cell covered electrodes on 
different chips were in the range of 4–4.5 kΩ with baseline noise level of 2 Ω. The change in 
absolute impedance for 1 pM SP was similar to the stable NK1 expressing HEK293 cells 
(~16 Ω). For higher concentrations of 10 and 100 pM, the average impedance changes were 
37 and 62 Ω respectively (Fig. 6B). No significant impedance changes were observed in the 
blank experiment with no SP in HEPES media. 
 
 
Figure 6.Transient response of NK1 reverse transfected HEK293 cell lines on 500 µm IDE’s 
to the SP ligand. A: shows the combined data of the impedance response as a result of a 
series of injections of 1 nM SP on reverse transfected HEK293 cells with NK1 plasmid DNA 
at cell seeding density of 1×104 cells/ml, the sequence of injection is represented by the 
notation 1–6 in the legend of the plot, where 1 represents the first injection while 6 represents 
the last injection. B: shows the combined data for impedance response with different 
concentrations of ligand doses ranging from 1 pM to 100 pM on interdigitated electrodes 
covered with reverse transfected NK1 HEK293 cells at cell seeding density of 1×106 
cells/ml. The notation 1–5 in the legend of the plot represents the sequence of injection. 
Assay-independent drift was corrected as in Figure 3. 
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7.4 Discussion 
 
Multiwell assays are the basis of the current impedance- and molecular probe-based 
analytical platforms of measuring specific cell or receptor responses [15, 43, 44]. These static 
assays are relatively costly, labor and reagent intensive, wasteful (single use only), and with a 
relatively low information content (only on-rates of compound addition, no off rates of 
compound removal, no internal calibration with injection of a standard) [45, 46]. In view of 
the demand for smaller, parallel, multiple use, dynamic fluidic assays, we therefore 
developed a prototype system potentially combining all these desirable traits. The system 
consists of a flowcell enclosing multiple interdigitated micro-electrodes that can be 
specifically reverse transfected with DNA plasmids encoding different cell membrane 
receptors to create receptor cell arrays. DNA-printed electrodes can be stored for months until 
use and the cell arrays can be addressed repeatedly due to the reversible nature of the 
morphological changes. In addition, the transient activation provides the kinetic profile of 
both activation and de-activation at the level of changes in cell morphology. 
  
Cell-based biosensors exploit cellular receptors of specific analytes to trigger an 
intracellular signalling pathway and measure cellular responses (e.g. changes in calcium ion 
concentrations) as the sensing principle. A wide variety of transducers such as electrical, 
optical, mechanical, thermal principles have been utilized for cell based sensing [47]. Cell 
impedance spectroscopy in a microfluidic setting was set up to develop an assay which could 
potentially detect infections such as tuberculosis in body fluids. As a model, a HEK293 
mammalian cell line expressing the NK1 GPCR receptor was immobilized as the biosensing 
layer, on the hybrid surface of an interdigitated electrode chip. Ligand SP specifically was 
shown to trigger the NK1 receptor already at very low concentrations. IDE arrays in a single 
flow cell would enable the possibility of multiplexed assays and detection of multiple 
analytes in one sample. We have shown that by means of reverse transfection receptor cell 
arrays may be generated on chip from a wild type cell line, thereby excluding the need for 
tedious procedures involving maintaining and depositing separate receptor cell lines on one 
IDE array chip. Thus, a generic application of impedance based measurements of changes in 
cell shape induced by the specific activation of arrays of receptors potentially provides a 
novel tool for diagnosing a broad set of disease conditions including TB in human body 
fluids. 
 
Human infections with pathogens such as Mycobacterium tuberculosis trigger specific 
endogenous biomarkers in the human host. On the one hand, those are antibodies targeting 
components of the pathogen, but on the other hand there is also a large range of other factors 
specifically inducing or induced by the human cellular defense. These factors often act via 
interaction with certain cellular receptors some of which belong to the GPCR family. The 
biomarkers that are known to be correlated with a TB infection are interferon gamma (IFN-
γ), fork-head box P3 (FOXP3), interleukins (IL-1RA, IL-8, IL-18, IL-12), IP-10 and mast cell 
protease (MCP-1, MCP-2, MCP-3) [36-41]. IL-8 in the group of interleukins is specifically 
recognized by the GPCRs, CXCR1 and CSCR2. A closely related Gαi dependent chemokine 
receptor CXCR3 was shown in cells to yield impedance changes when specifically 
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challenged by CXC chemokine [42]. The potential exists, therefore, to develop cell 
impedance-based biosensors for tuberculosis infection that can assist in disease diagnosis.  
 
Current limitations of the system prototype are: (i) Due to electrode interference 
during simultaneous measurements the technical set up did not allow reading more than one 
sensing electrode. Systems sequentially addressing electrodes at intervals have been 
developed for the existing microtiter plate formats, however, so that we do not foresee a 
technical hurdle for flow cell arrays; (ii) the design of the flow cell did not allow higher flows 
than one flowcell volume per minute. Future designs with wider and/or higher flow cells will 
allow larger flow volumes as described by Roelse et al. with greater convenience in terms of 
the speed of delivery of series of samples [28]; (iii) The non-monotonous drift could not be 
addressed in the present system with a read out of only a single receptor. Drift compensation 
methods need to be realised by adapting the design of the chip layout for example by 
arranging a rows-column format with electrical connections lying plane perpendicular and at 
the underside of the sensing area thereby minimizing the chances of drift due to thermal and 
electrical interferences from neighbouring electrodes [48]. If drift is IDE independent 
compensation may also be achieved by subtracting the signals of control electrodes. If drift is 
IDE dependent the process of cell division may be responsible. The mitotic cycle induces 
strong morphological changes that likely disturb signal stability on small electrodes with only 
few cells contributing to the total signal. Arresting the cell cycle with chemicals may 
therefore be another effective way of suppressing drift.  
 
HEK293 cells were seeded on the chip typically 48 h prior to use. Depending on the 
chosen cell densities, this yielded well-attached, uniform, 50-100% confluent cell layers. 
Loading higher densities and spinning cells down to reduce the adhesion time from 48 h to < 
2 h was not effective, as cells could not withstand medium flow speeds higher than 2 µl/min, 
due to poor adherence (data not shown). It is noted that the morphological changes of cells 
can involve both shrinking and stretching, depending on the nature of the activated receptor 
[49, 50]. This probably has some implications for the most adequate cell coverage in case of 
mixed cell responses. In the present study the NK1 receptor activation with SP resulted in 
shrinkage of cells (blebbing), and therefore, near confluent cell coverage yielded the best 
differential signal. In a mixed situation it may be better to aim for 70–80% cell coverage, in 
order to allow for efficient measurements of cell stretching as well.  
 
The signal responses obtained with various ligand doses were generally reproducible 
for both stable as well as reverse transfected cell lines. Noise levels were typically 2~5% 
relative to response signals of ~20 Ω and higher. The response profiles of stable and reverse 
transfected cell lines were, however, a little different. Stable cell lines displayed an initial 1–2 
min steep decrease followed by a 3–4 min slightly rising saturation plateau, succeeded by a 
1–2 min steep rise when the ligand was removed. Both the fall and rise of the signals could 
be delayed up to 100 sec. We suspect that this might be due to failure of the pump to deliver a 
constant low flow in our system. By comparison for reverse transfected cell lines the decrease 
was less steep, taking 4–5 min to reach a shorter, yet still decreasing, saturation plateau, 
which would extend 1–2 min beyond the point that the ligand was removed. Recovery was 
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also slower taking up to 4–5 min. A possible explanation might be that HEK293 cells were 
present in a multilayer, with only the lower layer being transfected and responding. In 
comparison to uniform stable transfected cell lines, the ligand may reach the bottom reverse 
transfected cells less efficiently.  
 
 
Figure 7: Dose-response curve of the relative change in impedance at 15 kHz, 10 mV, 
for different SP concentrations for both stable and reverse transfected NK1 cell lines seeded 
at a density of 1×106 cells/ml. All changes were negative, resulting in a lower impedance as 
a result of the interaction with SP. The data points are mean values obtained from 2 or 3 
injections of the same concentration 
 
The dose response curve for the stable cell line showed an estimated EC50 value of 
~10 pM (Fig. 7), which was 140 times lower compared to the EC50 reported by Meshki et al. 
experiments in a microtiter plate on large electrodes [15] and about 10 times lower than a 
complementary microfluidic system where cytoplasmic [Ca2+] changes were measured [28]. 
One reason for this higher sensitivity could be the very low cell density used by Meshki et al. 
in the wells, i.e. 4000 cells/6.4 mm well diameter. Based on a cell size of 100 µm2 these 
results in coverage of only 1.25% compared to 80-100% coverage in our sample preparations. 
This was also evident with the experiment involving repeated injections of 1 nM, where the 
signal obtained was diminished for lower cell inoculation of 104 cells/ml compared to higher 
cell inoculation 106 cells/ml. In addition, we incubated cells 3 times longer (48 h) allowing 
stronger electrode adhesion of cells. Secondly, the reported lower sensitivity values from 
Meskhi et al. could be due to SP not being fully active as it quickly inactivates after dilution 
in buffer according to our experience. Thirdly, considering the mean cell size (10 µm), the 
line spacing used in our case was very narrow (12 µm) compared to commercial devices (50 
µm) used by Meshki et al. As described by Radke and Alocilja, for sensitive impedance 
measurement of cellular organisms, electrode spacing should be proportional to the 
dimensions of cells [49], so as to minimize the influence of events occurring due to some 
random particle floating over the sensor electrode. In their study where they utilized E. coli 
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bacteria with average length of 2.5 µm, the optimum spacing between the electrodes was 4 
µm which minimized up to 98% of external interference caused by random particles floating 
at a distance of 10 µm over the sensing area [51]. 
 
For proof of concept, the NK1 receptor was utilized as a model GPCR. Upon 
activation by SP, the NK1 receptor triggers both the Gαq and the Gα12/13 pathways. 
Presumably, the activation of the Gα12/13 pathway induces a contraction of the membrane 
cortex termed as blebbing [52]. There are three main GPCR pathways, which are mediated by 
four (Gαs, Gαi/o, Gαq/11 and Gα12/13) subclasses of G-proteins [53]. Although, the pathway best 
known to induce such morphological changes is the Gα12/13 pathway, it appears that the 
activation of other pathways might also lead to changes in actin and myosin complexes of the 
membrane cortex that are essential for cell shape and locomotion [52]. There have been 
similar demonstrations, however, for the histamine (H1), serotonin (5-HT1A) [14], dopamine 
(D2, D5), cannabinoid 1 (CB1), melanocortin-4 (MC4R) [17], cannabinoid 2 (CB2), 
metabotropic glutamate 1 (mGluR1) [18] and chemokine CXCR3 [19] receptors with 
activation pathways mainly involving Gαs, Gαi/o and Gαq/11. Furthermore, also the ligands of 
nuclear receptors such as glucocorticoid, mineral corticoid, progesterone, androgen receptor 
induce morphological changes in cells [54]. The presented novel microfluidic system of 
impedance measurements on microelectrodes in a flow cell is therefore potentially useful for 
a much wider array of receptors. In fact, if they do not naturally change shape, their 
signalling pathway can be altered in order to do so. Recently, Gαq proteins could be 
engineered into chimeric versions with Gα12/13, which would bind Gαq GPCRs, but trigger the 
Gα12/13 pathway [55], thus opening up further possibilities to use impedance measurements as 
a generic platform for GPCR research.  
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In this PhD project, various diagnostic methods were developed for potentially sensitive and 
early detection of TB, which in some cases may also be applied in resource-poor areas. This 
final chapter focuses on the achievements of the project and highlights the further work 
required along with future perspectives. 
 
8.1 Need for better biosensing tools in TB 
 
Tuberculosis (TB) is affecting people across all continents, and is a global problem 
for our modern society demanding urgent attention. Early and sensitive detection techniques 
applicable in remote areas remain the mainstay for the fight against TB. Unfortunately, 
detection tools for TB still fall short from the required qualities.  
 
As mentioned throughout in this thesis, a crucial step towards TB management is 
early detection. In Chapter 2 we introduced the different diagnostic platforms that have been 
developed and used so far for TB detection and we stressed that a highly sensitive and user-
friendly diagnostic tool to analyze biological samples (like – sputum or blood) for the 
presence of Mycobacterium tuberculosis (M.tb.) is still not available. Moreover the situation 
is complicated by the fact that TB is most prevalent in tropical and poor countries with 
inadequate infrastructure and lack of funds to support the current diagnostic tools.  
 
In summary the motivation for this thesis work has been as follows: 
 
(1) The seriousness of the problem - TB as a disease has a worldwide presence and the socio-
economic burden that it projects on a global scale is enormous [23]. 
 
(2) The key point in TB management is early detection – if possible even at the latent 
infection stage. It needs to be emphasized that the major hurdle lies here as most of the 
latent TB cases are either asymptomatic or with few symptoms which makes it difficult to 
diagnose at an early stage [24]. However, medical literature has reiterated over and over 
that a diagnostic tool that can be used in detecting such (a) symptomatic cases would 
greatly improve the opportunities for TB management. In other words – there is strong 
support for developing a diagnostic tool that can be implemented to screen entire 
populations irrespective of symptoms [55]. 
 
(3) As M.tb. infections stimulate the production of specific antibodies – a set of serological 
assays have been reported over the last few decades [56,57]. Unfortunately, most of these 
assays are not user-friendly, require strong logistic support, are expensive, offer 
inadequate sensitivities and cannot distinguish between old and new infections. 
Moreover, in July 2011 the World Health Organisation issued a warning against the use 
of such tests stating, “Test results are inconsistent, imprecise and put patients’ lives in 
danger” [23]. In a nutshell, the current available biosensing tools fail to live up both to 
the expectations and performance standards. 
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(4) During the last few years, nano- and microtechnology have experienced explosive 
growth. Unique properties of these materials and techniques (such as – superconductivity, 
paramagnetism, fluorescence, higher chemical reactivity, microfluidics) over bulk 
materials and volumes offer unprecedented opportunities to develop novel tools for 
medical diagnostics [58].  
8.2 Biosensor-based detection of TB biomarkers and research questions 
 
Despite the fact that recently there have been remarkable advancements in biosensing 
based approaches towards detection of TB, the currently available techniques are still limited 
to laboratories. The expected features/criteria that an effective and suitable biosensor for TB 
detection should possess are: 1) high cost-effectiveness, 2) high sensitivity, 3) good 
reliability, 4) portability, 5) simple use and 6) having disposable parts.  
 
In chapter 2, classification of biosensors was done on the basis of their signal 
transduction principle.  
 
For electrical biosensors, an electronic nose-based method has been developed for 
detection of TB. Electronic nose based biosensors recognize volatile substances that are 
produced by the M.tb. in liquid medium [1-3].  
 
For optical biosensors, techniques utilizing fibre-optics, surface plasmon resonance 
(SPR), resonant mirror and breathalyzer based biosensing methods have been demonstrated 
for TB detection. Fibre-optic based biosensors were shown to recognize compounds that are 
secreted by M.tb. into sputum [4], while SPR [5-12], resonant mirror [13] and breathalyzer 
based biosensors focused on the recognition of M.tb. produced byproducts or the whole M.tb. 
bacterium [14-16]. 
 
For mechanical biosensors techniques like quartz crystal microbalance (QCM), 
multichannel series piezoelectric quartz crystal (MSPQC) and acoustic wave biosensors have 
been explored in relation to TB. Where QCM based methods rely on the detection of whole 
M.tb. bacterium [17], MSPQC and acoustic based sensors recognize volatile and non-volatile 
products that are produced due to the growth of M.tb. bacterium [17-19]. For magnetoelastic 
and magnetic TB biosensors, techniques such as magnetoelastic strip, diagnostic magnetic 
resonance (DMR) and magnetic barcode-based biosensors have been developed. 
Magnetoelastic strip-based sensors are designed to detect by-products produced from M.tb. 
from their specific signature, while the other two techniques are lab-on-a-chip techniques, 
where whole M.tb. bacterium are analysed in crude sputum samples in an automated, high 
throughput, miniaturized NMR platform towards identification of on-chip RT-PCR amplified 
16S rRNA [20-22]. 
 
The research presented in this thesis has been part of a large interdiciplinary project 
initiative of the Dutch technology foundation STW involving four main partners with one 
PhD student at three location i.e. Laboratory of Organic Chemistry/ Plant Research 
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International (Wageningen University), NanoOrganic Chemistry Group (Technical 
University Delft) and the Delft Institute of Microsystems and Nanoelectronics (Technical 
University Delft) and a technician at Viroscience division (Erasmus Medical Center-
Rotterdam). The role for Wageningen was to work on the biosensing layer and test and apply 
nanowires for the detection of pathogens like TB. The technician involved in the project at 
Rotterdam had the task to provide virus-specific antibodies and recombinant virus proteins 
for initial assay set-up, along with clinical specimens for test validantions. The other two PhD 
students involved in the project at Delft were expected to construct the nanowires and 
functionalize them with chemical monolayers suitable for the immobilization of a biosensing 
layer by the Wageningen PhD. However, due to a delay in the deliverables from the project 
partners, alternative detection platforms were improvised and initiated. As a result, lateral 
flow immunoassays, microsieves for upconcentration and detection, and cell-based 
biosensors were developed and evaluated, with the original global aim to address the existing 
challenges of sensitivity and simple use in TB diagnosis utilizing micro- and nanomaterials, 
and testing novel electronic and optical options for detecting either pathogen or host 
biomarkers in simple one step procedures. The resulting research questions addressed in this 
thesis were:  
 
1. Development of antibody pairs for a novel TB biomarker HSP which can be 
concentrated by concentrating the bacteria first to meet the sensitivity benchmark 
(8.3). 
2. Development of a one step capture and detection procedure of HSP with those 
antibodies to meet the simplicity benchmark (8.4 and 8.5). 
3. Development of labelfree one step detection of host biomarkers using cellular 
membrane receptors to meet both the sensitivity and simplicity benchmark (8.6). 
 
8.3 Characterization and upconcentration of the M.tb. HSP internal antigen  
 
For the development of antibody pairs for a novel TB biomarker that could be 
upconcentrated by concentrating the bacteria, it was crucial to identify a suitable intracellular 
target and bacteria capture method. In the selection of the biomarker protein we looked for a 
protein, which would be abundant and immunogenic. A good candidate was the 16 kDa heat 
shock protein (HSP) which has long been known to be a critical pathogenic component of 
infectious TB. It is highly immunogenic leading to high titres in patients’ sera. It has been 
claimed to exist as monomer, dimer, trimer, trimer of trimers (i.e. nonamers) or dodecamer 
structures and was analysed using various techniques like reverse-phase high performance 
liquid chromatography, cryoelectron microscopy and size exclusion chromatography (SEC) 
analysis [26]. In earlier research, a set of llama antibodies had been selected using phage 
display against this protein [11]. In order to understand the optimal capture-detection probe 
combinations and, in continuation, to design highly sensitive biosensing tools, it was 
important that the protein epitopes of HSP in relation to existing antibodies were sorted out. 
In Chapter 3 the multimeric structure of HSP was investigated. The denaturation due to heat 
and harsh isolation and purification methods was coupled to an SEC and mass spec analysis 
that allowed for the first time a reliable size determination of the various protein forms [26].  
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We demonstrated the configuration of denatured-renatured protein to be a dimer, and 
identified and characterized via epitope mapping experiments the antigenic regions of the 
HSP protein, with a collection of HSP-specific VHH llama antibodies. Different VHH 
antibodies showed specific binding to many different epitopes of 16 kDa HSP. It was 
observed that the best binders of HSP, VHH A-23 and B-F-10, recognized non–overlapping 
epitopes of the HSP protein [26]. Binding of HSP epitopes, protein and lysates to different 
VHH antibodies was modelled leading to recommendations of the most suitable capture-
detection probe combinations for detection of TB.  
 
The elucidation of the antigenic structure of the 16 kDa HSP has been a matter of 
debate for a long time. The improved understanding of the structure and the availability of 
VHH antibodies against this clinically and pathologically relevant protein of M.tb. may be 
relevant towards the development of sensitive biosensors specific to diagnose HSP. The use 
of VHH llama antibodies [27] has been quite successful in a range of diagnostic applications 
due to their unusually robust properties. This work, therefore, laid the foundation for research 
towards the development of novel biosensing tools in TB especially if also straighforward 
methods of upconcentrating mycobacteria from sputum would be available. A method to 
achieve that was described in Chapter 4. A homopolymer of diallylimethylammonium 
chloride (polyDADMAC) was coated as capturing agent on microsieves and was used to 
concentrate acid-fast Gram-positive Mycobacterium from test samples. The concentrated 
Mycobacteria, may subsequently be lysed and the released biomolecules (DNA, RNA, 
proteins like HSP) will be available in concentrated form for various detection assays. This 
may be useful in detecting Mycobacteria not only in human samples but also in other media 
like milk or water [29]. Furthermore, with the use of other specific capturing agents, the 
scope for such functionalised microsieves could be broadened to other pathogens.  
 
8.4 Sandwich immunoassays of TB HSP antigen 
 
Sandwich assays are usually more specific than direct assays if the capture and 
detection of the analyte molecule is done using two different epitopes, i.e. first epitope 1 by 
the capture antibody and subsequently epitope 2 by the detection antibody [28]. A positive 
signal is only obtained when both the capture and detection antibodies have bound the same 
target molecule, thus making the system more specific than systems depending on one 
capturing epitope. Two strategies were followed, that focused on capture/detection of M.tb. 
cellular internal 16 kDa HSP antigen protein using sandwich assays (Chapters 4 and 5). 
  
In the first strategy, the detection of HSP was based on a step-by-step build-up of a 
sandwich assay involving two complementary biotinylated VHH antibodies, HSP target 
protein and alexa-fluoro labelled streptavidin on a flow-through microsieve platform (Chapter 
4). Flow-through assays may be advantageous over traditional flow-over assays due to 
increased contact of antigens in solution and bound antibodies. By passing through the 
surface apart from diffusion also physical mass flow parameters come into play. 
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Interestingly, the dimeric nature of the HSP protein seemed to result in the formation 
of aggregates on the sieves in sandwich assays combining HSP dimers with VHH antibodies 
coupled by quaterneric streptavidin. Assays involving multivalent recognition pairs can easily 
lead to aggregate formation similar to the well-known agglutination reaction used for 
bloodtyping. Detection of this aggregate sandwich pair was studied with the help of a DLS 
(dynamic light scattering) method [32]. Interestingly, DLS could measure aggregation down 
to 10 ng/ml suggestion that the reaction is potentially very sensitive and might be used to an 
advantage as an alternative way of measuring low titers of M.tb. antigens. To improve the 
method, replacing streptavidin by avidin-coated fluorescent/polystyrene beads or 
microspheres may represent a way to enhance the size and visibility of aggregates [33]. The 
aggregated beads will be more easily detectable and be retained on the sieves. Quantification 
of such complexes could be an issue however due to the time and environmental dependence 
of the formation of random and chaotic 3D complexes. 
 
In the second strategy, the detection was based on a lateral flow immunoassay 
(LFIA). Two complementary VHH llama antibodies (with and without biotin tag) were pre-
mixed with the HSP target protein along with a neutravidin-coated carbon NP in a single step 
detection procedure. The assay detected a lower limit of 0.25µg/ml of purified recombinant 
HSP antigen (Chapter 5). The LFIA set up was highly specific for M.tb. as it could 
discriminate M.tb. from atypical Mycobacterium (like Mycobacterium smegmatis/M.smeg.). 
This is highly relevant as the traditional immunodiagnostic tests often employed in the field – 
like Mantoux test – yield many false positives due to cross-reaction between antigens shared 
within different Mycobacterium sp. bacteria [31]. LFIA is an established and mature 
technology, where minimal operator-dependent steps and interpretations are required, thus 
making it an easy to handle assay [25]. It also has the flexibility to be integrated with on-
board optical, reader and information systems. More importantly the assay offers high 
sensitivity, specificity, speed and stability at a relative low cost [30].  
 
8.5 A NW FET-based assay of TB HSP antigen 
 
NW-based sensors gained attention during the last decade due to their outstanding 
semiconductor properties as well as large surface to volume ratio that seemed to enable ultra-
sensitive reversible assays utilizing electrical detection of the charge properties of an analyte 
bound to a surface [34-37]. It was the main original aim of this thesis to exploit these 
properties of NWs towards the development of a detection platform for TB. In this study - 
streptavidin coated NWs were functionalized with biotinylated VHH antibodies against the 
16 kDa HSP antigen protein to form the biosensing layer of the sensor. NW-based detection 
is a direct detection method capable of sensing charges of biomolecules within the Debye 
layer. As a result it is not dependent on any labelling for signal production, but does require 
close proximity of the target molecule to the NW and changes in charge distribution at the 
surface. For connecting the NW with the readout electronics, a compact biosensing module 
equipped with automated microfluidics for controlled injection of the ligand was developed 
as well. The microfluidics potentially allows the user to control assay speed and throughput 
by means of flow speed, mixing, multiplexing and parallel assay designs. The functionality of 
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the sensing module with the NW chip was characterized by flow injection analysis of pH 
solutions, flow rate induced sensitivity changes and receptor-ligand binding in real time. The 
lowest concentration of HSP that appeared to be detected was 100 ng/ml, but further dilutions 
HSP and controls were not tested due to a lack of functional nanowire chips available to the 
project. This also prevented a further study of additional aspects such as specific 
functionalization with different probes of nanowires that are part of an array, allowing for 
better internal calibration of the signals. Other elements that needed testing were use of 
shorter cross linkers for anchoring VHH antibody at reduced salt concentrations of the 
running buffer to overcome the Debye length ionic screening effects that strongly influence 
the sensitivity of the system.  
 
SiNW-FET-based biosensors may have potential in TB detection, but apart from this 
project - little research has been performed so far towards such an application. The results 
obtained in this PhD project, make clear that such SiNW-based devices will require a lot of 
further optimization. The challenges are to (i) obtain electronically functional nanowires 
reliably, (ii) to functionalize them with antibodies without increasing the distance to the wire 
too much, and (iii) to realize sufficient multiplexing to allow an analysis yielding robust data. 
Although several groups have shown better results with SiNW [37, 60, 61], there are still 
several issues such as device-to-device variation due to which results are not reproducible. 
Also, electrical drift and Debye screening and complex handling procedures are major 
drawbacks of the technique. Hence, the development of such SiNW-based tools is 
handicapped by the lack of proper nanofabrication and surface functionalization techniques. 
Finally, a point of concern for the development of microfluidic biosensing systems of TB is 
also their difficult compatibility to the kind of biological samples derived from TB patients. 
Sputum samples are viscous and irregular and may obstruct the microchannel and subsequent 
electrical measurements in various ways.  
 
8.6 Development of labelfree one step detection of TB host biomarkers 
using cellular membrane receptors 
 
Apart from producing specific biomarkers itself, M.tb. also induces host-derived 
biomarkers that circulate through the body in sputum, blood, urine, etc. These biomarkers are 
cellular messengers/hormones that are recognized by a range of cellular receptors. Host 
derived biomarkers released and circulating in response to an infection by TB are interferon 
gamma (IFN-γ), fork-head box P3 (FOXP3), interleukins (IL-1RA, IL-8, IL-18, IL-12), IP-10 
and mast cell protease (MCP-1, MCP-2, MCP-3) [38-43]. Of these, IL-8 has a significant role 
in pathogenesis of TB and is specifically recognized by the G protein-coupled receptors 
CXCR1 and CXCR2. GPCR activations can be monitored by various assays but cell 
impedance, measuring changes in cell shape in response to a ligand, is particularly interesting 
as it requires no labeling, is highly sensitive and fast. For the related Gαi dependent 
chemokine receptor CXCR3 it was already established that this technique worked well [44]. 
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Cell-based biosensing platforms are developing fast and finding their place in 
diagnosing complex disease conditions. The basic principle of such cell-based assays depends 
upon the activation of specific cellular signalling cascades upon activation by specific ligands 
[45]. A broad range of such cell-based assays have been reported [45]. In order to apply such 
principles to the detection of M.tb. induced host biomarkers a microfluidics supported cell 
impedance measurement set up was built (Chapter 7). With the implementation of 
microfluidics, practical point-of-care needs such as high throughput, low amount and 
concentration of samples and lower costs may be achievable. Microfluidics based systems 
also allow user control over the assay in terms of flow rate, mixing and multiplexing along 
with parallel assay designs. This is true for both antibody and cell based assays. For proof of 
concept with cell based assays – a mammalian cell line expressing the Neurokinin 1 (NK1) 
pain receptor (which is a GPCR expressed in lungs) was utilized and Substance P (SP) was 
used as its ligand. It was found that SP could successfully trigger an impedance response 
upon activation of the NK1 receptor.  
 
The SP activates the Gα12/13 pathway and causes blebbing (local constrictions) of the 
membrane [46]. In general and depending on the sub-classes of G-proteins – four categories 
of GPCRs are recognized which are Gαs, Gαi/o, Gαq/11 and Gα12/13 [47]. Although the Gα12/13 
appears to be the predominant pathway, emerging data suggest that the other pathways also 
affect cell movement and shape [48]. Many studies so far have demonstrated impedance-
based assays based with different GPCRs [49-53]. Interestingly GPCRs which do not utilize 
the Gα12/13 pathway upon activation can be manipulated with chimeric G-proteins to redirect 
the response towards the Gα12/13 pathway [54]. Apart from GPCRs, it has been reported that 
also other (nuclear) receptors like for interleukins and interferon also induce morphological 
changes in cells [59]. Thus many opportunities exist to develop new impedance-based 
diagnostic tools targeting the circulating ligands of these receptors.  
 
Although not demonstrated within this thesis, IDE receptor arrays in a single flow cell 
can introduce a possibility of multiplexing and automation with HTS capabilities. Reverse 
transfection was shown to be a feasible technique to create local spots of cells on IDEs with 
specific receptors based on spotted plasmid DNA carrying the receptor gene. That technique 
will allow the creation of receptor cell arrays on different micro-IDEs. The possibility of 
arrays potentially provides the system with much better internal controls than microwell 
based systems. Such controls are essential for robust diagnostics. A downside of a fluidic 
system with repeated injection of samples over the same cells is the formation of memory in 
those cells. For this reason any diagnostic application of a fluidic system will probably work 
with disposable single use cartridges. In summary, impedance-based fluidic assays reporting 
receptor specific morphological changes can potentially provide an interesting new addition 
to the diagnostics repertoire.  
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8.7 Conclusions and Future Perspectives 
 
In this thesis, LFIA, coated microsieves, nanowire FETs and cell impedance were 
developed and/or tested as potential diagnostic platforms for the sensitive and one step 
detection of TB. Some of the most important findings of this work include: 
 
1. Succesful characterization of the epitopes of 16kDa heat shock protein in relation to a 
large set of VHH llama antibodies. This intracellular protein may be upconcentrated 
from patient sputum by pre-concentrating the bacteria before lysing them. This 
procedure may potentially lead to more sensitive detection of tuberculosis. 
Interestingly, the HSP protein is a major protein especially in the latent phase. An 
immunoassay based on that protein might therefore potentially enable earlier diagnosis.  
 
2. The polyDADMAC coated microsieve assisted up-concentration of M.tb. cells from 
samples such as sputum might be very useful in obtaining sufficient bacterial counts for 
any desired detection assay. 
 
3. The LFIA based assay may present a promising platform for providing an affordable, 
fast and simple detection assay. We failed to establish reproducible results, possibly 
due to the deterioration of the protein sample. 
 
4. Prototypes of the compact, modular, microfluidic biosensing platform with both NW-
FET and IDE microelectrodes developed in this thesis are relevant first examples for a 
development of on-chip high throughput assays where simultaneous detection of 
multiple targets is possible. Assays equipped with microfluidics  allow a more precise 
control over the volumes, read outs and timing of the assay, thus reducing time and 
reducing overall cost of the assay without compromising on the sensitivity. 
 
5. The cell based impedance sensor of chapter 7 is the first demonstration of microfluidic 
cell impedance measurements. The experiments showed exquisite sensitivities and 
reversibility of the responses which both were new. Both reverse transient and stable 
transfected cells showed sensitive impedance responses. This marks a great potential of 
these types of fluidic and multiplexed assays for GPCR research and possibly 
diagnostics.  
Cumulatively, the research demonstrated in the thesis will be useful in understanding 
the complexities and possibilities towards the development of effective biosensing platforms 
for TB detection. The main areas for improvements, building on the current advances are: 
 
1. The development of a one step M.tb. cell concentration and lysis protocol from samples 
such as sputum where the viscosity of the sample obtained from the patients is too high.  
With the current available liquification techniques only half of the total cell present in 
the sputum could be extracted thus reducing the cell count for the desired assay. 
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2. The prototype biosensing module developed in this thesis, lacks the possibility to tackle 
thermal control and suffers from a poorly understood drift. Another shortfall of the 
module was its inability to perform simultaneous AC measurement on two parallel 
electrodes due to interferences originating from neighbouring electrodes. This was only 
an issue while doing AC measurement, as during DC measurement interference from 
neighbouring electrodes was not observed. These issues could be tackled in a next 
design of the module where sequential addressing of the electrodes could be 
implemented as in the case of existing microtiter plate format. Also electric drift 
compensation methods could be adapted in the chip layout by arranging a row-column 
format so that electrical contacts are better distributed at the sensing area. 
 
3. The flowcell used in the prototype biosensing module did not allow a higher flowrate 
than typically one flowcell dead volume per minute. This slows down the step of 
delivering the samples through long tubing but this issue can easily be tackled in future 
designs by creating a wider and/or higher flowchannels. 
An ideal diagnostic test for tuberculosis would be an assay that enables accurate diagnosis 
within the time of clinical consultation. So, far most of the approaches that emerged over the 
past few decades all have their own disadvantages and this work also did not bring the ideal 
outcome. 
 
In final words, it can be stated that developing a highly effective biosensing platform 
remains a dream to achieve, and thus a topic for further research. This thesis may provide 
material for the interested researcher and developer to further work on one of these platforms 
to achieve a potent and sensitive detection assay for TB. Although the focus of the present 
thesis was TB, the scope of the evaluated diagnostic platforms is not limited to TB alone.  
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Appendix A 
 
Supporting Information: Chapter 3            
 
Table 
 
Table S1.  Comparison between the actual and estimated molecular weights of the standard 
proteins along with the deviation percentage while calibrating the SEC column. 
 
Protein Mw (kD) Ve (mL) Est. MW Deviation (%) 
Blue Dextran 2000 2000 8.38 1736.89 13.16 
Ferritin 440 10.72 538.94 -22.49 
Catalase 232 12.7 200.21 13.70 
Aldolase 158 13.22 154.37 2.30 
Albumin 67 14.33 88.61 -32.25 
Ovalbumin 43 15.43 51.11 -18.86 
Chymotrypsinogen A 25 17.42 18.89 24.44 
Ribonuclease A 13.7 18.19 12.85 6.20 
 
Figures 
 
 
Figure S1: Arrangement of odd and even epitopes on the 16kDa heat shock protein from 
M.Tb. 
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Figure S2: Plot for calibration of Superdex 200 10/300 GL SEC column with known 
standards.  
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Summary 
 
Tuberculosis (TB), caused by the bacteria Mycobacterium tuberculosis (M. Tb.), is a 
contagious disease, affecting mainly the human respiratory system. It causes millions of 
deaths worldwide every year. With the emergence of multiple drug resistant (MDR) strains, 
TB imposes a revived and stimulated health threat to humanity on a global scale. It causes 
diseases to patients coming from every age group and from all the continents. Usually 
patients with low immunity status are the main target for getting infected with TB and hence, 
it is making the situation difficult in sub-Saharan Africa where almost one-third of the TB 
population is also suffering with either an active or passive human immunodeficiency virus 
(HIV) infection. 
 
One of the major obstacles in the management of TB is an early detection of the 
cases. Unfortunately, the popular techniques today lack the desired amenities to apply them 
in resource-poor areas. Moreover, most of the current techniques demand laboratory and 
logistic back up which further hinder their scopes. In this PhD project amongst others unique 
properties of nanowire-based biosensing techniques were investigated to see if fast, 
affordable and more sensitive detection methods for TB diagnosis can be obtained. 
 
Chapter 1 gives an introduction on the topic along with outlining the needs for the 
present PhD project. In order to do so, the chapter first outlines the seriousness and 
emergency caused by TB as a disease along with some initiatives taken on a global scale, like 
that by the World Health Organization (WHO), to eliminate TB. The introduction will lay the 
background for the necessity of the introduction of novel techniques in order to tackle TB 
while recognizing the inadequacies of the current techniques. The desired characteristics of 
an ideal TB detection platform were also discussed and the potential of nanotechnology 
towards development of new biosensing platforms for TB detection was accounted for. The 
concept of silicon nanowires and microchips in detection of TB was also introduced. 
 
However, in order to streamline the research towards developing novel 
nanotechnology-based biosensing platform, it is essential to make a concise review of the 
current techniques in TB detection. Therefore, chapter 2 gives a detailed review of the current 
biosensing modalities present in the field of TB detection along with enlisting their pros and 
cons. 
 
The heat resistant 16 kDa heat shock protein (HSP) had been repeatedly recognized as 
an important factor in the pathogenesis of TB. However, considerable discrepancy and debate 
exists over its structural format and about its antigenic components. For example, it is still 
debated if it exists as a dimer, tetramer, nonamer or dodecamer in its native form. Thus to 
understand such mysteries lying with HSP, sandwich ELISA and SPR experiments were 
designed where 12 different VHH Llama antibodies were used and their binding kinetics 
were assayed against 14 overlapping epitopes (each epitope 20 amino acid long). It was 
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found that 8 out of 9 VHH antibodies recognized 7 out of 14 epitopes.. The most effective 
binding was shown by both the B-F10 and A-23 antibodies. While the B-F10 could be used 
as secondary antibody, both B-F10 and A-23 can be used as anchoring antibodies. Finally, a 
homodimer model was suggested to describe the structure of the HSP, when it is isolated 
using harsh conditions like urea lysis. 
 
One of the key challenges in TB detection is the rather low sensitivity of most 
prevalent techniques. In chapter 4, an effort has been made to improve the sensitivity of M. 
Tb. detection. In order to do so, a two-step approach was undertaken. First, the concentration 
of M. Tb. bacteria in biological samples was increased/densified by concentrating the bacteria 
on a PolyDADMAC coated microsieve followed by a lysis step using standard procedures in 
order to extract the cellular internal proteins. In a next step, another set of microsieves were 
surface functionalized utilizing biotin-streptavidin coupling chemistry to attach the antibody 
VHH A-23 on the microsieve for capturing the HSP dimer. When HSP dimer has been 
captured on the surface of the microsieves, they were sandwiched using a biotinylated 
secondary antibody i.e. VHH F-10, followed by detection using a fluorescence labelled 
streptavidin. The results revealed protein aggregates on the microsieve which were confirmed 
and measured on their sizes with the help of Dynamic Light Scattering. This new approach 
may offer a new detection method and could improve the sensitivity level with respect to 
prevalent techniques. 
 
In chapter 5, a lateral flow immunoassay (LFIA) technique is reported to improve the 
sensitivity of detection in TB while demonstrating the capture of HSP dimer in a sandwich 
assay. In order to do so, nitrocellulose membranes were cut into strips and fixed on a plastic 
backing. The LFIA strips were sprayed with anti-VSV capture antibody as a test line where 
the pre-mixed antibody-antigen complex coupled with carbon nanoparticles (CNPs) could 
bind. CNPs were used in the assay as black labels to visualize the results. The technique 
demonstrated detection capabilities at a range of 0.25 µg/ml which is comparable in 
efficiency to other popular techniques while potentially being easier to implement. 
 
In chapter 6, a compact modular biosensing system was developed utilizing nanowire 
field effect transistor (FET)-based devices hosted under a re-sealable glass microfluidic flow 
cell. The sensing module was equipped with an option to perform both AC impedance as well 
as DC conductivity measurements. To demonstrate the usefulness of the set-up, DC 
conductivity responses to sequential injections of different iso-ionic pH solutions and AC 
impedance responses to sequential binding of proteins (streptavidin, antibody, protein ligand) 
to the surface were done in real time. Though there were certain limitations such as drift and 
inability to perform simultaneous measurement on more than one electrode (due to electrical 
interferences) the system showed considerable promise and can be used in high throughput 
screening (HTS) assays. 
 
In chapter 7, the compact modular biosensing system developed in chapter 6 was 
utilized by replacing the nanowire FET chips with interdigitated electrodes (IDE) to perform 
AC impedance electrochemical measurement towards interrogation of ligand specific 
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reversible activation of live mammalian (HEK293) cells expressing specific G protein-
coupled receptors (GPCRs). A comparative study was also performed where stable GPCR 
transfection was compared with GPCR expressed via reverse transfection in HEK293 cell 
lines. The focus was to validate and provide a proof of concept to show that GPCR 
expressing mammalian cell with AC impedance measurement could be applied towards the 
detection of endogenous TB biomarkers produced within the cells. In relation to TB, 
biomarkers such as interferon gamma (IFN-γ), fork-head box P3 (FOXP3), interleukins (IL-
1RA, IL-8, IL-18, IL-12), IP-10 and mast cell protease (MCP-1, MCP-2, MCP-3) are shown 
to be interesting. The GPCR used in the study was Neurokinin receptor 1 (NK1) with its 
specific ligand i.e. Substance P (SP). Upon activation of NK1 receptor, the Gα12/13 pathway is 
activated, causing the cell to undergo a morphological change (shrinking of membrane 
cortex) termed as blebbing. Due to this blebbing, a decrease in the overall impedance of the 
system was observed. Sensitive measurements at a flow speed of 10 µl/min were done up to a 
concentration of 1 pM of SP using impedance measurements at 10 mV and 15 kHz, which 
was many folds more sensitive than the existing techniques. Though the response profiles 
obtained for stable as well as reverse transfected cell lines were a little different, the overall 
signal obtained with various ligand doses were generally reproducible and thus facilitating 
the possibilities to perform parallel measurements on IDE arrays with distinct receptors per 
IDE in a single flow channel. The present system could directly be applicable for other 
GPCR’s which utilize the Gα12/13 pathway upon activation but for GPCRs which do not 
naturally follow the Gα12/13 pathway, chimeric versions could be produced and utilized. These 
findings open up further possibilities to use impedance measurements as a truly generic 
platform for GPCR research. 
 
Finally, chapter 8 concludes the thesis with general discussion while outlining the 
scopes for further research. 
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Samenvatting 
 
 
Tuberculose (TBC), veroorzaakt door de bacterie Mycobacterium tuberculosis 
(M.tb.), is een besmettelijke ziekte, die vooral het ademhalingsstelsel aantast en wereldwijd 
jaarlijks tot miljoenen doden leidt. Met de opkomst van multi-drug resistente (MDR) 
stammen, is het aantal TBC gevallen weer toegenomen en vormt deze een groeiende 
bedreiging voor de gezondheid van mensen in elke leeftijdsgroep en op vrijwel alle 
continenten.  De belangrijkste groep die besmet raakt met TBC zijn patiënten met een lage 
weerstand. In Sub-Saharisch Afrika is de situatie het meest ernstig, en lijdt bijna een derde 
van de door TBC getroffen mensen ook nog eens aan een actieve of passieve human 
immunodeficiency virus (HIV) infectie. 
 
Een van de grootste obstakels voor de beheersing van TBC is een vroege opsporing 
van de besmetting. Helaas ontbreken in arme gebieden veelal de gewenste faciliteiten evenals 
getraind personeel om de hedendaagse technieken toe te passen. In dit promotieonderzoek 
worden nieuwe, innovatieve “biosensing” methoden bestudeerd of ontwikkeld om snelle, 
betaalbare en gevoelige diagnostiek van TBC mogelijk te maken. 
 
Hoofdstuk 1 bevat een inleiding over het onderwerp en beargumenteert de motivatie 
achter dit promotieonderzoek. Hiertoe wordt eerst de ernst van TBC als ziekte geschetst en de 
rol van initiatieven, zoals van de World Health Organization (WHO), om TBC te elimineren. 
Hieruit volgt een noodzaak om nieuwe technieken te ontwikkelen, door  tekortkomingen van 
huidige technieken om tuberculose aan te pakken te identificeren.  Hierbij worden de 
gewenste eigenschappen waaraan een TBC opsporingsplatform geschikt dient te zijn voor 
ontwikkelingslanden besproken, alsmede het potentieel van nanotechnologie om daarin een 
bijdrage te kunnen leveren. De mogelijke bijdrage van silicium nanodraad- en microchip- 
gebaseerde oplossingen in de opsporing van tuberculose wordt hierbij aangegeven. 
 
Om het onderzoek naar de ontwikkeling van nieuwe, op nanotechnologie gebaseerde, 
‘biosensing’ platforms goed te positioneren, is het essentieel om een beknopt overzicht van 
de huidige technieken te geven. Hoofdstuk 2 geeft derhalve een meer gedetailleerd overzicht 
van ‘biosensing’ oplossingen voor de opsporing van TBC die de afgelopen jaren gepubliceerd 
zijn met een inschatting van de voor- en nadelen van de voorgestelde technieken. 
 
In de pathogenese van TBC wordt het 16 kDa heat shock eiwit (HSP) aangemerkt als 
een belangrijke indicator. Tot nog toe niet volledig begrepen is de exacte quaternaire 
conformatie van dit multimere eiwit evenals de positie van de belangrijkste epitopen. Er zijn 
publicaties die HSP typeren als een dimeer, tetrameer, nonameer of dodecameer. Om deze 
puzzle van HSP eerst te begrijpen, zijn sandwich ELISA- en SPR-experimenten uitgevoerd, 
waarin de bindingskinetiek van twaalf verschillende VHH-lama antilichamen werd getest 
t.o.v. veertien overlappende epitopen (elk epitoop 20 aminozuren lang). Het bleek dat acht 
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van de negen gebruikte VHH-antilichamen bonden aan zeven van de veertien epitopen. De 
meest effectieve binding werd geregistreerd voor het B-F10 en A-23 antilichaam. B-F10 kon 
het meest effectief gebruikt worden als detectie-antilichaam, terwijl zowel B-F10 als A-23 
gebruikt konden worden als anker-antilichaam. Op grond van  experimenten na urea lysis en 
renaturatie werd een homodimeer model voorgesteld om de structuur van de HSP te 
beschrijven. 
 
Eén van de belangrijkste beperkingen in de opsporing van TBC is de lage 
gevoeligheid van de huidige technieken. In hoofdstuk 4, is een poging gedaan om de 
gevoeligheid voor M.tb opsporing te verbeteren. Hiertoe werd een tweestapsbenadering 
gekozen. Voor de eerste concentratiestap, werd een techniek ontwikkeld om de concentratie 
van M.tb. bacteriën in monsters van patienten te verhogen door het vangen/concentreren van 
de bacteriën op een met poly-DADMAC gefunctionaliseerde microzeef. De bacteriën kunnen 
hierna gemakkelijk worden gelyseerd met behulp van standaardprocedures om interne 
cellulaire eiwitten, zoals HSP, vrij te maken. In een tweede detectiestap werd het oppervlak 
van een tweede type microzeven gefunctionaliseerd met antilichaam VHH A-23 voor het 
binden van te detecteren HSP-dimeren. Eventueel HSP-dimeer op het oppervlak van de 
microzeven werd vervolgens gekoppeld met gebiotinyleerd VHH F-10 detectie-antilichaam, 
waarna fluorescente detectie mogelijk werd gemaakt met behup van een streptavidine marker 
voorzien van een flourescent label. De resultaten gaven tevens opmerkelijke fluorescente 
eiwitaggregaten te zien welke waren gevangen of gevormd op de microzeef. Met 
Dynamische Licht Verstooiing (DLS) werd dit beeld bevestigd en kon een schatting van de 
grootte van deze aggregaten worden gedaan. Toepassing van elementen van de gevonden 
resultaten en gebruikte methodes kunnen mogelijk de gevoeligheid van de huidige methodes 
aanzienlijk verbeteren. 
 
In hoofdstuk 5 wordt een laterale flow immunoassay (LFIA) techniek voor de detectie 
van M.tb. beschreven. Daarbij wordt gebruikgemaakt van een sandwich asay met lama 
antilichamen gericht tegen de HSP-dimeer. Hierbij werden nitrocellulose membranen in 
stroken gesneden en op een cellulose basis vastgehecht. De LFIA strips werden besproeid 
met een testlijn van een anti-VSV anker-antilichaam. Daaraan kan een voorgemengd complex 
van twee detectie-antilichamen (met VSV of biotine tag), een HSP monster en 
koolstofnanodeeltjes (CNPs) bedekt met neutravidine binden. CNP’s werden in de test 
gebruikt om het signaal te versterken, met als bijkomend voordeel dat CNP’s heel eenvoudig 
met een relatief goedkope scanner gekwantificeerd kunnen worden. Met de techniek kon in 
een 25 µl sample 0.25 µg/ml HSP gedetecteerd worden, wat vergelijkbaar is met gangbare 
technieken, maar die vaak complexer zijn om uit te voeren. 
 
In hoofdstuk 6 is een compact modulair biosensor-systeem ontwikkeld waarbij 
gebruik gemaakt werd van een nanodraad-field-effect transistor (FET) principe. De sensor 
werd toegankelijk gemaakt voor het sequentieel screenen van een monster door het op te 
sluiten in een hersluitbare glazen microfluïdische flowcel. De sensor module is verder 
uitgerust met de mogelijkheid om zowel AC impedantie, als DC geleidbaarheidsmetingen uit 
te voeren. Om de bruikbaarheid van de opstelling aan te tonen werden twee type metingen 
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gedaan, één waarbij de DC geleidbaarheid reageerde op opeenvolgende injecties van iso-
ionische oplossingen die verschilden in hun pH waarden (hetgeen verklaarbaar is door 
verschillen in de protonering van het oppervlak van de sensor) en één waarbij de AC 
impedantie reageerde op een opeenvolgende binding van eiwitten (streptavidine, antilichaam, 
en HSP eiwit ligand) aan het oppervlak.  Beide veranderingen in de lading aan het oppervlak 
van de nanodraad konden in real time gevolgd worden. Hoewel er bepaalde beperkingen 
waren zoals drift van het signaal en de onmogelijkheid om gelijktijdige metingen uit te 
voeren aan meer dan één nanodraadje is  aangetoond dat dit meetsysteem bruikbaar kan zijn 
voor gebruik in high throughput screening (HTS) methoden. 
 
Het compacte modulaire biosensor-systeem, dat beschreven is in hoofdstuk 6, werd in 
hoofdstuk 7 gebruikt voor AC impedantie-metingen aan cellen, welke speciaal gegroeid zijn 
op ‘interdigitated’ (kam-vormige) electrodes. Het betreft hier humane HEK293 cellen, die 
specifieke G-proteïne gekoppelde receptoren (GPCRs) tot expressie hebben gebracht. Stabiel 
getransfecteerde cellen werden hierbij vergeleken met cellen die op de electrodes zelf 
getransfecteerd werden m.b.v. de zogenaamde ‘omgekeerde transfectie’ methode. De focus 
van dit hoofdstuk was een proof of concept en aan te tonen dat GPCR expressie in 
zoogdiercellen met AC impedantie metingen kunnen worden gedetecteerd, waardoor 
mogelijk ook detectie van endogene TB biomarkers gerealiseerd kan worden. Met betrekking  
tot TB, zijn biomarkers zoals interferon gamma (IFN-γ), fork-head box P3 (FOXP3), 
interleukinen (IL-1RA, IL-8, IL-18, IL-12), IP-10 en mestcel protease (MCP-1, MCP-2, 
MCP-3) mogelijk interessant. De GPCR welke in deze studie is gebruikt is de Neurokinine 
receptor 1 (NK1) in combinatie met het specifieke peptide ligand ‘Substance P’ (SP). Na de 
activering van de NK1 receptor, wordt de Gα12/13 pathway/route geactiveerd, waardoor de cel 
een morfologische verandering ondergaat (insnoeringen/blebbing). Door deze insnoeringen, 
vermindert het contactoppervlak van de cellen met de electrodes en daalt de impedantie van 
het systeem. Metingen werden uitgevoerd bij een stroomsnelheid van 10 µl/min en signalen 
bij een concentratie van 1 pM SP konden nog worden gedetecteerd, wat aanzienlijk 
gevoeliger is dan tot nog toe gerapporteerd voor vergelijkbare technieken op veel grotere 
IDEs. Hoewel de reactieprofielen verkregen voor stabiele en reverse getransfecteerde 
cellijnen enigszins verschilden, waren de verkregen signalen over het geheel genomen 
reproduceerbaar en aantoonbaar concentratie-afhankelijk. De reverse transfectie methode 
biedt mogelijkheden voor het doen van parallelle metingen op verschillende electrodes en 
met cellen met verschillende receptoren per IDE allen in dezelfde flowcel. Het huidige 
systeem kan mogelijk rechtstreeks worden toegepast voor andere GPCRs, die eveneens 
gebruik maken van de Gα12/13 route, maar mogelijk ook voor GPCRs die niet de natuurlijke 
Gα12/13 route volgen. Deze vindingen maken het mogelijk om de hier gedane impedantie-
metingen aan cellen verder te ontwikkelen tot een generiek  platform. 
 
Hoofdstuk 8 van het proefschrift sluit af met een algemene discussie waarbij een 
overzicht van de mogelijkheden voor verder onderzoek wordt gegeven. 
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Overview of Completed Training Activities 
 
Discipline specific activities 
 
Micro-Nano conference’09 Delft, Netherlands 2009 
IPOP Bio-Nano Symposium Wageningen, Netherlands 2010 
14th International Conference on Miniaturized 
systems for Chemistry and Life Sciences. Groningen, Netherlands 2010 
Post Graduate Program in Bio-Nanotechnology & 
Medical Applications Noida, India. 2010 –2011 
EMBO Practical Course Methods in Chemical 
Biology  Heidelberg, Germany 2011- 2011 
3rd International Advance course on Proteomics Wageningen, Netherlands 2011 
GPCR Day 2011 Vlaardingen, Netherlands 2011 
 
General Courses 
 
Philosophy and Ethics of Food Science and 
Technology 
VLAG 2011 
Advanced Course Guide to Scientific artwork WUR Library 2011 
Adobe InDesign WUR Library 2011 
Techniques for writing and presenting a scientific 
paper WGS 2012 
NI Day 2012 for Labview Utrecht, Netherlands 2012 
NI Day 2013 for Labview Utrecht, Netherlands 2013 
Scientific Publishing WGS 2013 
 
Optionals 
 
Preparing PhD research proposal PRI, Wageningen 2009 
Weekly work discussion meetings PRI, Wageningen 2009-2013 
Weekly Bioscience Cluster meetings PRI, Wageningen 2009-2013 
Colloquium meetings ORC, Wageningen 2009-2013 
PhD study trip 2011 to Scotland and 
Northern UK ORC, Wageningen 2011 
PhD trip 2013 + Organisation ORC, Wageningen 2013 
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